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Abstract 
Introduction: Sacral nerve stimulation (SNS) has been increasingly utilised as a clinical 
treatment for chronic constipation (CC), but only a small subgroup of patients seem to 
respond to costly long-term treatment and the peripheral nerve evaluation test (PNE) 
appears less accurate than in other conditions. The lived experience of patients receiving 
SNS treatment, within a trial or in routine practice for any condition, is also unknown. 
Methods: Two systematic reviews were conducted to evaluate i) the efficacy of SNS testing, 
and ii) the patient experience. This was followed by a randomised sham-controlled 
crossover trial of a newly devised enhanced peripheral nerve evaluation (ePNE) test for SNS 
(the TiLTS-cc study), and a qualitative study of experiences of receiving SNS treatment for 
CC (the Essence study). 
Results: A total of 45 people were randomised, from which 29 (64%) were responders and 
27 were implanted with a permanent pulse generator. At 6 month follow up there was no 
evidence of a difference in response between ePNE discriminate responders (60%) or ePNE 
indiscriminate responders (57%) (P=0.76, sensitivity 75%, specificity 15%). The study was 
terminated early (45/75) due to concerns regarding safety, with an infection rate of 22%. 
Qualitative findings, with a total of 8 people, demonstrate a constant pursuit for control 
over the disease, a willingness to participate in an invasive trial motivated by desire for a 
curative treatment, and perceptions of symptom benefit that trial definitions of benefit did 
not fully capture. 
Conclusion: The ePNE test of SNS cannot be recommended for any condition due to the 
high infection risk. The effect of SNS in treating CC may simply be a placebo effect, or sub-
sensory SNS may be ineffective for CC. Because of patient willingness to participate in highly 
invasive and intrusive trials, trial design in this population should carefully monitor ongoing 
patient burden and patient perceptions of benefit. 
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Dedication 
 
 
Working as a surgeon causes an enormous strain on any family. I frequently regret 
the amount of time I spend at work and wonder why I chose this profession. In 
those times I try to remember that without modern medicine and surgery,              
I would have no family. 
 
 
This thesis is dedicated to my children; 
Abigail, the bravest little girl in the world, and 
Kate, the most caring little girl in the world. 
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“The art of medicine consists in amusing the patient while 
nature cures the disease” 
Voltaire 
 
 
The words of French author and enlightenment philosopher Francois-Marie 
Arouet [Voltaire] (1694-1778) describe what is now referred to as “the placebo 
effect”. Patients can improve their symptoms simply by believing that a doctor’s 
amusing treatments are helping them or because their bodies are naturally 
healing (regression towards the mean).  
Scientific medical research in pursuit of the philosophical truth about the efficacy 
of a given treatment should always adjust for this, and surgeons in particular 
should pay heed to this advice. 
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Chapter 1- Stimulation for constipation: the pathway from 
community to tertiary intervention 
1.1 Introduction to the Thesis 
This thesis will present original research on a novel testing technique devised in an 
attempt to predict long term response to sacral nerve stimulation (SNS) in patients 
suffering from chronic constipation. I will present a background to the disease and 
the current treatments used for it in Chapter 1, and then proceed to highlight the 
knowledge gaps on SNS for constipation through systematic literature reviews in 
Chapters 2 and 3. Chapter 4 will use the conclusions of the reviews to synthesise 
the research aims and objectives used to inform quantitative and qualitative study 
designs presented and discussed in Chapter 5. Chapters 6 and 7 will present and 
discuss the research findings, and Chapter 8 will then fuse the key knowledge into 
a formal conclusion for the thesis.  
Current evidence shows that only a small proportion of patients who suffer from 
medically refractory chronic constipation will benefit from SNS, and the current 2-
3 week peripheral nerve evaluation test does not adequate identify them before 
implantation with a permanent SNS device. Identifying the true responders within 
this group would mean SNS has the potential to prevent these patients from 
progressing to more expensive and potentially dangerous surgical treatments, and 
may potentially offer relief from a debilitating disease. As little is known about how 
to select these patients, and of their perceptions and lived experience of the 
disease and interventional treatment, a quantitative and qualitative research 
approach will be used to allow a greater breadth and depth of possible research 
findings and conclusions within this thesis. 
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Introduction to Chapter 1 
This chapter will examine the epidemiological, clinical and experiential challenges 
in treating chronic constipation (CC) in the context of patients suffering from a 
“functional” disorder (a debilitating condition with no clear pathological 
explanation), and give a critical appraisal of the standard treatments these patients 
encounter in routine NHS practice and internationally.  The chapter will then 
outline the background to and rationale for, the positioning of sacral nerve 
stimulation (SNS) for treatment refractory individuals within current treatment 
pathways for chronic constipation. The nature and aims of the proposed research 
will be outlined within this context. 
1.2 Aetiology 
Constipation is a word used by patients and physicians to describe a wide range of 
symptoms perceived and attributed to infrequent defecation, or inadequate 
function of defecation. The majority of patients have secondary causes for their 
constipation which are mostly reversible or easily treated with simple, low cost 
laxative therapies. Doctors are becoming increasingly aware of a minority who are 
a severely affected group of patients, and thought to have primary progressive 
symptoms.  Common pathologies are routinely excluded in this group. Their 
symptoms have been categorised extensively by the Rome foundation which has 
led to a definition of “functional” or “chronic” constipation (CC), which is a primary 
idiopathic condition; an unknown aetiology. When doctors do not understand the 
mechanism of symptoms and have excluded known pathologies, patients are often 
referred to as having a functional disorder.  
The word constipation is used, therefore, to describe both symptom(s) due to diet, 
medication or secondary to other pathology, and a severe but poorly understood 
primary functional gastrointestinal disorder (FGID). The prefix “chronic” is 
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frequently used to indicate the persistent and treatment refractory nature of the 
condition. Those suffering from chronic constipation (CC) are usually further 
divided after specialist investigations into separate groups: those who have a slow 
gut transit speed (termed slow transit constipation-STC), those who have a normal 
gut transit speed (termed normal transit constipation-NTC), and those who suffer 
from mechanical obstruction during defecation (termed obstructed defecation-OD) 
(1, 2).  
In practice, patients are not neatly defined by these groups as there is a substantial 
number of patients who can fulfil inclusion criteria for 2 of these groups. For the 
purpose of this chapter, I will therefore focus on the whole group of patients 
classified within CC for this study. 
Recent years have seen widespread acceptance that there are likely to be 
undiscovered pathological mechanisms playing a role in CC, and there is evidence 
of this emerging in academic journals. This ranges from understanding the role of 
“normal” neuromuscular bowel physiology in humans (3), to a focus of laboratory-
based animal research into the enteric nervous system and its role in the 
pathophysiology of CC (4). Histological reports of neural abnormalities in bowel 
sections of humans suffering from CC date back to 1977 when a case series of 4 
patients reported a possible developmental abnormality in the myenteric plexus 
(5). This is the poorly understood motor nerve supply (sympathetic and 
parasympathetic) of the intestinal circular and longitudinal muscles. Subsequent 
studies have reported further evidence of both neural abnormalities using standard 
and specialised tissue staining techniques (6-10), and of neuromuscular 
abnormalities in the bowel (11). Recently, leading academics in this field have 
published a classification system for histological findings of neuromuscular bowel 
pathology (12) and issued guidance on the specialist techniques pathologists should 
employ to identify them in affected patients (13). This is an attempt to standardise 
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the methods of tissue acquisition, pathological examination and reporting of these 
conditions across the world. This uniform scientific protocol and classification 
system will improve the production rate and quality of evidence of pathology in 
these “functional” gastrointestinal conditions. In future, researchers hope to be 
able to diagnose and ultimately treat specific pathological conditions that were 
once thought to be FGIDs. 
1.3 Classification of CC  
Doctors have struggled to understand and treat the patient with CC for many years 
now, and it was in 1990 that the term “functional constipation” was coined to 
describe a particular group of patients with similar symptoms in what was then the 
Rome I criteria. The latest incarnation of this is the Rome IV criteria; at the time of 
study design the Rome III criteria for FGIDs was used (14) and defined these patients 
according to the following criteria: 
Two or more of the following symptoms at least 25% of the time: 
 Straining at defecation  
 Lumpy or hard stools  
 Sensation of incomplete defecation 
 Sensation of anorectal obstruction/blockage 
 Manual manoeuvres to facilitate defecation 
 Less than 3 defecations per week 
To fulfil the criteria patients must also only rarely have loose stools unless laxative 
induced, and be consistent during the preceding 3 months with the onset of their 
symptoms at least 6 months prior to diagnosis.  
To clarify an important issue with the Rome criteria, there are also patients who 
suffer from similar CC but their predominant symptom is abdominal pain. These 
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patients are described as suffering from an irritable bowel syndrome (constipation 
predominant or IBS-C) within the Rome III criteria (14) and are defined as follows: 
Patients who suffer from recurrent abdominal pain or discomfort for at least 3 days 
each month in the last 3 months who have 2 or more of the following: 
 Improvement of pain with defecation 
 Onset of pain associated with change in frequency of stools 
 Onset of pain associated with change in form of stool 
They must also have lumpy or hard stools at least 25% of the time, and loose stools 
less than 25% of the time to fulfil the criteria. 
This causes confusion amongst clinicians, and is debated in both clinical and 
academic arenas; it is observed in practice that many patients fulfil both criteria 
simultaneously, and encounter the same medical investigations and treatments.  In 
2010 a prospective study reported 1100 adults attending primary care for self-
reported constipation, who together with 1700 age and gender matched controls 
completed a survey on study enrolment and again after 12 months (15). The 
authors reported that 90% of IBS-C patients also fulfilled FC, and 50% of FC patients 
also fulfilled IBS-C. The Durham constipation clinic (DCC) is a NHS tertiary centre 
whose prospective database has 90% of patients fulfilling criteria for FC, 50% 
fulfilling IBS-C, with 47% fulfilling both, 43% FC only, 3% IBS-C only, and 6% neither. 
However, these are patients suffering from symptoms severe enough to be referred 
to a tertiary centre for further investigation and treatment, all of whom would self-
report the main cause of their condition as chronic constipation. It is entirely 
plausible that the Rome III criteria does not adequately distinguish between what 
is likely to be a spectrum of similar symptoms caused by multiple but subtly 
different underlying pathologies. Its usefulness should therefore be questioned and 
its use in clinical studies should be to encompass both FC and IBS-C; consequently 
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patients in the TiLTS-cc trial (described in Chapter 5) are eligible if they fulfil FC but 
not excluded if they also fulfil IBS-C, and so termed as suffering from CC. 
1.4 Epidemiology of CC 
The epidemiological factors in chronic constipation have been well documented 
throughout international literature over the past 20 years. Clinicians and 
researchers throughout the world have finally grasped the scale of this problem, 
which is significant, and there are consistent findings which are giving new insights 
into the condition. 
1.4.1. Prevalence 
The prevalence of CC has been reported throughout the world at between 3.6% to 
almost 28%. Pre-1992 there was a paucity of data which led Lennard-Jones (St 
Mark’s Hospital, London) to highlight that this severe condition of young women 
had “remained largely unrecognised since the time of Arbuthnot Lane” (1909), and 
that “constipation is often regarded as a trivial symptom but for patients it was a 
major disability” (16). Post-1992 the problem was recognised internationally. There 
are over 100 papers to date and several systematic reviews and meta-analyses. The 
2004 North America review estimates the prevalence in a range of 1.9%-27.2%, 
with most between 12-19% of the North American population (17). A similar range 
was estimated in a 2008 review, with a mean value of 17.1% given for European 
prevalence and 15.3% for Oceania (18). The largest systematic review and meta-
analysis to date pooled a prevalence of 14% over 261,040 subjects from 41 
populations (19). These studies consistently demonstrate that CC is a common 
disorder affecting a considerable number of people across the world. The most 
striking finding, however, is the consistency in reporting a significantly higher 
proportion of affected females, with the female to male ratio always exceeding 
2.2:1, and becoming considerably higher when severity is taken into account. 
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The ongoing DCC database currently has data on 736 (88%) female and 101(12%) 
male, a F: M ratio of 7.3:1, a collective mean duration of symptoms of 19.53 years 
(range 0-76 years) (M=17.5, F=19.8), and a mean age at tertiary presentation of 
43.4 years (range 17-86 years) (M=51.7, F=42.2). 253 (30.23%) had onset of 
symptoms in childhood of which 122 (15%) were in infancy. This seems to suggest 
that females are more frequently affected by the severest form of the condition, 
and that most sufferers present or are referred for specialist investigation many 
years after onset, highlighting the truly chronic nature of the condition.  
Prevalence is also consistently reported as increasing with age (17, 20-22), 
socioeconomic deprivation (19, 23), psychological co-morbidity (24) and with a 
history of physical or sexual abuse (25). 
1.4.2. Burden of disease 
1.4.2.1. Quality of life 
Overall CC is recognised as common in Western societies and patients who suffer 
from this tend to be more commonly young and female, and report a significant 
deterioration in their quality of life (26). Their experiences are well documented in 
the literature and include “feelings of hopelessness” in the condition and 
“frustration” at perceived lack of clinician empathy or simply “not being taken 
seriously” (27). Several large studies have reported deterioration in health-related 
Quality of life (HRQoL) when measured using the short form-36 (SF-36). A Canadian 
study of 1149 subjects in 2002 demonstrated CC as a common and stable condition 
with significant impairment of HRQoL (28). A similar conclusion in a larger 
multinational study was reported in 2007, with the authors also noting that HRQoL 
impairment was greater in women than men and comparable across all countries 
involved. The cause of this is unknown but postulated to be either due to variation 
in underlying aetiology between the sexes or women being more likely to disclose 
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the severity of the disease and present to a healthcare provider for further 
investigation and treatment. The authors positioned the overall impairment as 
comparable in QoL impairment to well-known organic conditions such as chronic 
obstructive pulmonary disease, hypertension, diabetes, heart disease or 
depression (29).  
Survival 
There are conflicting data on morbidity and mortality in FGIDs, but the general 
consensus is that long-term survival is no different to the general population (30). 
Notable for our study participants is the recent suggestion that the FGID subgroup 
with chronic constipation may actually have a poorer survival when compared to 
FGIDs with other predominant symptoms (31). This may be due to the increased 
likelihood of surgical intervention in patients with chronic constipation, although 
incidence of surgical intervention was not considered by the authors and this 
warrants further investigation. 
1.4.2.2. The economic & health care burden 
A medical condition with global evidence of significant prevalence and chronicity 
on this scale undoubtedly causes strain in any healthcare system. The American 
Gastroenterological Association reported that almost 8 million primary care 
consultations in 2004 were attributable to constipation (1). In the NHS (in England) 
in 2011, 71 million pounds of laxatives were prescribed in the community, which 
accounted for 16.5% of the 429 million pounds of prescriptions for gastro-intestinal 
diseases (32). The economic and health care burden of constipation is further 
emphasised by the statistics for inpatient admissions, where more than 57,000 
patients were admitted to hospital in England in 2011 with primary discharge 
diagnosis of constipation, with over 42,000 presenting as emergencies, and an 
overall mean length of stay of 3.3 days (33). Sufferers of this disease who have a 
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significantly impaired HRQoL subsequently increase their health care utilisation 
(28); the condition therefore poses a challenge to any healthcare system (34) 
especially as the treatment costs increase with disease severity and bowel 
symptom exacerbations(35). 
 Psychological considerations in CC 
Most clinics who treat patients suffering from CC adopt a biopsychosocial model of 
treatment, recognising that these patients cannot be effectively treated solely with 
a medical or surgical therapy, and that there is a preponderance of psychological 
and social influences in their condition (27). Wainwright et al speculate that 
clinicians will view the social and psychological influences as less relevant and 
important if future treatments improve sufficiently to be considered as a cure for 
the condition, which would then be regarded as organic in aetiology (as opposed to 
functional). Researchers are far from this position and recognise that psychological 
distress could be involved in the pathogenesis of CC (36), that anxiety and 
depression are prevalent in this group (36) and it is widely accepted that the 
associated chronic pain can improve with a variety of psychological and behavioural 
treatments (37). Psychotherapy, in particular seems to be an effective adjunct to 
medical treatment in some patients (38), and this may be due to the widely 
recognised association of physical and sexual abuse amongst sufferers (25, 36, 38). 
My experience, and that of the Durham Constipation Clinic, suggests patients tend 
towards being a highly motivated group of individuals who are seeking a resolution 
to their condition and therefore demonstrate a willingness to participate in clinical 
trials (evidenced by high recruitment rates at DCC). There is a knowledge gap 
surrounding their motivations for this alongside anecdotal evidence of a 
heightened placebo response to therapies which this study will seek to address 
using both qualitative and quantitative methods. 
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1.5 Summary of treatments 
1.5.1. Medical  
When patients first attend their GP with the symptoms of constipation they will 
usually receive dietary advice (increase dietary fibre and adequate hydration), and 
be prescribed simple first line laxatives (sometimes fibre supplements). If other 
symptoms or signs on examination are suggestive of a secondary cause for their 
constipation they may be investigated for underlying pathology. Table 1 below 
outlines the usual first line laxatives GPs will prescribe from using the British 
National Formulary (2019). 
 
Table 1- First line laxatives, compiled from BNF 77 (March-September 2019) 
Type of laxative Generic name (brand name) Mechanism of action 
1.Bulk-forming 
laxatives 
Ispaghula husk (fybogel®) 
Methylcellulose (celevac®) 
Sterculia (Normacol®) 
Stimulates peristalsis by 
increasing faecal mass 
2.Faecal 
softeners 
Arachis oil enemas (non-proprietary) 
Paraffin liquid (BP) 
Lubricant and stool 
softening properties 
3.Osmotic 
laxatives 
Lactulose (lactugal®, Laevolac®) 
Macrogols (Movicol®, Laxido®, 
Molaxole®) 
Magnesium salts (various) 
Phosphates-rectal (various) 
Sodium citrate (Micolette®, 
Micralax®) 
Increase water content of 
colon through either 
osmosis (from serum) or 
decreasing absorption. 
4.Stimulant 
laxatives 
Bisacodyl (Dulcolax®) 
Sodium Picosulphate (Dulcolax®Pico) 
Anthraquinones 
(Sennokot®Manevac®) 
Docusate Sodium (Dioctyl®, Docusol®) 
Intestinal motility 
increased 
5.Bowel 
cleansing 
preparations 
Macrogols (Klean-prep®, Moviprep®) 
Magnesium citrate (Citramag®) 
Phosphates-oral (OsmoPrep®, Fleet 
Phospho-soda®) 
Sodium Picosulphate with magnesium 
citrate (Picolax®, Citrafleet®) 
Combinations of 3&4 
above with 5 to prepare 
bowel for surgery or 
endoscopy. 
Not licensed for chronic 
constipation but used by 
GP’s and specialists in 
practice. 
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Patients will usually receive combinations of bulk-forming laxatives and osmotic 
laxatives initially, progressing onto combinations of osmotic and stimulant laxatives 
if their symptoms persist. The majority of patients will respond to these simple 
dietary and laxative treatments; those truly suffering from chronic constipation will 
be laxative refractory and may even use bowel cleansing preparations on a regular 
basis (once to twice weekly). These patients are usually referred to specialist 
secondary/tertiary care after failing 2-3 combinations of treatment with their GPs. 
All patients referred to specialist care for diet and laxative refractory constipation 
are assessed according to the Rome III criteria, and a detailed medical history and 
examination obtained to rule out pathological causes. Patients are then classified 
as truly functional in aetiology and appropriate investigations are requested to 
demonstrate if slow colonic transit, disorders of defecation or both are 
contributory. Initially patients will be prescribed a course of a selective serotonin 
5HT4 receptor agonist (Prucalopride, Resolor®), which is NICE approved (2010) in 
patients with evidence of chronicity. This has prokinetic properties that decrease 
colonic transit time, and has recently been studied in phase 3 trials which have 
concluded that it is safe and effective in CC (39-42). 5 years ago 2 intestinal 
secretagogues (Linaclotide and Lubiprostone) became FDA approved for CC; these 
primarily act by increasing intestinal chloride content through mucosal secretion, 
which results in water being drawn into the lumen (43). These were recently 
licensed in the UK although most clinicians in primary care will not commence 
treatment with these and they are primarily prescribed in secondary care. A meta-
analysis of placebo controlled studies of osmotic laxatives, stimulant laxatives, 
Prucalopride, Linaclotide and Lubiprostone for CC has demonstrated superior 
response in the treatment groups (44), which firmly underlines their position as first 
and second line treatments in CC. 
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1.5.2. Minimally Invasive Therapies 
Patients who fail to respond to these first and second line medical treatments 
may be treated with biofeedback or trans-anal irrigation. 
1.5.2.1. Biofeedback 
Patients are selected for treatment with biofeedback by physiological testing which 
seems to indicate “anismus”—a paradoxical contraction of the anal sphincters on 
attempted defecation. It is performed by physiotherapists and nurses throughout 
the NHS, with several techniques employed to help them relax these muscles at the 
appropriate physiological part of defecation. The methods employed vary from a 
practitioner using a digit to physically feel when the patient is contracting the 
muscles incorrectly during a simulated strain, or using a catheter and balloon which 
measure manometric pressures which are “fed back” to the patient via either 
auditory or visual stimulus. In the DCC an electromyography (EMG) tracing is used 
to visually feedback when patients are contracting the muscles during a simulated 
strain, where they try to expel a rectal balloon. This has been likened, to the sort of 
muscle training and co-ordination learned when playing a video game, which itself 
is a form of visual biofeedback, or pelvic floor muscle re-training exercises for 
urinary incontinence, which are also efficient and effective. 
The evidence for this treatment is subject to debate amongst experts, with reviews 
demonstrating evidence of efficacy in defecation disorders (43, 45), whilst also 
admitting that the controls used in these studies are very different to the treatment 
(consequently un-blinded) and variable (either standard laxatives, or muscle 
relaxants). It is difficult to design a RCT with a suitable control group for 
biofeedback, and future studies should aim to achieve this in order to provide high 
quality evidence that can be subject to consistent eligibility criteria in meta-
analysis. In the 4 trials that have attempted a control group to date, 2 were positive 
for biofeedback (46, 47), whilst 2 reported an improvement against baseline 
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symptoms but not between treatment and control groups (48, 49). Biofeedback 
currently seems to have a place in the treatment of defecatory disorders in CC, 
although more conclusive evidence is required in the longer term. 
1.5.2.2. Trans-anal Irrigation (TAI) 
Colonic or trans-anal irrigation has been performed as a medical treatment for 
Millennia, TAI is simply the latest incarnation, although arguably the only form with 
any substantial evidence. Little is known about the extent or exact mechanism of 
action, but it is thought that irrigation helps to effectively mechanically empty the 
descending colon and bowel distally, which has been demonstrated 
scintigraphically (50). The first long term follow-up published in 2004 looked at a 
consecutive series of 267 patients with either faecal incontinence (FI) or obstructed 
defecation (OD) who had failed conventional medical treatment and biofeedback, 
reporting an effective response to treatment of 65% in the OD group at 80 months 
(51). More recently a systematic review reported successful treatment in the CC 
group at 117/259 reported cases or 45% of the treatment population (52). The 
authors proposed that the treatment should be administered after patients had 
failed medical therapy and before considering irreversible surgery. The Durham 
experience replicates these results, where a retrospective study demonstrated TAI 
as an effective second line treatment for a large proportion of patients (48%) who 
continued treatment for mean duration of therapy of 75 weeks (53). The procedure 
has been extensively reported as simple to perform and relatively safe (54), with 
the estimated risk of the most serious complication (TAI induced colonic 
perforation) being less than 0.002% per irrigation.  
1.5.3. Surgical 
Only the most severely affected and treatment refractory individuals suffering from 
CC deteriorate further to be considered suitable for attempted treatment through 
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neuromodulation. Evidence about rates of surgical interventions is currently 
unavailable but prevalence is thought to be low. 
1.5.3.1. Neuro-modulation (SNS) 
Sacral nerve stimulation (SNS) is the original form of abdominal neuromodulation 
that has proven to be a successful treatment for patients suffering from non-
obstructive urinary retention, urinary urge incontinence and faecal incontinence, 
and is currently approved for use in these conditions in the NHS (12, 55, 56). It is 
not FDA approved for use in the US (1), or NICE approved in the UK for the 
treatment of CC. Recently European centres have published several case series (57, 
58), pilot studies (59, 60) and a clinical trial suggesting SNS may benefit a proportion 
of CC sufferers (61). The procedure involves a testing phase which attempts to 
predict if a sufferer will demonstrate a long-term response to the permanently 
implanted pulse generator (IPG), and this is far less accurate in CC sufferers with a 
predictive success of just over 50% (62). Patients require a primary procedure to 
implant a testing lead under anaesthetic which is externalised to a temporary 
testing stimulator which they can adjust, and typically sensory stimulation is given 
for 2 weeks. If bowel diaries and validated questionnaire scores (PAC-SYM and PAC-
QOL) demonstrate a response to stimulation then patients are offered a permanent 
IPG in a secondary procedure. The poor performance of the test in CC may be due 
to many various factors. These may include a potentially enhanced placebo effect 
in CC sufferers, the short duration of the test (2 weeks) due to limitations in the 
temporary testing lead, and biases in the clinical interpretation of testing results. 
The test itself is a cumbersome experience for patients and there is no evidence of 
patient acceptability, satisfaction or experience in the literature. However, the 
Durham experience (see below) suggests a strong safety profile and the potential 
for SNS to avoid high-risk, high-cost, low efficacy surgical interventions outlined 
below. These issues will be addressed in detail in Chapter 2 and provide a rationale 
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for a trial to examine a novel testing method for SNS which forms the main part of 
this thesis (Chapters 5 and 6). 
1.5.3.2. Percutaneous tibial nerve stimulation (PTNS) 
PTNS is a new form of neuromodulation that is currently being investigated for 
similar applications as SNS. It involves inserting a small needle like electrode under 
the skin near the tibial nerve at the ankle, and patients receive weekly exposures 
of stimulation lasting 30-45 minutes in an outpatient clinic. It is considered to be a 
serious rival to SNS in the treatment of faecal incontinence (FI), and studies are 
underway to compare the procedures in this condition. One small pilot study to 
date has provided empirical evidence of treatment response in CC (63), with 18 
patients demonstrating improvement in Wexner score, PAC QOL and stool 
frequency. The Confident study group reported, however that there was not effect 
over sham stimulation for FI (64), and therefore PTNS needs a well-designed longer 
term multicentre trial in order to provide any evidence for use in CC. 
1.5.3.3. Stomas/ACE procedure 
Patients who fail to respond to neuromodulation, and who also have severely 
affected quality of life are offered surgical irrigation through formation of an 
appendicostomy (ACE), or a defunctioning stoma. This is anecdotally reported as 
between 5-10% of severely affected individuals who progress to more invasive 
surgical treatments, with a large proportion of patients choosing to live with the 
burden of disease. There is no formal evidence in the literature of the true 
proportions and these may therefore be higher. 
Antegrade Continence Enema (ACE)  
This procedure was first described by Malone in the 1980’s and involves use of the 
appendix using the Mitrofanoff principle: to create a fistula for the passage of either 
urine (when the fistula is to bladder) or enema (appendicostomy-the fistula is to 
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the bowel), with a continent valve fashioned (65). Through this patients with CC can 
perform antegrade colonic irrigation to relive CC. The literature predominantly 
reports efficacy in children with those suffering from CC showing an overall 
improvement in well-being, albeit with significant stomal complications (stenosis, 
leak and pain) (66). There is little evidence in adults with CC, and these are limited 
to a few case series reporting a general improvement. These typically report an 
improvement in defecation time and quality of life (67), but both adults and 
children  require revision surgery in a significant proportion of around 17% (68), 
usually for stenosis, hernia or infection. This seems to be the most common 
complication of ACE, and can be either as a self-limiting superficial wound infection, 
or a deeper abscess, with either occurring in up to 45% of all patients (69). Overall 
it appears that using an appendicostomy is still relatively safe and does give a 
proportion of patients’ symptomatic relief without major sequelae, and typically 
the fistula and irrigation can be managed for up to 5 years, after which the fistula 
tends to fibrose and stricture, and can no longer be used. This justifies 
consideration of ACE irrigation prior to major surgery or stomas. 
Defunctioning loop Ileostomy 
A loop ileostomy, sited on the right of the abdomen, can be either an acceptable 
treatment for CC (for patients who tolerate a long-term stoma), or a way to trial if 
a total colectomy and ileorectal anastomosis will actually improve their symptoms.  
It has the advantage of being completely reversible if symptoms remain unchanged 
and/or the patient cannot cope with or manage the stoma. Ileostomies have a high 
rate of complications in general (29%), mostly due to infection, hernia or retraction 
requiring surgical revision, and to minimise these a loop ileostomy should be 
performed via a trephine rather than a laparotomy (70). If the stoma seems to 
considerably improve symptoms and function, then the patient may benefit from 
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either continuing or proceeding to a subtotal colectomy with ileorectal 
anastomosis. 
Colostomy 
The use of a formal colostomy, which is typically sited on the left of the abdomen 
and formed from an end of descending colon after sigmoid colectomy (Hartmann’s 
procedure), has only been reported in a small cohort of children with severe CC. 
This seems to be effective for up to 3 years with high patient satisfaction and low 
morbidity (71). There is no evidence of this in adults other than a single case report 
(72), and this is not recognised by experts as an accepted form of treatment. 
Between 2002-2008 endoscopically assisted percutaneous colostomy (PEC-to 
create a conduit for distal colonic irrigation) was attempted in adults, but the 
associated morbidity was unacceptably high (73). Colostomies and PECs are 
therefore not now considered to be a relevant treatment option. 
1.5.3.4. Surgery for obstructed defecation 
When symptoms of obstructive defecation (OD) are demonstrated through 
physiological testing and imaging to be primarily due to an anatomical change in 
the rectum, then procedures to repair these changes may benefit. These changes 
can be due to a forward pouching of the rectum (rectocele) which is common in 
women, or to a type of internal prolapse in the rectum (IRP) termed an 
intussusception. The stapled trans-anal resection of the rectum (STARR procedure) 
is one option but has failed to gain credence in either America or Europe due to 
concerns regarding its safety and efficacy (74, 75). Laparoscopic ventral mesh 
rectopexy (LVMR) is a laparoscopic procedure and a more popular option amongst 
UK surgeons who report it as a safe and effective procedure for both external rectal 
prolapse (ERP) and IRP causing OD (76, 77). This evidence is methodologically weak, 
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however as there are no prospective controlled trials, and surgeons have selected 
patients before assessing and reporting their own results. 
1.5.3.5. Colonic resections  
Patients who have failed management of their CC with either SNS or ACE irrigation 
may be considered for major surgery if their symptoms are severe and impacting 
on their quality of life. All experts agree that this decision is not to be taken likely 
as there are considerable risks over benefit. There is evidence that this should only 
be considered in patients with physiologically demonstrable slow transit 
constipation (78, 79). 
The first surgical treatment of severe constipation by total colectomy and ileo-
rectal anastomosis was described more than 100 years ago (80) , and is now 
considered a last resort in extremely treatment refractory patients who are 
suffering, due to the associated high morbidity and even mortality of this operation 
(7, 81). Experience in Australia and the UK during the 1990s was similar, with 
studies reporting an improvement in patient symptoms, at the cost of unacceptably 
high morbidity and even mortality (82, 83). Most recently and surprisingly critical 
of all, was a 2009 study where the authors concluded that the morbidity and 
mortality rates after colectomy were inadmissibly high, and with such poor 
functional results that they would no longer recommend colectomy for slow transit 
constipation (84). Whilst there is evidence that laparoscopic colectomy for CC has 
an enhanced recovery time, there is no evidence that this reduces the post-
operative morbidity and mortality compared to open surgery (85, 86). 
Colectomy for severe constipation has been performed and evaluated for over 100 
years now with little improvement in the outcomes. Patients appear to benefit from 
relief of their constipation in a range of between 70-90% depending on how 
carefully they are selected for surgery, but with high rates of morbidity and an 
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associated mortality of between 3-5%. Overall most surgical procedures do not 
appear to be particularly effective in treating CC, and the evidence to date would 
suggest that more conservative and minimally invasive treatments would be safer. 
1.6 Algorithms of treatment 
International experts in neurogastroenterology have been attempting to construct 
treatment algorithms in recent years for chronic constipation. There are specific 
differences in opinion regarding minimally invasive techniques and surgery, and 
the issue is further complicated by the licensing of secretagogues in the US which 
have not been licensed in Europe until recently, and the licensing of 5HT4 agonists 
in Europe earlier than in the US. 
The American perspective 
The American Gastroenterological Association (AGA) issued a technical review in 
2013 (1) that separates treatments into primary care and specialist use. In primary 
care they emphasise investigations to exclude organic pathology and other 
reversible causes of constipation and the use and safety of dietary changes and 
osmotic/stimulant laxatives in CC. Patients failing to respond to these simple 
treatments are recommended for specialist referral and further investigation, 
ultimately with classification into 3 groups: obstructed defecation disorders (OD), 
slow transit constipation (STC), and normal transit constipation (NTC), with 
acceptance that there is overlap between them. Biofeedback is recommended for 
obstructed defecation initially, and when structural anatomical changes such as 
internal rectal prolapse are thought to be contributory; but the surgical repair of 
internal prolapse is not recommended by the AGA. Surgical repair of rectocele is 
recommended when physiological testing implies it is contributory to the 
obstructed defecation, but the method of rectopexy is not indicated. Patients with 
slow and normal transit constipation are recommended to have failed several 
combinations of stimulant and osmotic laxatives before proceeding to 
38 
 
secretagogue treatment with Linaclotide or Lubiprostone. Prucalopride is 
recognised as having good evidence of efficacy in slow transit constipation, but FDA 
approved for CC at the time of this technical guidance. No mention is made of 
irrigation as a possible short or long term treatment. Psychological support is 
recommended when patients are refractory to medical treatments and surgery is 
not indicated. Surgery is recommended principally to treat either obstructive 
defecation or slow transit constipation, but ACE irrigation, SNS, and STARR 
procedures are not recommended due to a lack of empirical evidence. A heavy 
emphasis is placed on carefully selecting patients for Arbuthnot Lane’s procedure, 
with only those who have true colonic inertia and normal upper gastrointestinal 
motility, without evidence of obstructive defecation, and who respond to a de-
functioning ileostomy being considered suitable for this procedure. This heavy 
emphasis on colectomy is likely driven by the private healthcare system in the US. 
 
The European perspective 
A collaboration of European experts published a treatment algorithm in March 
2011 (87), which classified CC into the same 3 groups with recognition of overlap 
between them. Their primary care recommendations again emphasised the use of 
dietary changes, osmotic/stimulant laxatives whilst excluding secondary causes or 
serious organic pathology, but also included the use of the prokinetic drug 
Prucalopride after combinations of laxatives have failed and prior to specialist 
referral. Patients are considered refractory only after failing an adequate trial of 
this drug, and specialists then perform full physiological testing. Biofeedback is 
again recommended for obstructed defecation, but no mention is made of further 
surgical therapies for either obstructed defecation or slow transit constipation, 
other than stating that surgery should be focussed on particular disorders that 
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require anatomical correction, and only “as a last resort”. SNS does not feature in 
this guidance primarily due to the lack of high quality trials at this time. 
The Durham perspective 
The current practice in Durham encompasses these international opinions with a 
heavy emphasis on a logical progression of treatments in the refractory patients 
with CC from minimally invasive procedures to formal surgery. SNS is tentatively 
placed on the algorithm after failure of irrigation therapies and before intra-
abdominal surgery. This is based on the safety profile of SNS in comparison with 
these procedures, although its efficacy and cost-effectiveness remains to be 
established. Psychotherapy is indicated wherever treatment refractory individuals 
seem to report psychological issues that may be contributory or deleterious to their 
condition. In parallel to this patients are offered holistic therapy in the form of 
relaxation, mindfulness and neuro-linguistic programming (NLP). An example of the 
Durham algorithm that patients experience in their pathway to SNS on this study is 
outlined below. If a patient fails a treatment or has no indication for a treatment 
they descend in the algorithm. Experience of using this pathway suggests that SNS 
presents an acceptable, safe alternative to high-risk, high-cost surgery. Current 
testing regimes, however are inadequate at effectively selecting those patients 
most likely to benefit from SNS. There is an urgent need to understand more about 
the place of SNS within the treatment pathway for this challenging condition.  
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1.7 Aims and scope of the thesis studies 
Chronic constipation is a common disorder worldwide, mostly severely affecting 
women, with a significant impact on patient quality of life and on healthcare 
systems. There is good evidence of a particularly severe form of chronic 
constipation that is refractory to simple first line primary care treatments and which 
therefore requires specialist intervention. Patients who are refractory to new 
medical treatments may benefit from minimally invasive measures such as sacral 
nerve stimulation, biofeedback and trans-anal irrigation in order to avoid 
progressing to risky, costly surgical interventions with little effect. Biofeedback and 
irrigation are currently under investigation internationally but sacral nerve 
stimulation (SNS) has no firm evidence to substantiate a position on the treatment 
algorithm between minimally invasive procedures and intra-abdominal surgery, 
although this is the logical position for SNS when considering complication profiles. 
The main obstacle for SNS to evolve as an accepted treatment in chronic 
constipation, and in gaining support from regulatory authorities, lies in the ability 
of the SNS test to accurately predict long-term response to treatment. It also needs 
to be confirmed as cost-effective in any healthcare system it is used, and to have a 
reasonable level of patient tolerance and acceptability in treating their condition. 
For a small proportion of patients with treatment refractory chronic constipation, 
SNS has the potential to prevent progression to these expensive, high risk, and low 
efficacy surgical procedures, but little is known about how to effectively select the 
patients most likely to benefit. SNS is thus worthy of further investigation, and so 
this thesis will explore the utility of SNS as a treatment by focussing on a novel idea 
for a new percutaneous nerve evaluation (PNE) test. This test is termed an 
enhanced PNE, and may be able to adequately discriminate between long term 
responders and non-responders to treatment. This thesis will also explore the 
patient experience of the disease, treatment and perceptions of treatment effect. 
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I will explain the current research knowledge on SNS for chronic constipation in 
Chapters 2 and 3 highlighting the knowledge gaps both within quantitative and 
qualitative studies after performing a systematic review of the literature. This will 
be used to synthesise the relevant aims and objectives of the thesis (Chapter 4), 
and inform the design of quantitative and qualitative research studies, the 
methodology of which will be presented and discussed in Chapter 5. Chapters 6 and 
7 will present the findings of these studies and discuss their implications within the 
chapters independently. Chapter 8 will then summarise the key knowledge gained 
from each chapter and discuss the key study findings in a fusion of the two research 
strands to synthesise a formal conclusion to the overall thesis. 
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Chapter 2 Sacral Nerve Stimulation (SNS) 
2.  Introduction  
This chapter aims to critically analyse the evidence about the effectiveness of SNS 
and current clinical practice to justify the aims and objectives of the TiLTS-cc study 
and explain the research questions that provoked the study design. I will explain 
the background to the interventional treatment under investigation (SNS) and its 
evolution into a clinical therapy for chronic constipation (CC), the methods used to 
perform a systematic review of the quantitative literature in search of high quality 
evidence of the efficacy and safety of SNS for CC. I will present and discuss the 
results of this search and explain how this was used to synthesise the aims and 
objectives of the TiLTS-cc study. This chapter will therefore clearly emphasise the 
relevant knowledge being sought by this research before moving onto the review 
of the qualitative literature in Chapter 3, a summary of the combined aims and 
objectives of the thesis studies (TiLTS-cc and Essence) in Chapter 4 and a description 
of the methodology used to collect the required data in Chapter 5. 
2.1 Overview 
The conditions commonly treated with SNS in a number of countries include faecal 
incontinence and urinary dysfunction; in the UK, the National Institute for Health 
and Care Excellence (NICE) has approved SNS for use in these conditions (88-90). 
Clinicians consider SNS for patients suffering from chronic constipation (CC) who 
have failed all standard medical treatments (laxatives, pro-kinetics and 
secretagogues), lifestyle changes (diet and exercise), behavioural treatments 
(biofeedback, neuro-linguistic reprogramming, cognitive behavioural therapy), and 
minimally invasive interventions such as retrograde bowel irrigation. SNS is an 
unproven surgical intervention for CC with potential to benefit a small proportion 
of patients in the long-term. Clinicians across the UK currently consider it an 
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acceptable low-risk therapy positioned on the treatment algorithm before more 
invasive and potentially dangerous treatments such as abdominal surgery. 
2.1.1. History of SNS for CC 
SNS began with the first permanent implant procedure performed in 1981 for 
bladder dysfunction (91), and since became established as a treatment for urge 
incontinence and non-obstructive urinary retention. In the subsequent years 
clinician’s observations of this group of patients seemed to suggest a concurrent 
improvement in bowel functions particularly constipation (92, 93) following which 
SNS became increasingly investigated and used clinically as a possible alternative 
therapy to invasive surgery for the treatment of CC (4, 60, 94, 95). Local experience 
of its use in Durham concurred with the opinion that it had the potential to help a 
minority of these patients (62). Several small prospective but uncontrolled studies 
claimed to observe an effect of SNS for constipation, albeit with a lack of data on 
patient characterization (94-97). In 2007, a Cochrane review concluded that the 
evidence of effect for CC was very limited, the standard temporary test could not 
predict long-term response and that high quality RCTs were required (98). In 2010, 
research interest in SNS for CC was further popularised by a prospective open label 
cohort study (99) that demonstrated a successful standard temporary SNS trial in 
45 (66%) out of 62 patients with severe refractory constipation. Following 
permanent stimulation in these responders there were improvements in 
constipation scores, QOL, symptom severity and transit times at a median follow-
up of 12 months. Other uncontrolled prospective case series using standard 
temporary SNS peripheral nerve evaluation (PNE) were less positive (60), but all of 
these studies seemed to suggest that SNS was effective in a sub-group of patients 
with CC, but that the standard two week PNE stimulation was a poor predictor of 
the patients long-term response to treatment.   
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2.1.2. SNS testing technique and implantation procedure. 
SNS involves the use of mild electrical pulses to stimulate the sacral nerves located 
in the lower back. Electrodes are placed next to a sacral nerve, usually S3 as 
standard, by inserting the electrode leads into the corresponding foramen of the 
sacrum.  This is performed as a day-case procedure with the patient under local 
anaesthetic or a short general anaesthetic (depending on the surgeon’s standard 
practice). Adequate electrode placement is confirmed using pulsed fluoroscopy and 
by obtaining the appropriate low voltage anal motor responses.  The electrodes are 
inserted subcutaneously and are subsequently attached, during permanent 
implantation, to an implantable pulse generator (IPG) sited in the ipsilateral 
buttock. SNS is minimally invasive, fully reversible, and does not preclude further 
treatment, but the expense of IPG insertion (NHS tariff is currently £12,745) means 
that a high long term failure rate would make it economically questionable.  A 
preliminary test stimulation phase (PNE) is therefore conducted to try and predict 
responders. Patients are currently selected for IPG through a two-week PNE using 
a unipolar temporary plain electrode with an externally attached pulse generator. 
Using this method, only about 40% of patients receive long term benefit from SNS 
(100), threatening the viability of NHS provision. Failure may be due to a short term 
placebo response or a variation in electrode position at permanent lead 
implantation.  
2.1.3. Mechanism of action  
The mechanism by which SNS modulates bladder and bowel dysfunction is at best 
poorly understood. Early research assumed an efferent modulation of the pelvic 
floor muscles, sphincters and bladder. Recent evidence in physiology research 
seems to suggest an afferent modulation of somatic and visceral nerves suggesting 
a more complex mechanism of action that may possibly involve cerebral cortex 
modulation (101). Further evidence for this afferent mechanism of rectal 
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neuromodulation has also been observed in a prospective randomised controlled 
trial of SNS (102). Physiology studies in FI sufferers have demonstrated increased 
retrograde propagating colonic sequences during active SNS versus sham SNS (103), 
although another study contradicted this by demonstrating pan-colonic ante-grade 
propagating pressure waves in response to active SNS compared to basal activity 
(104). The same group demonstrated that sensory SNS caused more ante-grade 
colonic propagating pressure waves than sub-sensory SNS (105). As the exact 
mechanism is unknown, settings of pulse width, frequency and voltage for SNS have 
been largely guided by trial and error over the years. Increasing frequency settings 
has reportedly improved outcomes for FI sufferers (106), although this could not 
be repeated in a RCT for CC sufferers (107), suggesting different mechanisms of 
neuromodulation or even hinting at no mechanism in the CC group.  
2.2 Cochrane reviews 
To date there have been several Cochrane reviews of SNS in FI and CC. Due to a lack 
of trials with robust methodology the authors of these reviews have concluded that 
SNS may help a proportion of FI sufferers(98), but no effect had been demonstrated 
to date for CC(108). They go on to urge further high quality trials to investigate the 
value of SNS further. The latest review was in 2015 and requires updating as several 
higher quality studies have investigating the efficacy of SNS for CC have since been 
published. 
2.3 Systematic literature review of SNS trials in CC 
2.3.1. Aims 
The main aim of this systematic literature review was to methodically collect, 
analyse, critically interpret, summarise and present the published high quality 
clinical evidence for SNS as a treatment for CC, and the long-term predictive ability 
of the standard tests used in these studies, along with adverse event (AE) reporting. 
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The aim was to synthesise high quality evidence of effect, predictive ability of 
testing, and safety profile within the treated cohort of patients suffering from CC. 
2.3.2. Methodology used in the systematic review 
A review of all available peer-reviewed articles published in indexed scientific 
journals on SNS was conducted according to the methodology described below. The 
Oxford centre for evidence based medicine (OCEBM) (109) levels were used to 
define high quality evidence, of which the target was level 1 and 2 evidence of 
efficacy and safety for SNS treatment of CC. Evidence of OCEBM levels 3 and 4 were 
also collected and reported, but not planned to be included in meta-analysis of 
efficacy due to the inherent low quality methodologies used for data collection 
within these studies. Risk of bias assessments were made using the appropriate 
Cochrane risk of bias assessment tools (110, 111). 
2.3.2.1. Search strategy  
The search strategy of bibliographic databases (example in Appendix 1) was 
designed to specifically find high quality clinical studies assessing the effectiveness 
and safety profile of SNS testing and IPG treatment for chronic constipation (CC), 
where “chronic” can also be described as a functional or idiopathic aetiology. 
Online systematic searches were carried out on the following electronic databases 
in March 2014 and repeated in February 2019: AHMED, EMBASE, HMIC, MEDLINE, 
BNI, CINAHL, COCHRANE, OVID, and Web of science ™ Core Collection (Thomson 
Reuters™). The search utilised Boolean logic operators using truncated search 
topics which were standardised and consistent in each database search. The 
searches were restricted to journal articles and English language publications only. 
All studies involving animals and children were removed at screening.  
2.3.2.2. Inclusion Criteria 
The titles and abstracts of all studies revealed through the database searches were 
vetted and requested as full documents if they appeared to be eligible. These were 
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then further screened for eligibility and excluded as appropriate. The inclusion 
criteria for study data extraction and analysis were strictly adhered to and all 
studies fulfilling the following criteria were selected for further review: 
Types of studies- one of the following 
 Prospective randomised controlled/clinical trials 
 Prospective case controlled studies 
 Prospective cohort studies 
 prospective case series  
 Studies written in English 
 Patient demographics-all of the following 
 Subjects > 18 years of age, male or female. 
 Subjects suffering from chronic, functional or idiopathic constipation; i.e. an 
unknown aetiology of CC. 
 Subjects receiving SNS as an interventional treatment for CC 
2.3.2.3. Exclusion criteria 
Studies selected for further review were assessed and excluded from data 
extraction and analysis if they fulfilled any of the following criteria: 
 Studies not fulfilling all of the inclusion criteria 
 Retrospective studies 
 Studies with an unclear/contradictory study design 
 Studies without baseline temporary SNS testing data 
 Studies with <10 patients 
 Systematic reviews of SNS for CC 
 Prospective RCTs of SNS with no reported ethical approval 
 Prospective RCTs of SNS with no WHO ICT registration  
 Studies focussed on subjects (male or female) who are paediatric or adolescent  
(<18 years of age) 
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 Studies where subjects concurrently suffered from other symptoms such as  
faecal incontinence or  urinary dysfunction 
 Studies with evidence for aetiology of constipation (i.e. secondary, not 
idiopathic, including obstructed defecation and neurogenic causes) 
 Studies where patients received any other form of nerve stimulation before, or 
during the study; for example spinal cord stimulation, percutaneous tibial nerve 
stimulation (PTNS), percutaneous sacral nerve stimulation (pSNS). 
Studies shortlisted for further review after fulfilling the inclusion and exclusion 
criteria were assessed against the inclusion criteria by both KE and HC 
independently in order to maintain consistency and prevent selection bias. The 
reference lists of shortlisted studies were used to try and identify further studies 
that may have been eligible for inclusion. Potentially eligible studies were also 
assessed against the inclusion criteria. 
2.3.2.4. Data extraction and synthesis 
Prospective, double-blinded, randomised sham-controlled trials were considered 
the highest quality evidence of the efficacy of SNS for CC and were planned for 
meta-analysis if they had similar outcome measures and homogeneity allowed for 
a pooled analysis with fixed effects methods. Study quality was assessed using the 
Cochrane handbook to determine the individual study risk of bias in each 
proscribed domain (112). If the studies demonstrated at least moderate 
heterogeneity through an I2 test, a random effects meta-analysis of study 
proportions was performed for testing response, long-term response to treatment, 
and safety profile. The Cochrane handbook (112) definition of heterogeneity was 
used for this classification, where moderate heterogeneity is considered when 
I2=30-60%, substantial when I2= 50-90%, and considerable when I2= 75-100%, 
where a Chi-squared test has also provided evidence of a significant difference 
between the groups. The Cochrane handbook specifically states that meta-analysis 
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of crossover studies is complex and this relates to the mixing of parallel group 
studies with crossover group studies in the meta-analysis of effect size for the 
interventional treatment. This is due to crossover studies having a smaller variance 
than parallel group studies and so they would be over-weighted in a mixed meta-
analysis. The solution usually involves using complex statistics utilising multilevel 
modelling through a Bayesian framework or generalised estimating equation (GEE) 
regression to manage the design differences. This complex analysis would be 
beyond the scope of this review, and as such crossover studies and parallel group 
studies would be reported and pooled separately using fixed or random effects 
meta-analysis as appropriate. Lower quality evidence in the form of prospective 
cohort studies, prospective case controlled studies, and prospective case series 
were assumed to be of an insufficient standard to allow pooled effect analysis and 
were planned for simple tabulation and description according to the reports within 
the studies. Study characteristics were extracted including the centre, study design 
and OCEBM level of evidence. Cochrane risk of bias assessments were made for 
each study using the appropriate risk of bias tool. Patient characteristics were 
extracted including demographics, aetiology of CC, use of Rome III criteria, and 
evidence of slow transit. Testing and implantation procedure specifics were 
extracted. Efficacy of SNS was considered to be a global improvement in the 
symptoms of CC; increased frequency of bowel movements, reduced abdominal 
pain, reduced bloating, reduced straining, reduced toileting time, and a reduced 
laxative use or dependence on other medications/treatments. Primary outcome 
measurements were extracted, but where the efficacy of SNS was assessed in 
studies by a variety of different primary outcome measures, I calculated and 
assigned studies a long-term response rate as a proportion of the original intention 
to treat (ITT) or implantation population (IP) that demonstrated efficacy. All 
adverse event safety data were extracted and reported through tabulation. A 
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random effects meta-analysis was planned for explantation rate of IPGs for all 
studies as a surrogate marker for long-term SNS treatment failure. I deemed that 
the weak methodologies of cohort studies and case series (a cohort study with no 
robust patient selection) had no effect on eventual explantation of the device, and 
so could be used to demonstrate a pooled failure rate for the treatment. Mixing the 
proportion of long term failures in crossover studies with long term failures in 
cohort studies in this way does not encounter the same methodological problems 
mentioned earlier as these are not treatment effects within the crossover period.  
2.3.3. Results and analysis 
The search strategy (Table 2) identified 266 records through combining the 
population and treatment search terms (Figure 2 PRISMA). 3 more records were 
identified by cross-referencing, giving a total of 269 records identified for screening. 
Of these 248 were excluded from full paper review during screening for 16 different 
reasons (Table 3). Twenty-one records were retrieved for a full paper eligibility 
review against the inclusion and exclusion criteria.  
 
Table 2 Search results of bibliographic databases for quantitative literature  
Search n  Search term (patient population) Results 
1 ALL=functional constipat* 4,098 
2 ALL=idiopathic constipat* 1,881 
3 ALL=chronic constipat* 5,989 
4 ALL=refractory constipat* 697 
5 ALL=slow transit constipat* 1,540 
6 1 OR 2 OR 3 OR 4 OR 5 
Target patient population 
10,344 
Search n Search term  (treatment) Results 
7 ALL= sacral nerve stimulat* 2,501 
8 ALL=percutaneous nerve evaluation 380 
9 ALL= sacral neuromodulat* 1,968 
10 ALL=SNS 15,254 
11 7 OR 8 OR 9 OR 10 
Target treatment  
18,599 
12 6 AND 11 
Target research studies for screening 
266 
ALL= All fields 
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Fourteen were excluded with reasons as follows: 
 One paper of a prospective cohort study was excluded due to participants 
suffering from a neurogenic cause of constipation (113)  
 Three papers were excluded for insufficient study participant numbers  
o 1 RCT had 2 participants (94) 
o 1 prospective case series had 4 participants (114) 
o 1 prospective case series had 8 participants (95) 
 Two papers were excluded for including patients suffering from obstructed 
defecation, one of which was a mechanistic RCT of SNS for evacuatory 
dysfunction (97, 102). 
 One paper of a RCT did not include temporary SNS testing data or patient 
selection data before IPG implantation, and had no ISRCTN registration, or 
any national or international registration that I could find (107). 
 Seven papers of retrospective cohort studies were excluded (115-120) 
 
Table 3 Records excluded in screening 248 
Screening exclusions n 
Studies of other diseases 72 
Studies of other interventions 38 
Discussion papers 32 
Studies in children 29 
Conference abstract/proceeding 16 
Systematic reviews 15 
Mechanistic physiology study 13 
Consensus statement / paper 8 
Book(s) or book section/chapter 7 
Guidelines 6 
Animal studies 3 
Cochrane systematic reviews 2 
Letters to the journal editor 2 
Individual case reports 2 
New SNS study protocol (ongoing trial) 1 
Postal survey study 1 
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Figure 2:  PRISMA Flow Diagram
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The remaining 7 articles representing 5 individual studies met the eligibility 
requirements after full paper review, 3 of which were articles relating to 2 RCTs 
(121-123). Of the remaining 4 articles, 3 described 2 prospective open label cohort 
studies (99, 124, 125), and one was a prospective case series (126), and they are 
included in a narrative synthesis.  
2.3.3.1. Quality of included study methodologies 
Study quality was assessed using the Cochrane collaboration risk of bias tool for 
randomised controlled trials (111),  to determine the individual study risk of bias in 
each proscribed domain for these studies (Tables 4&5). 3 papers relating to 2 
crossover RCTs were identified from the search (121-123). The Zerbib study was a 
high quality and well designed and conducted RCT that was judged to be of unclear 
risk of bias due to the primary outcome measure (Table 9). The primary outcome 
measure was achieved if a patient had an improvement in one of three well defined 
symptom responses to SNS, and in my opinion it is unclear if this has influenced the 
findings. Two of the articles were identified as belonging to the same study RCT 
cohort (Dinning /Patton) but from different phases of follow up; the first study the 
testing phase (121), and the second the follow up response phase to SNS treatment 
with an IPG (122). This study was deemed at high risk of bias towards the 
intervention due to investigators and participants being aware of one of the active 
intervention periods, although this is completely unavoidable for supra-sensory 
SNS. In both studies the specific Cochrane questions for crossover trials were 
satisfactory as the disease was chronic and stable, the interventional treatments 
were compared to a sham and the crossover order was randomised, and there was 
an adequate washout between arms with no evidence of a carry-over effect. 
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  Table 4 Cochrane risk of bias in RCTs, Zerbib et al 2017 
Bias Domain Source of bias Support for judgement Author’s 
Judgement 
 
Selection  
Random sequence 
generation 
Centralised remote randomisation in permuted blocks of 4 by 
study statistician only 
Low risk 
Allocation 
concealment 
Centralised remote randomisation in permuted blocks of 4 by 
study statistician only 
Low risk 
 
Performance  
Blinding of 
participants and 
personnel 
True sub-sensory SNS to participants, setting investigator did not 
collect outcome measures, all other investigators blinded 
 
Low risk 
Detection Blinding of outcome 
assessment 
Identical outcome assessments at end of each stimulation phase Low risk 
 
Attrition  
Incomplete outcome 
data 
No attrition by end of crossover period for POM, intention to 
treat for crossover and follow up period. 
 
Low risk 
Reporting  Selective reporting All pre-specified outcomes reported Low risk 
 
Other  
Anything else ideally 
pre-specified 
Cochrane specific questions for crossover trials: design was 
appropriate, treatments were randomised, no obvious carry over 
effect (washout period was adequate). 
The POM was a choice of 1 of 3 separate improvements in 
symptoms 
 
Unclear risk 
Overall 
Summary 
The concerns regarding unclear risk of bias in this study centre around the primary 
outcome measure, where one of three well defined symptom responses would imply 
overall treatment response.  
Unclear risk of 
Bias 
POM= Primary outcome measure, SNS= sacral nerve stimulation 
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Table 5 Cochrane risk of bias in RCTs, Dinning/Patton et al 2015/2017 
Bias Domain Source of bias Support for judgement Author’s 
Judgement 
 
Selection  
Random sequence 
generation 
randomisation performed off site by clinical trials unit, but 
further description not included 
Unclear risk 
Allocation 
concealment 
randomisation performed off site by clinical trials unit, but 
further description not included 
Unclear risk 
 
Performance  
Blinding of 
participants and 
personnel 
Participants blinded to sham and sub-sensory but not supra 
sensory SNS. One Investigator set allocation, all others were 
blinded 
 
Unclear risk 
 
 
Detection 
Blinding of outcome 
assessment 
Participants aware of supra-sensory SNS testing period, but 
unaware of sham or sub-sensory. Impossible to blind from 
supra-sensory, main comparator was sham and sub-sensory 
versus supra-sensory. 
 
 
High risk 
 
Attrition  
Incomplete outcome 
data 
Losses to follow up disclosed and intention to treat analysis 
performed. Loss to follow up long term presumed to be due to 
treatment failure 
 
Low risk 
Reporting  Selective reporting All pre-specified outcomes were reported Low risk 
 
Other  
Anything else ideally 
pre-specified 
Cochrane specific questions for crossover trials: design was 
appropriate, treatments randomised, and no obvious carry over 
effect (washout period was adequate) 
 
Low risk 
Overall 
Summary 
The main concerns of bias centre on participants and investigators being aware of one 
of the active interventional treatment phases, although this is unavoidable with supra-
sensory SNS. 
High risk of 
bias. 
POM= Primary outcome measure, SNS= sacral nerve stimulation 
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Table 6 Risk of bias in cohort/case series studies 
 Type of bias with risk classification per study 
 Pre-intervention Post-Intervention 
Study  
Confounding 
Selection 
Of 
participants 
Classification 
Of 
interventions 
Deviations 
from 
intervention 
Missing 
data 
Measurement 
of outcomes 
Reporting Overall 
Kamm, 
Maeda 
2010/17  
 
Low 
 
Low 
 
Low 
 
Low 
 
Moderate 
 
Serious 
 
Low 
Serious 
favours 
intervention 
Carriero 
2010 
 
Moderate 
 
Moderate 
 
Low 
 
Low 
 
Moderate 
 
Critical 
 
Moderate 
Critical 
favours 
intervention 
Graf  
2015 
 
Serious 
 
Low 
 
Low 
 
Critical 
 
Low 
 
Moderate 
 
Moderate 
Critical 
unpredictable 
direction 
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Of the 5 studies found 3 articles represented 2 prospective open label cohort 
studies (99, 124, 125) which were included in the narrative review. One of these 
cohort studies was described in two papers.  The first describing the initial testing 
and response to IPG (99), then longer term follow up to 60 months (124).  These 
cohort studies were defined as level 4 evidence under the OCEBM classification due 
to their lack of controls. The search found 1 prospective case series (126) which was 
included in the narrative review. This was defined as level 4 evidence under the 
OCEBM classification as a case series study. A risk of bias assessment was 
undertaken for these studies using the Cochrane risk of bias in non-randomised 
studies tool (ROBINS-I) (110) (Table 6). This revealed that the overall methodology 
employed in these 3 studies was of very poor quality, with one judged to be 
suffering from serious risk of bias, and two from a critical risk of bias. The 
Kamm/Maeda study was judged overall to be suffering from a serious risk of bias in 
favour of the intervention; moderate risk of bias for missing data due to the high 
loss to follow up, and serious risk of bias due to measurement of outcomes due to 
no intention to treat analysis, the variation in timing of primary outcome 
assessment from intervention, and the subjective definition of the primary 
outcome measure as judged by participants and investigators who were aware of 
the intervention. The Carriero study was judged to be suffering from a critical risk 
of bias in favour of the intervention due to a moderate risk of bias from confounding 
and selection factors due to the MMPI-2 questionnaire used for SNS testing 
selection and including patients with outlet obstruction, and a critical risk of bias in 
measurement bias due to the subjective nature of test response, and no longer 
term primary outcome measure with participants and investigators aware of the 
intervention. The Graf study was judged to be suffering from a critical risk of bias in 
an unpredictable direction mainly due to deviations from the intervention as 
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participants received surgery (rectopexy) and biofeedback therapy during the SNS 
intervention period. There was also a moderate risk of bias due to confounding 
factors, due to the inclusion of patients with obstructed defecation and past surgery 
such as rectopexy. This risk of bias analysis further justifies their non-inclusion in a 
meta-analysis of efficacy data. 
 
 
Table 7 reveals the types of studies, ethics approval, trial registration and levels of 
evidence from OCEBM classification of the methodology. The study demographics 
are shown in table 8, of note all studies demonstrated similarly high proportions of 
female sufferers, a similar age group within the RCTs, demonstrable long chronicity 
of CC, and a high proportion of patients with slow transit time. The main inclusion 
criteria within the RCTs were almost identical using 2 or less spontaneous complete 
bowel movements per week as the main classification of CC similar to recent 
Table 7 Studies included in the systematic review 
Study Groups Centre 
N units 
Country Ethics 
approval 
Trial registration OCEBM 
level 
Prospective Randomised Sham Controlled Crossover Trials 
Zerbib et al 2017 
Constimod Study 
Bordeaux 
8 units 
France Yes NCT01629303 
www.clinicaltrials.gov 
 
2 
Patton et al 2016 
grant ID 630502 ¥ 
 
Sydney 
2 units 
 
 
 
Australia 
 
Yes 
08/CRGH/59 
HREC07198 
 
ACTRN12611001192976 
Australian New Zealand 
Clinical Trials Registry 
ICTRP WHO registry 
 
 
2 
 
Dinning et al 2015 
grant ID 630502 ¥ 
Prospective open label cohort studies 
Maeda et al 2017 *  
St Marks 
7 units 
 
UK 
 
Yes 
 
NCT00200005 
 
4 Kamm et al 2010 *,α 
Carriero et al 2010 Montecchio 
Emelia 
1 Unit 
 
Italy 
 
NR 
NR 
No ISRCTN registration 
No ICTRP WHO  
 
4 
Prospective case series 
Graf et al 2015 Uppsala 
1 unit 
 
Sweden 
 
NR 
NR 
No ISRCTN registration 
No ICTRP WHO 
 
4 
OCEBM=Oxford centre for evidence based medicine, *Funded by Medtronic, NR=Not Reported 
 ¥ independent funding,α  2 papers relate to one study in separate follow up phases 
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pharmaceutical trials for CC. Most other studies inclusion criteria were based 
around the Rome III classification for CC. 
 
 
 
The RCTs had a similar design in that they were randomising to sequences of “ON” 
or “OFF” after patients had been implanted with an IPG, in other words study 
Table 8  Demographics of review studies 
Study Groups SP 
 
 
 
N  
 
Female 
 
 
 
N  
(%SP) 
Age 
 
 
 
years  
Main Inclusion 
Criteria for study 
recruitment 
Chronicity 
of 
idiopathic 
constipation 
Years 
(%SP) 
Slow Transit 
constipation 
 
 
N 
(%SP) 
Prospective Randomised Sham Controlled Crossover Trials 
Zerbib et al 
2017 
Constimod 
Study 
 
 
 
36 
 
 
 
34 
(94%) 
 
Mean  
(SD) 
45  
(14) 
-two or fewer complete bowel 
movements per week 
-straining to evacuate at more than 
25per cent of attempts 
-sensation of incomplete 
evacuation after defaecation on 
more than 25 per cent of occasions 
 
 
36 
> 1yr 
(100%) 
 
 
28 
(78%) 
Patton et al 
2016 
 
 
 
 
59 
 
 
 
55 
(93%) 
 
Median 
(range) 
42 
(19-74) 
-SCBM < 3 days/week for 2/3 
weeks 
- colonic isotope retention ≥20% at 
96 h - normal anorectal 
manometry 
-No obstructive defecation 
-Failed medical treatments 
-Normal colonoscopy within 5 
years 
>10 y N=43 
(73%) 
5-10yrs N=7 
(12%) 
2-5yrs N=9 
(15%)  
NR 
(NR%) 
68% mean 
isotope 
retention (<1% 
normal) 
Dinning et al 
2015 
 
Prospective open label cohort studies 
Maeda et al 
2017 
 
 
 
 
62 
 
 
 
55 
(89%) 
 
Median 
(range) 
40 
(17-79) 
 
< 2 Bowel movements a week, and 
/or straining/incomplete emptying 
>25% 
 
Median 
(range) 
10 yrs 
(1-60) 
 
50 
(81%) 
Kamm et al 
2010 
 
Carriero et al 
2010 
68 55 
(81%) 
59 
(19-78) 
-Fulfil Rome II Criteria for FC 
-failed all medical therapy 
MMPI-2 score =0 -selection for PNE 
 
NR 
68 
(100%) 
Prospective case series 
Graf et al 2015 44 38 
(86%) 
Mean 
(range) 
55 
(20-78) 
-CC > 6 months 
-Failed conservative therapies 
-Failed TAI and biofeedback 
-Willing to participate 
Mean 
(range) 
16.4 
(1.5-50) 
 
21 
(48%) 
SP=Study Population, ITT=intention to treat, NR=Not reported, SCBM= Spontaneous complete bowel movements 
TAI=Trans Anal Irrigation 
MMPI-2= Minnesota Multiphasic Personality Inventory-2 test 
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subjects all received the normal PNE and had their response assessed beforehand. 
The main methodological difference was that the Dinning/Patton study implanted 
patients regardless of PNE response (patient choice) and the Zerbib study only if 
there was a positive response to PNE (normal practice). In both studies the primary 
outcome measure was used to classify a response to testing or long term IPG. The 
Patton/Dinning study had clearly defined the POM as per table 9 below, whereas it 
is unclear if the POM in the Zerbib study affected the response classification. The 
other studies all had clear outcome measures apart from Carriero which was very 
vague and clearly at critical risk of bias. 
 
 
 
 
 
 
Table 9  Definition of response classifications of included studies 
Study Groups Classification of testing response POM 
PNE and [Sham vs active sub-sensory] 
Classification of Long-term response POM 
Prospective Randomised Sham Controlled Crossover Trials 
Zerbib et al 2017 
Constimod Study 
POM any one of three from : -increase from <2 to >3 SCBM/week or 
                               ->50% reduction in straining or 
       ->50% reduction in incomplete emptying sensation. 
Objective assessment of other characteristics (Wexner score, GIQLI score, VAS 0-100) 
Patton et al 2016 
 
 
POM= SCBM 2 days/week for 2/3 weeks for supra- and sub-sensory SNS 
 
Pain score, bloating score, laxative free days, stool f and form, SF36-SOM 
Dinning et al 2015 
 
Prospective open label cohort studies 
Maeda et al 2017 
 
POM is any one of the following: 
- bowel frequency from <2 to >3/week 
->50% reduction in straining 
->50% reduction in incomplete evacuation 
POM is any one of the following: 
- bowel frequency from <2 to>3/week 
->50% reduction in straining 
->50% reduction in incomplete evacuation 
Kamm et al 2010 
 
Carriero et al 2010 POM= appearance of spontaneous necessity 
of evacuation and a referred improvement of 
quality of life 
No declared long term POM 
Bowel diary, Wexner score and SF 36 
measured 
Prospective case series 
Graf et al 2015 POM= 50% reduction in constipation 
symptoms 
POM= 50% reduction in constipation 
symptoms 
GIQLI-Gastrointestinal Quality of Life Index, SCBM-Spontaneous complete bowel movement, POM-Primary outcome measure, SOM-
Secondary outcome measure 
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The RCTs had almost identical PNE techniques (Table 10) and equipment apart from 
the stimulation parameters as Dinning used a slightly higher pulse width of 
300µSec. Testing stimulator model 3625 was used by all without evidence of 
calibration (incidental findings-chapter 4). Of note Dinning had a 27% response to 
PNE but implanted 93% of participants with an IPG, compared to Zerbib who had a 
78% response and implantation rate. Carriero did not comment on the equipment 
used or on settings, and Kamm did not comment on the technique used to assess 
adequate lead placement at surgery. There was a high proportion of test 
responders in the cohort studies (up to 85%) and a lower proportion in the case 
series (a case series has no robust patient selection). All studies used supra-sensory 
test settings for PNE which is effectively open label at this stage.
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Table 10 SNS PNE technique and response  
Study Group ITT  
N 
Testing PNE type  
duration 
(Weeks) 
Testing 
TP 
N  
Test 
responder 
N   (%TP) 
IPG 
implanted 
N   (%TP) 
Testing 
stimulator 
model 
Sacral formen cannulated 
Response measured 
Testing lead model 
Stimulation settings 
Pulse width ( μsec) 
Frequency (HZ) 
IPG 
model 
Prospective Randomised Sham Controlled Crossover Trials 
Zerbib et al 2017 
Constimod Study 
 
 
 
 36 
 
Supra-sensory  
>100% ST 
(3) 
 
 
36  
 
 
 
20  
(78) 
 
 
20 
(78) 
 
3625 
No 
calibration 
S2,3,4 nerve roots 
Motor-bellows and great toe 
 
Tined Lead model 3093 
 
210  μsec 
14Hz 
 
Interstim 
3023 
Patton et al 2016 
 
 
 
59 
 
Supra-sensory  
>100% ST 
(3) 
 
 
59 
 
 
16 
(27) 
 
 
55 
(93) 
 
3625 
No 
calibration 
S3, S4 nerve roots 
Motor-Bellows and great toe 
 
Tined Lead model 3093 
 
300 μsec 
14Hz 
 
Interstim 
3023 Dinning et al 2015 
 
Prospective open label cohort studies 
Maeda et al 2017 
 
 
62 
Supra-sensory 
>100% ST 
(3) 
 
62 
 
45 
(73%) 
 
45 
(73%) 
 
3625 
No 
calibration 
 
NR 
 
210  μsec 
14Hz 
 
Interstim 
3023 Kamm et al 2010 
 
Carriero et al 2010 13 Supra-sensory 
>100% ST 
(4) range 3-6 
Tined lead test 
13 11 
(85%) 
11 
(85%) 
 
NR 
S3 nerve roots 
Patient Sensation (LA) 
Tined lead model 3889 
 
NR 
 
NR 
Prospective case series 
Graf et al 2015 44 Supra-sensory 
>100% ST 
(3) 
44 15 
(34%) 
15 
(34%) 
3625 
No 
calibration 
S2, S3, S4 nerve roots 
Motor-Bellows response 
Tined lead model 3093 
210  μsec 
14Hz 
Interstim 
3023 
ST=Sensory Threshold, ITT= Intention to treat, PNE=peripheral nerve evaluation, TP=testing population, IPG=Implantable pulse generator, NR=Not Recorded 
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I calculated the effect size of the test response from the RCTs and demonstrated 
significant heterogeneity between the groups (I2=75%, P<0.0001). The studies were 
pooled using a random effects meta-analysis (Figure 3), which found a pooled PNE 
response of 39% (95 % confidence interval,11.8-67%), which is considerably lower 
than reporting in most prospective cohort studies (70-85%). 
 
 
 
 
The RCTs were similar in that they randomised patients to sequences of sub sensory 
active SNS versus Sham SNS with an IPG in situ. In the Zerbib study participants 
were randomised to sequence and received 8 weeks of each in a crossover design 
with a central 2 week washout period and an equal allocation ratio. The Dinning 
study had 4 arms of 3 weeks each comparing randomised crossover sham versus 
sub-sensory SNS first, and then re-randomisation to crossover sham versus supra-
sensory second, again with a 2 week washout period between study arms. In both 
studies no significant difference was detected between sham and sub-sensory SNS 
using the primary outcome measure at the end of the testing periods (Table 11). 
Dinning also detected no difference between sham and supra-sensory SNS. 
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Table 11 IPG Randomization for controlled IPG SHAM / Active crossover  testing 
Study 
Group 
IP 
 
N  
 
SHAM  
RES 
N  
(%IP) 
SS 
 RES 
N  
(%IP) 
Duration 
of IPG 
testing 
arm 
 
Washout 
between 
arms 
Randomisation 
allocation 
Zerbib et al 
2017 
Constimod 
Study 
 
 
 
20 
 
11 
55% 
 
12 
60% 
 
P=0.75 
 
2 arms of  
8 weeks 
each 
 
 
2 weeks 
 
 
10 vs 10 
Study 
Group 
IP 
 
 
N 
 
SHAM 
RES 
 
N 
(%IP) 
SBS 
RES 
 
N 
(%IP) 
SHAM 
RES 
 
N 
(%IP) 
SPS 
RES 
 
N 
(%IP) 
Duration 
of IPG 
testing 
arms 
 
 
Washout 
between 
arms 
 
 
Randomisation 
allocation 
 
 
*Patton et 
al 2016 
*Dinning et 
al 2015 
 
 
55 
 
14 
(25%) 
 
 
14 
(25%) 
 
P=0.95 
 
11 
(20%) 
 
16 
(29%) 
 
P=0.23 
 
4 arms of     
3 weeks 
each 
 
 
2 weeks 
 
 
NR 
SHAM versus sub-sensory testing [Zerbib et al], 
SHAM Versus Sub-sensory & SHAM versus Supra-sensory testing [Dinning et al] 
*Identical study group, IP= implant population, SBS=Sub-Sensory IPG SNS,  SPS=SuPra-Sensory IPG SNS, RES=Responder,  
NR=Not Reported 
66 
 
 
 
 
Long term response to IPG SNS occurred at 12 months using the similar POM in 
both RCTs. Table 12 demonstrates response rates comparing the implant group 
response to an intention to treat (with PNE) response rate. Patton had a higher loss 
to follow up than Zerbib, and these patients were all considered treatment failures.  
 
 
 
 
 
 
Table 12 Long term response to IPG SNS 
Study Groups ITT 
 
 
 
N 
IP 
Implanted 
 
 
N 
(%ITT) 
Quadripolar 
Tined lead 
 
 
N 
(%ITT) 
Number 
in follow-
up 
N 
(%IP) 
End point 
FU  
 
 
(Months) 
End point 
response 
 
 
N 
 (%IP)  (%ITT)    
Prospective Randomised Sham Controlled Crossover Trials 
Zerbib et al 2017 
Constimod Study 
 
36 
 
20 
(78%) 
 
20 
(78%) 
 
16 
(80%) 
 
12 
 
11 
(55%) (31%) 
Patton et al 2016 
 
 
59 
 
55 
(93%) 
 
55 
(93%) 
 
31 
(56%) 
 
12 
 
10 
(18%) (17%) Dinning et al 2015 
 
Prospective open label cohort studies 
Maeda et al 2017 
 
 
 
62 
 
 
45 
(73%) 
 
 
45 
(73%) 
45 (100%) 
 
35 
 
18 
28 
 
48 
 
60 
39 
(87%) (63%) 
NR 
 
NR 
Kamm et al 2010 
 
Carriero et al 2010  
 
13 
 
 
11 
(85%) 
 
 
13 
(100%) 
 
 
11 
 
 
22 
NR 
Global 
improvement in 
Wexner/ diaries 
Prospective case series 
Graf et al 2015 44 15 
(34%) 
15 
(34%) 
11 24 5 
(33%) (11%) 
ITT=intention to Treat population, IP=Implant population (per protocol population) 
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Random effects meta-analysis (Figure 4) demonstrated a pooled 12 months 
response to IPG SNS of 33%, and again wide 95% confidence intervals. This figure 
corresponds well with the case series report from Sweden, but is far lower than all 
previously reported cohort studies, of note Kamm reported 87% response at a 
mean of 28 months. Carriero did not classify long term response to SNS and 
analysed mean Wexner scores and diary scores. 
 
 
 
In the Zerbib study secondary outcome measures such as bowel diaries, Wexner 
scores, VAS and Gastrointestinal Quality of Life Index (GIQLI) score, detected no 
evidence of a difference to short or long term SNS treatment. Similarly physiological 
measures of colonic transit time and anal manometry pressures had no evidence of 
significant change either. Patton replicated these results reporting no evidence of 
a change to colonic transit time either. Adverse events (Table 13) were reported in 
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all studies apart from Carriero who did not include any adverse event reporting in 
the paper other than commenting that there were no complications. Adverse 
events were common in the RCTs, with 25% of participants suffering a serious 
adverse event in the Zerbib trial. In the higher quality prospective RCTs, infection 
rates were considerably higher than the cohort studies, 10% and 22% compared to 
0%, 4% and 13%. Of note Dinning calculated wound infection as a proportion of all 
adverse events, not as a proportion of the study population which artificially 
lowered the reported infection rate. I adjusted this by recalculating the 12 
infections as a proportion of the intention to treat population of 59 patients (22%). 
 
 
Table 13 Adverse event reporting 
Study Groups Testing  
 
 
N 
(TP) 
Testing 
AEs 
 
N 
(%TP) 
IPG  
 
 
N 
(IP) 
IPG 
AEs 
 
N 
(%IP) 
SAEs 
 
 
N 
(%TP) 
Total 
AEs 
N AES 
N Pts 
(%TP) 
Infections 
 
 
N 
(%IP) 
ABX 
PXP 
Lead / IPG 
removed 
 
N 
(%IP) 
Other 
AEs 
Prospective Randomised Sham Controlled Crossover Trials 
Zerbib et al 2017 
Constimod Study 
 
36 
 
NR 
 
20 
 
NR 
 
9 
(25%) 
25 
11 
(30%) 
2 
10% 
 
Y 
 
2 
10% 
 
4 DM 
Patton et al 2016 
 
 
59 
 
NR 
 
55 
 
NR 
 
1 
(2%) 
73 
NR 
(124%) 
 
12 
(22%)* 
 
NR 
1(2%) 
12 months 
47 (85%) 
60 months 
23/59 
Lead 
migrati
on 
Dinning et al 
2015 
 
Prospective open label cohort studies 
Maeda et al 2017 
 
 
62 
 
NR 
 
45 
 
NR 
 
11 
(18%) 
 
101 
NR 
(224%) 
 
2 
(4%) 
 
Y 
3 
(7%) 
20 
(45%) 
Lead  
migrati
on Kamm et al 2010 
 
Carriero et al 
2010 
13 0 11 0 0 0 0 NR 0 0 
Prospective case series 
Graf et al 2015 44 8 
(18%) 
 
15 5 
(33%) 
1 
(2%) 
13 
NR 
(30%) 
2 
(13%) 
NR 4 
(27%) 
IPG  
NR =Not Reported, TP= Testing population, IP=Implant population, ABX PXP-antibiotic prophylaxis,  
DM=device malfunction, *Reported as 16% in study (error by using N=73 of AEs instead of TP=59) 
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Random effects meta-analysis of the RCTs demonstrated a pooled effect size of 
0.163 (16.3%) (95% CI 0.047-0.279) which is considerably higher than all of the 
previously reported infection rates in cohort studies of CC (Figure 5). 
 
 
 
 
 
Explantation of the IPG devices was performed either due to infection or lack of 
efficacy. I considered the methodological differences between the RCTs and cohort 
studies/case series, and I concluded that these designs could not ultimately prevent 
or promote device explantation which could be considered a surrogate marker for 
treatment failure. All studies were therefore included in a random effects meta-
analysis of explantation rate (Figure 6). The pooled proportion demonstrated an 
explantation rate of 41% (ES 0.409, 95% CI 0.095-0.722), with significantly high 
heterogeneity (I2=86%, P<0.0001) between study groups which is likely due to the 
methodologies used. The Patton study reported the long term response to SNS of 
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the Dinning trial subjects (prospectively planned) and had the highest reported 
explantation rate reported in the literature of 85% at 5 years follow up. 
 
 
 
 
 
The main design of the Dinning study was to implant a high proportion of PNE test 
patients in order to calculate the predictive value for PNE based on long-term 
response to IPG SNS. The Dinning paper reported this analysis based on response 
at 12 months after implantation which demonstrated a negative predictive value of 
78% and a positive predictive value of 50% (Table 14). Patton presented an 
interesting post-hoc analysis of 5 year response which demonstrated the PNE PPV 
as 6% and NPV as 94%. 
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2.3.4. Discussion of review findings 
The findings of this review using a strict high quality methodology only including 
OCEBM level 2 evidence studies in efficacy analysis is at odds with the majority of 
studies in the published literature. The overall quality of the prospective cohort 
studies and case series was poor (level 4), and the 2 RCTs were the highest quality 
studies published in the field of SNS for CC to date (level2). The long-term response 
rate of IPG SNS using a supra-sensory unipolar lead for PNE is nearer 41%, although 
as the Dinning study deliberately implanted non-responders to calculate the PPV of 
PNE this will undoubtedly have resulted in a higher proportion of non-responders 
in this trial at 12 months (17%) and 5 years (5%). The PPV of supra-sensory unipolar 
PNE is 50% at 12 months and 6% at 60 months, which effectively ends the utility of 
this form of testing for patients with CC. Both of the RCTs did not detect any 
physiological change to SNS or any difference between active sub-sensory or supra-
sensory SNS when compared to a sham stimulation using the IPG. This seems to 
imply that there may be a placebo response to treatment, although a significant 
proportion of these patients (33%) who have proven chronicity and were refractory 
to all known treatments, still appear to have a response at 12 months. Thus, there 
may still be a subgroup of patients within the cohort of CC that do respond to 
treatment, but no studies have demonstrated an ability to discriminately detect 
them during PNE. The 12 month pooled response rate of 33% is significantly lower 
than reported by the prospective and retrospective cohort studies who were 
Table 14 Predictive ability of supra-sensory PNE for IPG SNS response 
Dinning et al 2015- Positive responses to PNE and permanent IPG SNS 
 IPG SNS  
+ve Response 
IPG SNS  
-ve Response 
Total 
PNE +ve response 8 8 16 
PNE -ve response 8 29 37 
Total 16 37 53 
Sensitivity=50%, Specificity=78%, PPV=50%, NPV=78% 
PPV=Positive Predictive Value, NPV=Negative Predictive Value 
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typically reporting response rates of up to 87% at 28 months after IPG implantation 
(99). This is a clear demonstration of the inherent methodological flaws in cohort 
studies and case series, and an overreliance on these weak methods in fields of 
surgical research. The overall IPG explantation rate was pooled at 41% within 5 
years. This may be artificially higher due to the Dinning study implanting PNE non-
responders. Even so this device costs over £12,000 and battery life is typically 5-7 
years; this does not appear to be a cost-effective treatment for the NHS. The weak 
methodology of the cohort studies have also led to biases in under reporting 
adverse events, particularly infections of devices. The pooled infection rate of 16% 
within 12 months of IPG implantation is significantly higher than the average 4% 
reported within the weaker studies. In registered and monitored RCTs all safety 
data are independently scrutinised by university methodologists, and this is the 
likely explanation for the higher rates being reported in these studies. In order to 
understand the current research climate with respect to SNS for CC, I performed a 
search of the WHO International clinical trials registry on 1st March 2019. This was 
to identify historical clinical trials of SNS that had been registered and closed, and 
those that were registered and currently recruiting. The prospective RCTs described 
in the systematic review were included on the registry, as well as the Tilts-cc study. 
One further study of SNS for CC is currently underway in Holland and recruiting 
patients (127). This is an open label RCT of SNS versus personalised conservative 
treatment. The design of this study would not be considered evidence of effect for 
SNS in CC, and is as methodologically weak as the cohort studies described in the 
review. 
 
2.3.5. Conclusion of the systematic review of quantitative literature 
This review has demonstrated that a subgroup of patients with CC seem to respond 
to long term IPG SNS treatment, but that the supra-sensory PNE test is unable to 
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detect them. Consequently a large proportion of implanted patients fail the 
treatment at 12 months, which is expensive and they have a significant burden of 
complications (infection). There is also a possibility the testing and long term 
response may simply be a placebo response to treatment. There is an urgent need 
to develop an enhanced PNE test that adequately detects the sub group with long 
term response, in order to make SNS a viable and cost effective treatment for 
patients in the NHS. 
2.4    Rationale for the TiLTs-cc study 
There were no high quality level 1 evidence RCTs of SNS for CC identified in the 
literature. The 2 recent OCEBM level 2 RCTs (121-123) have not demonstrated an 
ability to detect long term response by PNE, or of any treatment effect of SNS over 
sham therapy. The earlier cohort studies were methodologically weak and overly 
optimistic, especially one multi-centre open label cohort study (99) which became 
more pessimistic in longer term follow up (124), and there remains uncertainty 
regarding the efficacy of SNS for chronic constipation.  Whilst there is some 
evidence of a persistent and significant benefit in a sub-group of patients, it is clear 
that not all patients benefit from this treatment.  The standard method of 
predicting response using a 2-week PNE technique does not seem as effective in CC 
as in treating faecal incontinence or bladder dysfunction.   
The success rate of PNE in urinary dysfunction and faecal incontinence was 
reported as between 63%-80% (128-131).  In contrast, the Kamm study 
demonstrated the predictive value for test stimulation in identifying 1 year 
responders was less than 50% (99), and recently the PPV has been demonstrated 
to be as low as 6% at 5 years (122). In an audit of patients with chronic constipation 
treated in clinics at Durham and Hull 60% of patients stopped responding to 
treatment in the first 6 months after permanent stimulation, despite strongly 
positive responses to standard 2-week test stimulation.  Local experience 
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anecdotally reported some patients with a strong response to test stimulation 
having a failure of therapy very soon after insertion of a permanent tined lead.   
Failure of the standard test stimulation to accurately predict outcome poses a 
major barrier to the viability of SNS in this condition, both from a patient 
perspective and an economic one. The predictive value of PNE in predicting long 
term response to implanted IPG was inadequate to allow NICE approval for the 
treatment in CC.  The reasons for the poor predictive performance of 2-week PNE 
stimulation in constipation are unknown. The qualitative literature review 
described a strong placebo effect in patients with functional bowel disorders (132, 
133), and this is a possibility. A placebo effect, if confirmed to be present, would 
most likely to be strongest following commencement of stimulation, and reduce 
with time (134).  Alternatively, the false positive PNE tests may arise because of the 
lack of objective testing of disease severity and the natural variation of symptoms 
over time (135). Finally, there is the possibility that the lead position in the S3 
foramen may be more critical in CC. This possibility implies that PNE is only effective 
at predicting the outcome of a lead in that specific position, and therefore once the 
testing lead is changed for a permanent tined lead, the small change in position 
results in a change in efficacy.  The use of a tined (barbed) lead during the evaluative 
phase (enhanced percutaneous nerve evaluation- ePNE) allows the same lead to be 
used for a permanent implant, precluding electrode re-positioning. It also allows a 
6-week evaluative phase which can include periods of active and sham stimulation 
for placebo control. We hypothesised that ‘discriminate’ responders (patients 
responding only to active stimulation) would receive long-term benefit from SNS, 
while patients responding ‘indiscriminately’ (during sham or both periods) would 
be less likely to benefit. Following a positive test with a tined lead, the same lead 
was used to connect with the permanent implant. This guaranteed that the position 
of the lead and the electrode did not change. Urological studies have shown the 
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tined lead testing to be safe and practical over several weeks (136) and therefore a 
six week period was viable. This also enabled observations of placebo responses, 
by using intermittent real/sham stimulation. The stimulation was provided using 
sub-sensory settings so that the patient would not be able to differentiate between 
real and sham stimulation.  The Tilt-cc study was thus designed to test with the 
permanent tined lead using a methodology that would generate OCEBM level 2 
evidence of the predictive ability of this ePNE test.  
I will now proceed to Chapter 3 where the results of the systematic review and 
scoping review of the qualitative literature for SNS in treating CC, are described and 
presented. 
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Chapter 3 Sacral Nerve Stimulation- Qualitative literature  
3. Introduction 
This Chapter aims to examine the current knowledge (at the time of study design) 
within the qualitative literature on patient experiences of sacral nerve stimulation. 
This is achieved by both a systematic review of the qualitative literature, and a 
scoping review of the remaining qualitative literature aiming to identify relevant 
patient experiences and issues that may have influenced the design of the Essence 
study. 
3.1 Systematic review of the qualitative literature  
In order to understand the existing knowledge of the lived experience of patients 
receiving SNS for CC, a systematic review of the qualitative literature was 
performed. This review aimed to highlight the knowledge gaps in order to inform 
the design of the Essence study. The review also aimed to provide evidence to assist 
the choice of the theoretical framework selected to be used in the study, and of the 
expected experiences of patients either in SNS treatment or related therapies. This 
section will present the methods used to perform this search, the results and 
discuss these findings and how they relate to the knowledge being sought through 
the Essence study. 
3.1.1. Criteria 
This review aimed to demonstrate the lived experience of patients undergoing SNS 
for chronic constipation. The following inclusion and exclusion criteria were thus 
applied: 
Inclusion Criteria: 
 Original qualitative research using a recognised qualitative theoretical 
framework for data collection 
 Full papers published in peer reviewed journal 
 Patients suffering from Chronic/ functional/ idiopathic constipation 
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 Patients who have been treated with SNS 
 English language articles 
 Adults 18 years of age or older 
Exclusion criteria: 
 Letters, abstracts, consensus opinions and review articles 
 Patients suffering from secondary constipation 
 Patients treated with other forms of neuromodulation 
 Children 17 years or younger 
 
3.1.2. Search strategy 
The following databases were systematically searched for papers written in English 
from 1900 to January 2014: AHMED, CINAHL, COCHRANE, EMBASE, MEDLINE, 
OVID, and Web of science ™ Core Collection (Thomson Reuters™). The search used 
truncated search topics which were standardised and consistent in each database, 
and refined by utilising the Boolean logic operators “AND” and “OR” to combine 
the searches accordingly. The patient population search terms were “constipat*”, 
“function”, “idiopathic” and “chronic” which were combined to identify the target 
patient group. The treatment search terms were “sacral nerve stimulation”, “SNS”, 
and “neuromodulat*” which were combined to identify the target treatment 
administered. The qualitative research search terms were “phenomeno*”, 
“ethnograph*”, “narrative”, “grounded theory”, and “qualitat*” which were 
combined to identify the target type of research. The literature for review were 
thus identified by combining the target patient population, target treatment and 
target research as demonstrated in Table 15 below. 
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3.1.3. Results 
 
3.1.4. Qualitative research in SNS for constipation 
One abstract was identified from the combined search target literature that was 
potentially of patient experiences of SNS for constipation (137), and the full paper 
was reviewed. This was a review and commentary of all treatments used in 
constipation with 3 references to other studies (25, 138, 139) of the condition, and 
not a formal qualitative study itself. These 3 studies were obtained in full text and 
none related specifically to experiences of treatment with SNS, but did have 
qualitative aspects to living with CC. They were included in the narrative of a further 
scoping review of the literature. 
 
Table 15 Search of bibliographic databases for qualitative literature 
Search n  Search term (patient population) Results 
1 ALL=constipat* 15,324 
2 ALL=function* 4,446,966 
3 ALL=idiopathic 94,894 
4 ALL=chronic 802,985 
5 2 OR 3 OR 4 5,170,514 
6 1 AND 5 
Target patient population 
7,273 
Search n Search term  (treatment) Results 
7 ALL= sacral nerve stimulat* 1,647 
8 ALL= neuromodulat* 13,959 
9 7 OR 8  
Target treatment population 
14,928 
Search n Search term (research type) Results 
10 ALL= phenomeno* 366,253 
11 ALL=ethnograph* 30,388 
12 ALL=narrative 72,138 
13 ALL= grounded theory 60,095 
14 ALL= qualitat* 321,988 
15 10 OR 11 OR 12 OR 13 OR 14 
Target research population 
819,212 
Search n Combining target populations Results 
16 6 AND 15 
Qualitative research in constipation 
118 
17 9 AND 15 
Qualitative research in SNS 
248 
18 6 AND 10 AND 16 
Qualitative research in SNS for constipation 
1 
ALL= all search fields 
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3.1.5. Qualitative research in SNS (any disease) 
Abstracts from the 248 items identified from the search as potential qualitative 
research studies of SNS (for any disease), were screened and excluded as follows: 
241 were not qualitative research studies, 5 were animal studies, and 2 were 
qualitative studies in different fields and unrelated to SNS; 1 in psychology relating 
to perceptions of treatment by neurosurgeons, and 1 in a patient’s experience of 
deep brain stimulation for an unrelated condition. No literature was therefore 
identified that specifically studied patient experiences of treatment with SNS for 
any disease process. 
3.1.6. Qualitative research in constipation 
Abstracts from the 118 items identified from the search as potential qualitative 
research studies of patients suffering from constipation were screened and 
excluded as follows: 93 were not qualitative studies, and 19 were qualitative studies 
of children. Of the remaining 6 qualitative studies of adults, 4 were excluded as 
follows: 1 was a case study of an unrelated condition (Charcot-Marie Tooth 
syndrome), 1 was of opioid induced constipation in cancer patients, 1 studied 
neurosurgeons perspectives on specific treatments, and 1 was of the gendered 
impact bias of IBS in healthcare. The 2 remaining studies were not specific to SNS 
treatment, but are to CC and were therefore included in the narrative of a further 
scoping review of the literature. 
3.1.7. Discussion of the systematic review of the qualitative literature 
No qualitative studies were identified during this systematic review of the 
qualitative literature that explored and reported patient experiences of receiving 
SNS therapy for chronic constipation. No qualitative studies were identified that 
explored and reported patient experiences of SNS as a treatment for any condition. 
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This review has therefore revealed a considerable knowledge gap in the literature; 
the experience of undergoing SNS treatment has never had the focus of dedicated 
qualitative research, and the experience of patients receiving treatment in this 
condition and others is therefore unknown. Following these findings, and in order 
to inform design of the Essence study appropriately, a further scoping review of the 
literature was performed in an attempt to anticipate the likely findings and 
potential problems that could be encountered in this further research. 
 
3.2 Scoping review of the qualitative literature 
This narrative scoping review was conducted to discuss the literature related to 
patients’ experiences of living with constipation and functional gastro intestinal 
disorders, of having colorectal surgery (such as SNS or other procedures), and of 
participation in surgical research trials. The aim of this review is to identify further 
knowledge gaps that would influence the Essence study design and data collection. 
 
3.2.1. Search strategy 
This scoping review utilised the search results of the specific searches conducted 
above in the systematic review for qualitative research in SNS and in constipation. 
The articles that were considered to be related to either SNS or living with 
constipation were reviewed and similarly referenced articles obtained in order to 
try and identify relevant themes that may be related to the treatment or condition. 
2 qualitative studies (27, 140) were identified that were specific to living with 
constipation, and 1 that was interested in gender bias in IBS (141). As such a 
narrative scoping review was written using these papers, related papers referenced 
in their bibliographies, and from conducting several searches of the literature for 
themes related to SNS and constipation that I and supervising researchers felt were 
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important to the study group. These included themes of “living with a functional 
gastro intestinal disorder”, the “motivations for patient participation in surgical 
trials”, the “lived experiences of patients through colorectal surgery”, the 
“experience of placebo effects in surgical trials” and “psychological considerations 
in sufferers of a functional gastro intestinal disorder.” 
3.2.2. Living with a functional gastrointestinal disorder 
Diagnosis and treatment of CC represents a significant burden to healthcare 
providers (34) with costs increasing with disease severity and bowel symptom 
exacerbations (35). Patients often suffer a significant and chronic deterioration in 
their quality of life (26), with many attempting a variety of complementary or 
alternative medicines to try and gain resolution (140). Specifically, the experiences 
documented in the qualitative literature in CC sufferers include “feelings of 
hopelessness” in the condition and “frustration” at a perceived lack of clinician 
empathy, or simply “not being taken seriously” (27). Similarly reported are the 
experiences of living with constipation predominant IBS (IBS-C), where patient 
perceptions of symptom unpredictability lead to them “feeling constrained and 
dependant” (142). One hermeneutic study demonstrated evidence of gender 
stereotyping by healthcare professionals which the authors concluded may 
“perpetuate the suffering” of women and men with identical IBS symptoms due to 
“women being trivialised and men overlooked” (141).  
3.2.3. Psychological considerations 
Studies have demonstrated that psychological distress may be involved in the 
pathogenesis of FGIDs (36, 138), that anxiety and depression are prevalent within 
this group (36), and that the associated chronic pain of FGIDs can improve with a 
variety of psychological and behavioural treatments (37). Psychotherapy, in 
particular seems to be an effective adjunct to medical treatment in some patients 
(38). This is possibly due to the increased reporting of physical and sexual abuse 
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amongst sufferers of FGIDs, especially when constipation is the predominant 
symptom (25, 36, 38, 139). Anecdotal evidence from clinical practice supports the 
suggested association between early life trauma and FGIDs. DCC audit data also 
suggests a significant proportion of patients with concurrent mental health issues 
such as obsessiveness, anxiety, depression and occasionally suicidal ideation.  
3.2.4. Motivations for participation in surgical trials 
Researchers have scarcely investigated the motivations of patient participation in 
medical or surgical trials in the last 3 decades. It has recently been recognised that 
using qualitative methods to understand why patients participate may have the 
potential to inform future trial design this may increase patient satisfaction, and 
consequently recruitment and retention which may improve the size and 
demographic of the study sample (143). Given the burden on participants in trials 
of SNS, and the potential placebo response, it seemed imperative to understand 
this issue in more depth.  
Altruism is frequently mentioned in the literature as a principle motivating factor 
for patient participation (in both therapeutic and non-therapeutic trials), by 
patients and the public. A US questionnaire study in 1982 demonstrated a positive 
public view of the “importance, ethicality and altruistic rationale” of participation 
in medical research when applied to “hypothetical others” (144). This was 
contrasted, however with patient reporting of motivations, where it seemed that 
“highly personal interests” prevailed. The authors concluded that people use “a 
different perspective” when viewing the motivating factors of study participation 
for others, and themselves (144). 
In the UK a small study demonstrated up to two thirds of unselected patients may 
participate in therapeutic trials with purely altruistic motives (145). Another study 
has contradicted this stating “gaining a personal benefit” is an important primary 
motivation, and altruism is “largely subsidiary” (146). A detailed mixed methods 
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study in Brazil has demonstrated that “financial gain and therapeutic alternative” 
were the most frequent  primary motivations for clinical trial participation, with 
altruism uncommon and secondary to other motivators when present (147). 
Adherence with research procedures, however may be linked to altruistic 
motivations at trial recruitment (148). Disease severity is likely to change 
participant motivations; an important hypothesis given the severity of quality of life 
changes in CC sufferers. A US questionnaire study in 1996 demonstrated that 
severely ill phase 1 subjects were primarily motivated by “a new treatment” before 
altruism, as opposed to phase 3 subjects who were primarily motivated by 
honorariums before altruism (149). Only one study was identified from the 
literature that was similar to the Essence study cohort: a qualitative study of 
women’s views and experiences of the CARPET1 trial. Participants had suffered 
severely from urinary incontinence and vaginal prolapse, and were randomised into 
one of two different surgical procedures as a corrective measure. Their primary 
motivations for study inclusion were “the possibility of additional care”, and a 
secondary altruistic motive of “the wish to help with research” (150). This literature 
review has failed to identify evidence of the motivating factors behind CC sufferers 
participating in medical and surgical trials. The evidence in this group seems to be 
anecdotally reported by clinicians recruiting them to trials. The general evidence 
collected above would seem to indicate that patients with severe conditions and 
undergoing invasive procedures are motivated by the possibility of a new treatment 
for their condition over altruism, and that altruism is present as a secondary motive.  
3.2.5. Experiences of placebo effects in surgical trials 
Patients with CC are often frustrated with their failed medical and surgical 
treatments to date, and have unsatisfactory experiences of care (27). The DCC 
experience anecdotally suggests they tend toward being a highly motivated group 
seeking a resolution to their condition and therefore demonstrate a willingness to 
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participate in clinical trials. They also demonstrate an expectation of a “cure” for 
the condition in the short term, and this may partly explain the heightened placebo 
response anecdotally observed by clinicians during SNS testing. Doctors treating 
these patients rarely have a simple cure to their ailments, are therefore eager for 
SNS to work, and so their perception of the patient’s symptom response may be 
biased. This could possibly be enhancing the placebo effect further. The placebo 
effect has been shown to be enhanced in patients suffering from functional bowel 
disorders (132, 133), is greatest at treatment initiation (such as SNS testing) and 
tends to decrease with time (135). The natural variation of symptoms in severely 
affected patients may also cause the perception of a “response to treatment or 
placebo effect” through regression towards the mean (134). Even the ritualistic 
nature of a testing procedure may change a patient’s self-awareness and behaviour 
such that the self-perceived effects may due to the “ritual” and not the treatment 
(151).  
3.2.6. Lived experiences through colorectal surgery 
Phenomenology has been used by researchers to interpret and describe the 
experience of having surgery in most body systems. Sacral nerve stimulation has no 
published qualitative data of patient experiences. This literature review has 
identified knowledge on the lived experiences of patients undergoing colorectal 
surgery, as a comparable group [to CC] with similar symptoms and clinical signs. 
Van Manen’s existential themes of spatiality, corporeality, temporality and 
relationality (152) have been used to demonstrate a patient’s existential situation 
pre-operatively in colorectal diseases (153). Patients were uncertain about how the 
surgery would affect their lived space, body, time and relations despite pre-
operative information (153). Hesitation, fear and anxiety about the surgery and its 
outcome were common findings, and the importance of life-partners for “trust and 
security” is highlighted. Moene et al demonstrate that patients did not adequately 
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have these concerns addressed at pre-operative clinics. The life adaptations 
required to live with an implanted SNS testing lead may potentially leave patients 
in a similar situation. 
A similarly complex surgical programme [to SNS testing] called enhanced recovery 
after surgery (ERAS) has demonstrated the importance of pre-operative 
information being supported by consistent post-operative instructions. Patients 
interviewed in 2010-2011 reported that whilst the preoperative information-giving 
made them feel “centre stage” and “felt taken care of”, they did not feel 
acknowledged in the subsequent post-operative ERAS experience (154). Trust in 
the health care providers was an important theme, with patients citing trust as 
crucial to them feeling safe and participating with ERAS post-operative care 
instructions. The authors concluded that more importance should be placed on 
acknowledging patients post-operatively in order to help them participate and 
improve self-care. This is likely to be relevant as ePNE is complex and requires close 
personal care of the exit lead site by patient, family and healthcare provider in order 
to minimise complications. In the TiLTS-cc study the exit SNS lead is cared for in a 
similar way to an intravenous central line. The rationale for this was drawn from 
the lived experiences of vascular nurse specialists who demonstrate lower infection 
rates when the central line exit site is closely cared for by nurse and patient (155). 
There are common themes that occur in other qualitative studies of colorectal 
surgery. Preoperative experiences commonly include those of fear, isolation, and 
uncertainty (156). Postoperative experiences are commonly of pain, loss of 
dignity/functional control, dependence for personal care (from nurses or partners), 
embarrassment, medical complications and changes to the body (157-159). 
However, the extent to which these are relevant to the experience of SNS remains 
unknown.  
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3.3 Discussion of systematic and scoping reviews of Qualitative literature 
There is a significant knowledge gap in the literature on the phenomenon of 
undergoing SNS for CC. Patients may undergo significant disruption to their daily 
lives; practical, personal and professional. The desperation and suffering of patients 
with CC is accepted, and may result in an eagerness to participate in trials which 
are likely to be perceived as a solution to their ailments. Their motivations for 
surgical trial inclusion are unknown and urgently require exploration to inform 
future trial design. Experiences and beliefs about the placebo effect have never 
been qualitatively evaluated in this population. These are important issues which 
may influence the potential for actual and sustainable patient benefit in current 
and future surgical trials of CC. The placebo effect may be heightened during SNS 
testing through a variety of mechanisms. The lived experience of having a testing 
placebo response followed by a deteriorating treatment response is unknown for 
treatment with SNS. The patient experience of how the procedure and complex 
nature of the testing is communicated preoperatively may have a marked influence 
on their perception of the treatment and attitude towards responsibility for taking 
care of the exit lead dressing. Patients may experience pain, dependency on others 
and loss of dignity during this time. Given the invasive nature of SNS, its cost, and 
its contested effectiveness, I wanted to understand the patient experience and 
acceptability of this procedure and of trial participation, from SNS testing through 
to long-term follow up.  
3.4 Conclusion 
The knowledge gained from the literature reviews will now be discussed to inform 
the rationale for the Essence study design, highlighting the knowledge deficits in 
the literature and why they are important to this research. 
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3.5 Rationale for the Essence study 
The lived experience of patients with CC undergoing SNS testing and treatment, 
their acceptability of SNS, their motivations to participate in a surgical research 
trial, and their beliefs of the placebo effect were unknown. A stand-alone 
quantitative trial would thus have been inadequate to understand all of these 
complex inter-related issues within a very heterogeneous group of patients, and so 
the Essence study was designed to capture this information following on from the 
TiLTS-cc study in a sequential fashion. This thesis will therefore present the 
methods for data collection in Chapter 5, and report, analyse and discuss the results 
of both studies in Chapters 6 and 7, and culminate in an informed conclusion at a 
higher taxonomic level than using a stand-alone quantitative study in Chapter 8. 
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Chapter 4 Aims and objectives of the thesis studies 
4. Introduction 
With these quantitative and qualitative knowledge gaps identified in Chapters 2 
and 3, the aims and objectives of both the TiLTS-cc and Essence studies were 
constructed accordingly as follows: 
4.1 Aims and objectives of the TiLTS-cc study 
The primary aim was to improve the predictive performance of test stimulation for 
CC by using an ePNE test with a tined lead and a double-blinded randomised cross 
over methodology of active versus sham stimulation testing.  
The secondary aims of the Tilts-cc study were hypothesis generating: whether use 
of this testing technique could improve the proportion of test positive patients with 
refractory CC who receive long-term benefit from SNS, which would require 
validation in a hypothesis testing study. Secondary aims also included assessing 
long-term efficacy of SNS for CC, detecting and quantifying any placebo response 
during testing, assessing any baseline predictors of response to treatment, 
assessing the effect of SNS on quality of life, and assessing the cost-effectiveness of 
the treatment within the NHS including modelling the transition from the standard 
test to the ePNE test. This knowledge would provide patient, clinical and policy-
level data to appropriately inform decision making within the NHS. 
4.2 Aims and objectives of the Essence study 
The primary aim was to explore the lived experience of a patient undergoing SNS 
testing for CC, and subsequently with the implanted permanent SNS device. Key 
topics were identified from the literature review as interesting areas for qualitative 
enquiry namely; participant’s experiences of living with CC and the treatments, 
their motivations to participate in a surgical trial, their experiences of care and 
support before/during and after a surgical trial, their perceptions of symptom 
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changes (physical or psychological) in respect to a possible placebo effect, and their 
experiences of SNS in relation to its effect on other aspects of their life 
(relationships, socially, professionally, and self-perception).  
4.3 Conclusion 
Chapter 5 will now examine in detail the methodologies used to collect data in 
these studies and justify the selection of these methods. Chapters 6 and 7 will 
present the findings of these studies and discuss their implications which will be 
used for the discussion in Chapter 8 to synthesise an overall conclusion to the 
thesis. 
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Chapter 5-Methodology of the TiLTS-cc and Essence studies 
used to examine enhanced Peripheral Nerve Evaluation testing 
of Sacral Nerve Stimulation for Chronic Constipation. 
5. Introduction 
Previous chapters have highlighted a chronic and poorly understood disease which 
has significant impact on sufferers’ health related quality of life (HRQOL), and the 
paucity of evidence about the place of SNS within treatment algorithms. A 
substantial knowledge gap is identified in SNS and other surgical research published 
to date for this condition. In particular, the current SNS test is poor at discriminating 
who will respond to the treatment in the longer term, the newly devised 
“enhanced” peripheral nerve evaluation (ePNE) test using a tined lead has not been 
investigated in this group of patients and consequently the diagnostic accuracy, 
feasibility, acceptability and transference of this test are unknown. This chapter 
describes the scientific methods used to achieve the aims and objectives of the 
thesis described in Chapter 4. The chapter is structured chronologically to represent 
the real life sequence of events as experienced by trial participants of both studies, 
following a quantitative-qualitative linear methodology. 
5.1 Introduction to the TiLTS-cc trial design 
 “Tined-lead test stimulation to predict long term benefit from sacral nerve 
stimulation in chronic constipation” (acronym TiLTS-cc) was a National Institute for 
Health Research (NIHR) Research for Patient Benefit (RfPB) portfolio study which 
had significant design and research contribution from myself, and therefore from 
which this thesis is partly composed. The concept to utilize the enhanced 
percutaneous nerve evaluation (ePNE) SNS test and apply the novel adaptation of 
a sub-sensory double-blinded sham controlled cross-over trial design was originally 
devised by the TiLTS-cc study team (of which I was part); consequently the 
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diagnostic accuracy, feasibility, generalizability, and transferability of this technique 
in these patients was unknown. The TiLTS-cc study had Research for Patient Benefit 
(RfPB) programme funding and NHS Research Ethics Committee (REC) approval to 
test the null hypothesis that ePNE SNS test discriminate responders are no more 
likely to have a 6 month response to an implanted SNS IPG stimulator than ePNE 
SNS test indiscriminate responders, in participants suffering from chronic 
constipation.  
This section will outline and explain the methods used in the REC approved trial 
design and conduct, in order to demonstrate the integrity and robust nature of 
methods used in collecting data for this study. The following overall trial schematic 
demonstrates the main trial activities experienced by participants during each of 
three phases of the study. 
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Figure 7 Overall Trial Schematic 
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The TiLTS-cc research questions 
The study is designed to address the following research questions: 
 Is TiLTS-cc testing in SNS predictive of long-term benefit to permanent SNS 
(PSNS) in patients with idiopathic chronic constipation? 
 Is permanent SNS (PSNS) an effective treatment for discriminate responders as 
identified by TiLTS-cc? 
 Is TiLTS-cc guided PSNS more cost-effective to the NHS than current TSNS 
guided assessment? 
 
Primary Objective of the TiLTS-cc study 
 To assess the predictive value of the TiLTS-cc method of temporary SNS testing 
for patients with severe idiopathic constipation. 
Secondary Objectives of the TiLTS-cc study 
 To detect and quantify any placebo response present during TiLTS-cc testing by 
a randomised and double-blinded 2 week cross-over of sham versus real 
stimulation. 
 To assess the efficacy of permanent SNS for patients with severe idiopathic 
constipation at 6 months after implantation. 
 To assess the cost effectiveness of TiLTS-cc testing to the NHS in order to inform 
policy decision making. 
 To assess any baseline predictors of response to treatment. 
 To assess the effect of SNS on quality of life at 6 months after implantation. 
Primary Endpoint 
The primary endpoint was the response rate comparing discriminate and 
indiscriminate responders at 6 months with baseline data. A responder was 
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characterised by a drop in PAC-SYM score of 0.5 or greater.  Since scores for PAC-
SYM have good floor and ceiling effects with ranges between 0.5 and 3.5, a drop of 
0.5 represents an average of 15-20% reduction in symptoms, which is highly likely 
to be clinically important (160, 161). 
Secondary Endpoint 
Secondary outcome measures were 6 month assessments comparing discriminate 
with indiscriminate groups against baseline data of global assessment of symptoms: 
PAC-SYM; scores from daily diary exercises; PAC-QOL; EQ-5D-3L, EQ-5D-VAS, 
Cleveland clinic questionnaire and Wexner Score. Those with no response during 
TiLTS-cc testing provided a 6 month reference group of untreated patients to help 
explore the absolute value of SNS.  
5.1.1. Phase 1         
5.1.1.1. Recruitment    
Potential subjects recruited were patients with severe idiopathic constipation 
refractory to treatment with dietary changes, laxatives, suppositories, and enemas. 
Participants were recruited across three sites from specialist clinics, the majority 
from the University Hospital of North Durham (UHND) with Queen Elizabeth 
Hospital in Gateshead (QE) and the Royal Victoria Infirmary (RVI) in Newcastle 
making up the rest. Two sites involved with the original trial design (Castle Hill 
Hospital in Hull and the Royal London Hospital) could not participate due to changes 
in Clinical Commissioning Group funding locally for the procedure. Eligible patients 
represent an unselected group of individuals with symptoms severe enough to 
justify specialist referral and tertiary intervention. Those who were considered 
suitable, via record screening by a research nurse, according to standard definitions 
and who fulfilled the inclusion/exclusion criteria were invited to participate. The 
study was a prospective randomised double-blinded crossover trial of sub sensory 
ePNE SNS testing, aiming to recruit 75 participants over an approximate 24-month 
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period across the three sites. Participants who were withdrawn on clinical or 
compliance grounds were allowed to be replaced in order to achieve the required 
sample size as calculated from pre-trial audit data. 
5.1.1.2. Inclusion Criteria   
Participants had to fulfil all of the following inclusion criteria in table 16 to be 
recruited into the study. 
Table 16 TiLTS-cc study inclusion criteria 
a Males and females aged 18 years or older. 
 
b 
Constipation according to the ROME III criteria for functional constipation. 
Participants were not excluded if they also fulfilled criteria for constipation 
predominant irritable bowel syndrome (IBS-C). 
c Unknown (idiopathic) aetiology of constipation, as determined by the recruiting 
clinician. 
d Symptoms not adequately relieved by the standard treatments of lifestyle 
modification, laxatives, suppository, and enema. 
e Symptoms not adequately relieved after a trial of Prucalopride 2mg once daily, given 
according to licence. 
 
f 
The recruiting clinician had to be confident of participant comprehension and that 
the consent process was adequate. Translation services were available for non-
English speaking participants, if required. 
The Rome III Criteria for functional constipation (Table 17) were accepted and 
used in the study. (162) The Rome III criteria were assessed using a questionnaire 
at the baseline interview appointments of participants. 
 
5.1.1.3. Exclusion Criteria  
Participants who fulfilled any one or more of the following criteria (table 18) were 
excluded from study recruitment. 
Table 17 Rome III Criteria of Functional Constipation 
Using the Rome III criteria the diagnosis of functional constipation requires                             
at least 2 of the following: 
1 Straining during at least 25% of defecations 
2 Lumpy or hard stools in at least 25% of defecations 
3 Sensation of incomplete evacuation for at least 25% of defecations 
4 Sensation of anorectal obstruction/blockage for at least 25% of defecations 
5 Manual manoeuvres to facilitate at least 25% of defecations                                                                    
(e.g., digital evacuation, support of the pelvic floor). 
6 Fewer than 3 defecations per week.  
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Table 18 TiLTS-cc Study Exclusion criteria 
a Age of less than 18 years. 
b Participants who were not fit enough to undergo the procedure (as per clinical judgement 
of the site researchers). 
c Severe psychiatric disease at the time of study recruitment. 
d Persistent diarrhoea (except when due to laxative over use). 
e Uncontrolled or decompensated cardiac, respiratory, endocrine, renal, or hepatic disease; 
as the clinical judgement of the site PI. 
 
f 
The presence of any progressive neurological disease, or any neurological disease deemed 
to be restricting participant mobility and independence. Participants who had a mild non-
progressive neurological disease not restricting their ambulation or independence, and not 
causing or contributing to their constipation were not excluded. 
g *Secondary causes of constipation (i.e. not idiopathic, e.g. obstructed defecation) 
h Any participants with an active systemic infection. 
i ** Participants known or suspected to be pregnant, or any participants intending to 
conceive within the timeframe of their study involvement. 
j Any participants who were participating in or within 30 days of participating in any 
interventional treatment study. 
k Any participants who had incapacity of higher mental function such that informed consent 
could not be achieved, as determined by the clinical judgement of the research team. 
l Any participants with incapacity of higher mental function or physical abilities that 
prevented accurate completion of study questionnaires. 
m Any participants using variable or unstable doses of an anti-cholinergic, iron, 
antidepressant, or opioid medication. 
 
*It was the clinical decision of the investigators as to the cause of secondary 
constipation, reiterating that this study was to investigate “idiopathic” chronic 
constipation. The assessing clinician decided whether the participant’s constipation 
was idiopathic and that it was not secondary to chronic drug (e.g. opioid) use. 
Secondary causes also included other aetiologies such as obstructed defecation, 
congenital, metabolic, traumatic, inflammatory, ischaemic, and neoplastic in origin. 
Obstructed defecation was consistently assessed by the pelvic floor MDT, and 
participants were excluded if they had evidence of obstructive defecation at 
proctogram through anismus, intussusception or other mechanical effects causing 
delayed emptying. Participants using stable doses (3 months of unaltered dose) of 
known constipating medications were considered suitable if these medications 
were deemed not causative (i.e. secondary) of their constipation.  
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**In ladies of child bearing age a pregnancy test was performed before transit 
studies at baseline, and participants agreed to use adequate contraception for the 
duration of the study, with signed consent to indicate their agreement. 
In forming these study eligibility criteria within the protocol I was consistently trying 
to keep the recruited population as homogenous as possible from the pool of 
participants who may be eligible. In particular, our research questions were aimed 
at adults who have chronic and medically refractory idiopathic constipation with 
demonstrable chronicity, hence the majority of these criteria. With regards to 
pregnancy, I could find no evidence of safety data in the literature for SNS during 
any trimester of pregnancy. The electrical field of the tined lead would be within a 
participant’s pelvis, and most participants would likely be of child bearing age, and 
so it would be impossible to guarantee that the forming foetus of a pregnant 
participant would not be harmed by the SNS field. In order to keep recruitment 
feasible I decided that we could allow participants who had stable doses of 
medications that may potentially affect constipation, and emphasise to the 
participants not to adjust the doses during the study.  
Patient and Public involvement 
The participant information sheet (PIS) was reviewed during the design phases by 
the constipation research advisory group (CRAG), which consisted of Durham clinic 
patients who had experience of constipation trial participation. They advised and 
helped with the design of the PIS and overall study, and approved these as 
acceptable to patients before ethical approval was sought for the study. The 
information on using appropriate contraception to prevent pregnancy within trial 
participation, and on stable dosing of constipation inducing medications was 
included in the participant information leaflet (Appendix 2) which was reviewed by 
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the constipation research advisory group, although I did not ask the group to 
specifically consider these issues. 
5.1.1.4. Criteria used for early study termination  
The study had a trial steering committee (TSC) which reported regularly to the 
sponsoring hospital trust (CDDFT) and a data monitoring committee (DMC) that 
comprised  independent academics (including a statistician) who both met at 
routine 6 monthly intervals (and at the urgent request of the sponsor) to advise the 
sponsor on study safety and futility. These committees considered criteria which 
were devised to protect trial participants from harm or unnecessary continuation. 
The TSC approved four conditions for early study termination (Table 19). 
 
 
 
Table 19 Criteria for early study termination. 
1 Futility: If the trial had no prospect of reaching its recruitment target within 
the given time frame 
2 If a substantial change in understanding/scientific advancement meant that 
continuation of the trial was inappropriate/unethical 
3 Safety: If overwhelming evidence for harm through adverse event reporting 
made continuation non-viable 
4 The sponsor requested trial termination 
 
 
5.1.1.5. Participant Withdrawal   
Withdrawal was defined as participant termination in the trial through; patient 
wishes, clinical grounds, compliance grounds, or data invalidation as decided by 
the investigators. Withdrawn participants were allowed to be replaced at each 
study site. Any phase 3 participant who was withdrawn before the 6 month follow 
up was offered a PAC-SYM assessment to complete which would be carried forward 
to the 6 month analysis. It was emphasised to all participants in both the PIS and 
consent form that if they withdrew of their own accord or were withdrawn for any 
other reason by the site PI, they would still receive the same provision of care and 
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follow up as per the standard in the NHS. It was important in the study design to 
emphasise this to participants in order that this was a continued process of consent, 
and to protect the data integrity through ensuring compliance with blinding and 
procedures. 
5.1.1.5.1. Patient wishes   
Patient wishes were defined as any reasons that the participant deemed 
continuation in the trial unacceptable to themselves. Participants were provided 
with contact details for their local investigators allowing them to discuss any issues 
or concerns if they considered withdrawal. Participants were able to terminate 
participation immediately or at any time during the study if they so desired. 
Participants were offered the opportunity to meet an investigator following 
withdrawal. Data already gathered from participants who had withdrawn were 
kept and used in the analysis; this fact was included in the participant information 
sheet and consent form. 
5.1.1.5.2. Clinical grounds   
Withdrawal of a participant on clinical grounds was considered by the investigators 
due to any illness that either made continued participation a threat to the 
participants’ health or that may invalidate the data collected from the participant. 
Pregnancy was an absolute indication for immediate withdrawal of active 
intervention on clinical grounds due to the unknown effects of SNS stimulation 
fields on embryogenesis. In the event of pregnancy a participant would be treated 
as per their clinical indication in conjunction with opinions from obstetricians and 
anaesthetists if surgery was necessary. Pregnancy during the testing phase 
necessitated a plan to prevent a general anaesthetic during the first trimester: I 
decided that the exiting extension lead would be removed under a local anaesthetic 
and the tined lead would remain in-situ for removal or re-testing at later date. I 
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decided that for pregnancy confirmed in participants during phase 3 the IPG battery 
would simply be turned off. I considered examples of continued trial participation 
becoming a threat to a participant’s health; one obvious situation would be when 
a participant required an urgent MRI investigation to assess another unrelated 
medical condition. In this type of situation, I designed the protocol so that the 
investigator would make a clinical judgement in conjunction with other treating 
clinicians before the decision to withdraw the participant and remove the IPG and 
lead were taken.  
5.1.1.5.3. Compliance grounds   
Withdrawal of participants on compliance grounds were considered where 
participants had non-compliance with assessments and/or any evidence of 
tampering with the security seals on the test box were demonstrated. This was to 
protect the integrity of the blinding which was an integral part of the study design. 
Participants were specifically told about compliance monitoring in the participant 
information sheet, and advised to contact investigators to arrange an urgent review 
if they suspected device problems rather than breaking the security seals in an 
attempt to rectify the problem themselves. In order to preserve their blinding 
during unlikely emergency situations such as stimulation becoming painful or supra 
sensory, I requested that participants pull the wire out of the test box rather than 
switch it off. The participant information sheet clearly stated that device tampering 
was an absolute indication for immediate withdrawal. I approached a security seal 
manufacturer and designed a study specific set of tamper proof security seals that 
could not be taken off from the device without becoming clearly voided. I 
demonstrated these at trial steering group meetings and as no collaborators could 
remove the seals without voiding them, they were approved for use in the study. I 
defined a security seal as “voided” when the bold (black) unique identifying number 
and/or trial lettering had apparent background lettering (“open or void”) across the 
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plain coloured (red) background. This was only possible when the central part of 
the seal was removed. Background lettering could potentially occur due to fraying 
of the seal edges from normal wear, but this would not cross over the bold central 
characters. Please see examples below: A) A normal seal, B) A frayed but valid seal, 
C+D) Voided seals front or back.   
Examples using the “verify” testing stimulator model 3531 Medtronic US 
 
 
  
 
 
 
A) A Normal Seal 
B) A Frayed but valid Seal 
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Examples using the “brown box” testing stimulator model 3625 Medtronic US 
A) A Normal Seal.           B) A Voided Seal
 
 
 
C) Voided seal-front 
D) Voided seal back 
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C) A Frayed but valid seal 
 
5.1.1.5.4. Data Invalidation  
Withdrawal of a participant for data invalidation was considered where a 
participant used a new (not previously used, or agreed at baseline) medication 
during the trial that was known to promote/decrease intestinal motility or influence 
intestinal bacterial flora. This was placed in the protocol to preserve the data 
integrity as the final analysis would be of a small sample (up to 75 participants) and 
consistency of treatments was therefore crucial, the only change should have been 
the SNS trial therapy. Apart from prophylactic use at surgery, antibiotic courses 
required during the trial had their indication recorded as an adverse event. 
Specifically, participants who required antibiotic treatment (not agreed at baseline) 
were not withdrawn from the study but had these courses of treatment closely 
recorded and monitored.  
5.1.1.5.5. Replacement of participants   
The protocol design allowed replacement of participants at each site in the event 
of withdrawal up to the point at which the 75th participant was recruited and 
completed the testing phase. Replacement of participants was allowed up until 8 
months before the anticipated end of all participant’s follow-up. Replaced 
participants were to be recruited and randomised at each site as per protocol and 
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would be given a new randomisation number and allocation on the permuted 
block. This was an important design aspect as reaching the sample size was going 
to be difficult to impossible without replacement of participants. 
5.1.1.6. The trial consent process 
Participants were required to give written consent in all cases (Appendix 3). The 
site investigators and clinicians explained verbally, in writing (or by using 
translators), the nature of the study. A copy of the participant information sheet 
(Appendix 2) was provided for consideration by the participant before consent was 
obtained. Participants were allowed to deliberate for a time appropriate to the 
participant after the initial discussions, before the consent process was completed. 
Participants were advised that they were free to withdraw from the study at their 
own request and at any time during the study. It was explained that the study had 
been designed following the edicts of the International Conference of 
Harmonisation – Good Clinical Practice (ICH-GCP) and that they were protected by 
the 2008 Declaration of Helsinki to ensure their rights, safety and wellbeing. 
Arrangements were made to ensure adequate consent for any participants who 
had impairments (e.g. visual or hearing) that could influence the consent process.  
Participants were advised that they would be invited to take part in the follow-on 
qualitative ESSeNCe study after they had completed the 6 month study 
questionnaires, and if they agreed this would involve structured interview at a later 
date to reflect on their experiences of the disease and TiLTS-cc trial participation. 
Funding changes locally in the NHS in the North East for SNS procedures also 
occurred in 2013. This resulted in SNS only being funded by the CCGs for patients 
with CC recruited to the TiLTS-cc study. I highlighted this fact in the consent process 
through the PIS. 
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5.1.1.7. Participant confidentiality    
Participant identification within the study was by a pseudo anonymous coded 
number which effectively ensured anonymity. A participant’s inclusion in the study 
was visible in their medical notes. Other medical practitioners involved in non-
research related care of the patients (for example in a medical emergency 
unrelated to the study) were able to use the information recorded in the notes 
about study participation and contact either myself or the local principal 
investigators if advice was required. Data were recorded on electronic case report 
forms (e-CRFs) using the DCTU online system with the participant’s study number 
only, and no other personal identifiable information. 
5.1.1.8. Information to General Practitioners   
General Practitioners were informed of their patient’s decision to participate in the 
study. The GP letter (Appendix 4) provided information about the study, and a copy 
of the participant information leaflet. The GP was invited to contact me or other 
site investigators if they had enquires or objections to their patient being recruited 
into the study. 
5.1.1.9. Baseline demographics and assessments  
5.1.1.9.1. Baseline assessments   
In phase 1 all participants had the severity of their constipation assessed at baseline 
for two weeks before their trial registration and surgery to implant the tined lead. 
Participants attended a baseline appointment where the severity was assessed 
through questionnaires measuring symptoms: PAC-SYM (Appendix 5), a daily diary 
exercise (Appendix 6), quality of life: PAC-QOL (Appendix 7), and health status: EQ-
5D-3L (Appendix 8). Baseline demographic data were collected and a transit study 
performed as a physiological measurement of colonic transit time (if the participant 
had not had a transit study within 6 months of baseline). Each participant was 
106 
 
classified as either “slow” or “normal” transit using the Metcalf protocol. In the 
original trial design I did not consider repeating the transit study in testing non-
responders (not implanted) as this could be considered an unethical use of ionising 
radiation. Anaesthetic pre-assessment was carried out if required, typically for 
participants thought to be at higher risk from general anaesthetic. All female 
participants who could potentially conceive had a pregnancy test performed at 
baseline, and agreed not to attempt to conceive during the study through the 
consent process. Participants were informed of theatre dates for both surgical 
procedures (tined lead implantation and either IPG or removal 6 weeks later) at 
baseline. I was keen to avoid anxiety caused by uncertainty as this may have 
affected data, and so each participant was given precise dates and times for 
surgery. Participants were placed as near to the beginning of the theatre list as 
possible to ensure the best possible infection control practice, and also to allow for 
same day randomisation as participants would have recovered sufficiently long 
enough to understand and remember instructions from the blinded and un-blinded 
researchers on the study devices. Continuous data collection through daily diaries 
commenced in the 2 weeks preceding the testing phase to generate baseline pre-
intervention scores. 
The following demographics were obtained together with specific clinical details: 
 Duration and onset of illness 
 Demographic profiles 
 Symptom profiles using a questionnaire based on the Cleveland clinic 
constipation score  
 Current symptoms and signs 
 Medication usage (except anaesthesia and other medication around GA) 
 Past medical/surgical history 
 Classification of IBS-C  
107 
 
 Eligibility check 
 Physiological parameters  
 At baseline in the assessment clinic: 
 Transit studyand βHcG (for female patients with child bearing 
potential only) 
The Transit study was performed at baseline, prior to tined lead insertion, where 
participants had not had a transit study in the preceding 6 months. 
Symptom profiles were recorded by clinicians using the Cleveland Clinic 
Constipation Score questionnaire at baseline and 6 month study visits (163).  This 
uses a Likert scale of severity scoring.   
5.1.1.9.2. Transit studies   
Transit time was a measured physiological parameter at baseline. This was not 
repeated if the patient had a transit study within 6 months of baseline. Each 
participant was classified as either “slow” or “normal”. The original study design 
was to reassess transit time by the same method at 6 months post IPG implantation, 
but this did not become feasible due to a sudden and unexpected change to the 
way the main site conducted the transit study investigations. The radiology 
department changed the type and number of capsule markers used during the trial 
without informing the study team, and so there could be no consistency in this 
analysis. Transit studies were therefore used simply to classify participants into 
slow or normal transit time. The standardised method used in Durham is a 
modification of the Metcalf protocol.  
The modified Metcalf protocol: This is measured by the patient swallowing 3 
standard Sitz marker capsules (total of 72 markers), and a plain abdominal 
radiograph taken at day 5 post ingestion. The number of remaining markers in-situ 
are simply counted and classified into 3 locations; right colon, left colon and recto-
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sigmoid. Slow transit constipation is diagnosed according to the Metcalf protocol 
when 45 or more markers remain at day 4 post ingestion (164). Recent expert 
consensus has established that a single day-5 X-ray is more accurate at 
discriminating between slow and normal transit and this is the accepted study 
method at Durham. The full Metcalf protocol demands a second X-ray for further 
classification when the first X-ray diagnoses slow transit. I felt that this was not 
useful information to collect, and therefore un-necessary irradiation of the patient. 
Discussions with our Constipation Research Advisory Group (CRAG) representatives 
suggested willingness for patients to undergo these extra investigations. 
5.1.1.9.3. Daily diary card exercise    
Participants were asked to fill in daily diary cards and return them on a weekly basis 
according to the participant’s self-completion schedule (Appendix 6) throughout 
baseline, the 6 testing weeks, and in phase 3 follow-up. The diaries were initially 
developed with user involvement, have been used in routine clinical practice, in a 
previous clinical trial, and their internal consistency was validated in over 50 
participants during a physiological and quality of life study/thesis (165). The diaries 
included assessments of:  
• Abdominal Pain Score 
• Spontaneous complete bowel movements 
• Bloating 
• Straining  
• Laxative score 
• Laxative intake  
5.1.1.9.4. PAC-SYM and PAC-QOL   
The Patient Assessment of Constipation (PAC) questionnaires consists of two 
separate scales, PAC-SYM (a 12 item measure of symptom severity across 3 
subscales, (example in Appendix 5) and PAC-QOL (a 28-item measure of health 
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related Quality of life across 4 subscales, (example in Appendix 7). The PAC-SYM 
questionnaire has validated and reproducible internal consistency, and is therefore 
an effective tool to demonstrate a response to medical treatment for constipation 
symptoms (166). The PAC-QOL questionnaire has demonstrated internal 
consistency which has been reproduced in multinational studies (167). Both of 
these questionnaires were administered at determined intervals through the 3 
phases of the trial (Participant self-completion assessment schedule-Appendix 9). 
These assessments are widely considered to be the most accurate for measuring 
the symptoms and quality of life of sufferers, amongst experts in the field. They 
were chosen due to their proven validity and consistency. PAC-SYM was chosen as 
the measure of the primary endpoint of the study. This would be defined as a 
reduction in mean total PAC-SYM score of >0.5 from baseline. 
5.1.1.9.5. TiLTS-cc VAS    
The TiLTS-cc visual analogue scale (TiLTS-cc VAS-Appendix 10) was constructed by 
the team to be a simple tool for the participants to demonstrate a subjective 
symptom response to the SNS testing. I designed this as a 20cm line with a scale 
from 0-100% which asked the participant to place a cross on the line corresponding 
to how much they feel the SNS has improved their constipation symptoms 
compared to baseline, with 100% representing a complete cure and 0% 
representing no change at all. This was used to identify test responders who were 
defined as placing a cross on the TiLTS-cc VAS line at or above 25%. The level of 25% 
was set at an investigators meeting where it was felt that this level would be a 
significant improvement in medically refractory chronic disease symptoms. The 
increments were percentage points on the line in order that participants and would 
not be guided by a scale in 5% increments. We also believed that this would 
correlate with an improvement in PAC-SYM of 0.5 or greater which is considered a 
significant response. Participants were obviously not informed of what level 
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constituted a response to the treatment in order to stop them from self-selecting 
into the testing response group. 
5.1.1.9.6. EQ-5D-3L   
EQ-5D-3L is a standardised instrument for measurement and valuation of health 
status developed by the Euro Qol Foundation (Appendix 8). It is used to determine 
the global and generic status of a person’s health and health related quality of life. 
It is designed for self-completion and is widely applicable to a variety of health 
conditions and treatments (168). It can be easily completed in a few minutes and 
has a 3-level design consisting of a five dimensional descriptive profile. The EQ-5D-
3L is applicable in clinical, economic and population-based studies. The 
performance of EQ-5D-3L in irritable bowel syndrome and inflammatory bowel 
disease has been evaluated in studies (169, 170).  The responses to the EQ-5D-3L 
can be converted to preference based health state utility values using a scoring 
system developed from a large sample of the UK general population.  These health 
state valuations can be used as an outcome measure in their own right or as the 
basis for the calculation of quality adjusted life years (QALYs).  The tool is very 
widely used and is the recommended tool by the National Institute of Health and 
Care Excellence as part of technology assessment reviews. The EQ-5D-3L consists 
of 2 pages - the EQ-5D descriptive system and the EQ visual analogue scale (EQ-5D-
VAS). The descriptive system assesses 5 dimensions of a study participants health 
related quality of life: mobility, self-care, usual activities, pain/discomfort, anxiety/ 
depression. Each dimension has 3 self-response levels: no problems, some 
problems, extreme problems. The respondent is asked to indicate his/her health 
state by ticking (or placing a cross) in the box against the most appropriate 
statement in each of the 5 dimensions. The EQ VAS records the respondent’s self-
rated health on a vertical, visual analogue scale from 0-100 in 1 % increments, 
where the endpoints are labelled “Best imaginable health state” and “Worst 
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imaginable health state.” Within this study, the EQ-5D-3L data would form the basis 
of QALY estimates used in turn to estimate the incremental cost per QALY (off xxx 
compared with YYY) on an intention to treat basis. The non-response group 
following the NR pathway (not implanted) was planned to provide a 6 month 
control group of disease symptom chronicity for these secondary analyses and 
would be compared with both the test discriminate and indiscriminate responder 
groups. This was planned to help to adjust for regression towards the mean. The 
EQ-5D-3L was administered at defined intervals as per the study assessment 
schedule. 
5.1.1.9.7. Laxatives and laxative score  
Laxatives were allowed as supplementary or rescue therapy in addition to SNS. 
During the study design stages I believed that participants would take these 
irrespective of instructions if they felt no effect from the treatment and were 
suffering. It was therefore more acceptable to allow this and ask that each 
participant documented the intake of any laxatives in the daily diary. Newly 
licensed agents (such as Prucalopride and Linaclotide) were prohibited in order to 
preserve continuity during the trial.  Since all participants were laxative-refractory, 
and on listening to advice taken from patient research advisory groups on the trial 
design, I opted to allow each participant to continue with their preferred usual 
laxative regimen.  A simple diary score was devised to assess whether laxative 
intake on a particular day was: less (-1), more (+1), or the same as (0), their usual 
daily intake.  This was previously validated in a similar clinical trial of SNS in 
neurogenic constipation (171). 
5.1.1.9.8. Medications     
All medications were recorded from baseline until the 6 month follow-up visit. The 
exceptions were medication given as part of routine anaesthesia during study 
related surgical procedures. 
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5.1.2. Phase 2-TiLTS-cc Testing 
This phase of the study commenced on the day of the tined lead implantation 
procedure and continued until the second procedure when it was either removed 
or an IPG battery was implanted and connected to it.  
5.1.2.1. Measures to avoid Bias  
To maximise the study quality, certain measures were taken to reduce bias. 
5.1.2.1.1. Randomisation  
Participants were randomised into either group A or B to decide the order of active 
and sham stimulation during the testing phase 2 of the trial (Table 21). The 
randomisation process was administered by Durham Clinical Trials Unit using a web 
based permuted block by site to evenly distribute participants to either group A or 
B, given the low numbers involved in the trial. The randomisation was performed 
by the un-blinded researchers only, and this was their only task in the whole study 
in order to preserve data integrity. There were several unique study design features 
written into the protocol for randomisation. I devised the concept of an un-blinded 
researcher who only handles randomisation in order to preserve my blinding of the 
participant’s sequence of SNS, in the knowledge that I may influence participants 
subconsciously during study visits if I were privy to their allocation. Using a 
crossover design also allowed participants effectively to act as their own controls 
which would further preserve data integrity in any analysis given the small sample 
size. 
5.1.2.1.2. Double-Blinding   
All investigators including myself and participants were blinded to the 
randomisation grouping of participants (A or B) during phase 2 of the trial. Only the 
university study monitors (DCTU) and one delegated member of the research team 
the “un-blinded researcher” were privy to the groupings. The participants were 
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prospectively informed of the allocation ratio of 1:1, and that the blinding 
prevented them from knowing their group allocation and thus the order of testing. 
To robustly conserve blinding, a delegated team member (the “un-blinded 
researcher”) modified the test box accordingly at the appropriate time intervals 
during phase 2 (Table 21), and the “blinded researchers” were not involved in this 
process, and the protocol mandated they must not be present in the same room 
during device randomisation. To further preserve trial integrity and minimise 
investigator bias, the “un-blinded researcher” was prohibited from any data 
collection, handling or interpretation. This prevented the un-blinded researcher 
from giving data feedback to participants which may have influenced their results. 
5.1.2.2. Tined lead insertion   
In order to ensure consistency of the technique between sites I standardised the 
surgical procedure and the equipment used (Table 20) in the protocol. Participants 
were admitted as day case participants on the day of surgery. General anaesthetic 
was preferred for the procedure, and all participants were administered 
prophylactic intravenous antibiotics as per the current version of the study 
antibiotic prophylaxis algorithm, and positioned by the surgeon in the prone 
position. The usual aseptic skin preparation technique was observed using Povidine 
skin preparation. Surface skin landmarks were drawn to aid percutaneous insertion 
of the testing needle to the 3rd sacral foramina (Figure 8). 
Table 20 Technical details of Medtronic kit used for the study 
CE Marks all CE0123 
Lead intro kit model 3550-18 Test stimulator model 3625 
Tined Lead model 3080 Test stimulator model 3531 (Verify) 
Lead introducer model 042294 Interstim extension twist lock cable
 model 3095 
Interstim 2 model 3058  
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Under image intensified fluoroscopic guidance the position of the testing needle 
was confirmed, and the side with the strongest low voltage anal motor response 
(bellows response) was selected. A guidewire was inserted through the testing 
needle and the needle removed. A small transverse incision (<5mm) was made 
around the guidewire to allow the trochar to pass through the skin easily, and 
cannulate the foramen. The trochar position was confirmed by fluoroscopy and 
aimed to stop within the bone of the foramen to prevent formation of a false 
passage within the pelvis. With the trochar needle removed an insertion sleeve 
remained in place to accurately place the tined lead within the foramen and this 
position was confirmed by lateral fluoroscopic visualisation. The aim was to place 
at least the two distal electrodes (0 and 1) within the pelvis and the two proximal 
electrodes (2 and 3) within the foramen (Figure 9).   
 
Figure 8 Insertion of the testing needle to the 3rd sacral foramen 
Reproduced with permission from Medtronic 
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Each individual electrode was pulsed with a testing box in order to observe the 
corresponding S3 anal motor response. Once the tined lead position was 
satisfactory, the tines were deployed by removal of the sleeve, and the tined lead 
was tunnelled to the ipsilateral buttock where a potential IPG cavity was 
constructed through a 5cm transverse incision. The tined lead was then connected 
to an extension lead via a boot connector and this was tunnelled and exited laterally 
on the contralateral side of the potential IPG pocket. The extra tunnelling was 
designed minimise the potential for infection spreading down the lead and into the 
potential IPG cavity or S3 foramen. The smaller wounds were closed with a single 
absorbable inverted subcuticular suture and sealed with tissue glue over the skin. 
The 5cm buttock incision was closed in layers, with absorbable interrupted sutures 
to the fascia over the leads, and a single absorbable continuous subcuticular suture 
to the skin with sealant tissue glue. A large transparent dressing was applied over 
all of the wounds. The extension lead electrodes were connected to a twist lock 
cable and this was anchored to the skin with another dressing to prevent traction 
on the exit lead site. Participants were instructed to keep the exit lead and all 
dressings dry, and to apply the further transparent adhesive dressings provided if 
the edges started to curl. 
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5.1.2.3. Test stimulator connection   
After participants were recovered the external temporary box stimulator (either 
model 3625 or model 3531) was attached to the external lead on the ward by the 
site-specific research nurse and the participant randomised into group A or B by the 
un-blinded researcher. The testing box was switched on a minimum of 4 hours after 
the procedure (a maximum of 24 hours), with new batteries fitted beforehand. The 
minimum duration of 4 hours was selected to ensure the participant had a 
complete washout of all sedating medications and local anaesthetics, to ensure the 
sub-sensory test calculated the correct habituated sub-sensory threshold. The 
TiLTS-cc test routine (Figure 10) was followed for test box set up and any 
subsequent alterations.  
5.1.2.4. Test assessments and routine   
5.1.2.4.1. Methods  
All participants underwent sub-sensory enhanced percutaneous nerve evaluation 
(ePNE) SNS (also referred to here as tined lead test stimulation [TiLTS-cc testing] 
the difference being with a sham control), and responders were classified into 
either discriminate (response to actual test stimulation only) or indiscriminate 
groups (response to sham or both sham and actual stimulation) after study un-
blinding for data analysis. Any responders, however, were offered permanent 
sacral nerve stimulation (PSNS).  Participants with no response in either period of 
testing were not offered PSNS and simply had the tined lead removed.  
Participants underwent the TiLTS-cc testing phase for a period of six weeks after 
being randomly assigned into one of two testing groups (Table 21). The participants 
and investigators were blinded to the groupings; this enabled a two week crossover 
for each participant, including two periods of two week tests (either actual 
stimulation “on”, or sham stimulation “off”) and two weeks of “washout” 
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(normalisation) between the periods. This washout was essential as a recent trial 
of temporary SNS in neuro-constipation demonstrated that only at three weeks 
after cessation of stimulation did positive responses return to normal, and 
confirmed that 2 weeks of actual stimulation produced a measurable effect (171).  
5.1.2.4.2. Assessments     
The analysis of test outcomes were performed at the end of week 2 and week 6 
using a visual analogue scale (TiLTS-cc VAS). This allowed more than three weeks of 
washout (Table 21) between the end of the second test period (week 6) and the 
end of the first test period (week 2), whilst allowing us to measure a washout effect 
(week 4).  Maintaining the 2 week daily diary exercise during the washout period 
also kept the blinded participants and researchers in a constant assessment routine 
which improved data quality. Please also refer to the full trial assessment schedule 
(Appendix 9). 
Table 21 Randomisation for TiLTS-cc testing phase 
Phase 2 TiLTS-cc 
Week 1 
TiLTS-cc 
Week 2 
TiLTS-cc 
Week 3 
TiLTS-cc 
Week 4 
TiLTS-cc 
Week 5 
TiLTS-cc 
Week 6 
Group A On On Washout Washout Off Off 
Group B Off Off Washout Washout On On 
On = Sub-sensory SNS stimulation received,  Off = sham SNS stimulation received 
(Figure 10 page 122, and test routine page 117) 
Washout = Device disconnected from the patient 
 
5.1.2.4.3. Test Routine  
The test stimulation was provided using sub-sensory settings to enable blinding of 
participants during on and off periods of the test. Conventional settings for 
frequency (14Hz) and pulse width (210µSec) were used so that only the amplitude 
(voltage or current) of the waveform was adjusted to provide sensory or sub-
sensory stimulation. These settings were conventional practice following years of 
trial and error in other physiological studies of FI and CC, and only in treating FI 
sufferers have changing frequency or pulse width settings been noted to improve 
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patient outcomes (102-107). The neuromodulation test box model 3531 behaved 
in an identical manner during both testing periods giving the impression to the 
participants and any other observer that it was providing stimulation. Each test box 
model 3625 was calibrated before and after phase 2 testing, and the digital test box 
model 3531 was considered calibrated per factory as a brand new box was used for 
each participant. The calibration of the 3625 “brown box” model was essential and 
is discussed further in Chapter 6 (Results-incidental findings). I had become 
suspicious of possible variability in its performance and reported this to my 
supervisors who suggested devising a calibration experiment to check the output 
waveform of the device. This found that the old analogue model 3625 was indeed 
highly variable in performance and did not deliver the same nerve stimulation each 
time to every participants, likely due to the analogue nature of its dials. These likely 
suffered damage through wear and tear leading to inaccuracy at setting the dials 
correctly, resulting in variable output waveforms. Re-calibrating the dials before 
every testing period was the only feasible solution to this problem and I devised a 
way for this to be done, as explained in Chapter 6.  
A delegated research team member was trained to set the positive and negative 
electrodes (as per a study specific SOP) prior to the TiLTS-cc testing routine. The 
research team member adjusting the box settings at the beginning of each testing 
period was not blinded (and so not involved in completing the case report forms) 
and performed an adjustment routine (Figure 10). This comprised a series of 
checks: participant identity, assessment compliance, current study week, 
randomisation grouping, test box number (the same box was retained unless 
malfunctioned), new battery change and box test. To minimise infection risks and 
damage to the connecting wire, the wire exit site was viewed through a clear 
dressing. This dressing was only removed or replaced if there were signs of infection 
or wear and tear.  
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Model 3625 testing routine 
In early protocol versions the analogue “brown box” model 3625 test stimulator 
was used and the output pulse width, frequency, and voltage was checked on an 
oscilloscope pre and post participant use to confirm the stimulation parameters 
were calibrated and consistent. The test was performed by the blinded researcher 
(usually myself) who set the device to a pulse width of 210µSec, Frequency of 14Hz 
and I would increase the voltage until sensation was just perceptible, and this was 
recorded as the participants sensory threshold (ST) = y Volts in the records. The 
participants then underwent a habituation period of 5 minutes before the 
habituated sensory threshold (HST) was recorded as HST= x Volts. In order to 
systematically set all participants to a very similar level of sub-sensory stimulation 
a value of 75% of HST was chosen for the settings. 75% of the HST value was then 
calculated (recorded in the notes) and the device was programmed to stimulate at 
this current; the participants were now receiving active sub-sensory stimulation at 
75% of their HST. I and other blinded researchers left the room and the un-blinded 
researcher set the device as per randomisation for that participant in that period of 
testing. The active testing period “on” demanded no further adjustments. The sham 
testing period “off” demanded that the device simply had all internal electrodes 
switched off by the un-blinded researcher. Two security seals were then placed 
over the front and battery cover to ensure that it could not be powered on or off, 
or opened to reveal the internal electrode settings, by either the participant, myself 
or other colleagues. The device appeared identical to any observer during both “on” 
and “off” settings with the visible external LED flashing continuously during both 
settings. 
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Model 3531 testing routine 
As of protocol version 14 (23/07/2013) only the “Verify” testing stimulator [model 
3531] was used in the study. The digital test stimulator model 3531 “Verify” (an 
automatic constant current, variable voltage device), was considered very accurate 
after calibration tolerance tests (Chapter 6) and as a new model was used for every 
recruited participant this calibration process was stopped. The stimulation settings 
were digitally programmed via a wireless control unit (after Bluetooth pairing) to a 
pulse width of 210µSec, Frequency of 14Hz, with the stimulation current (mAmps) 
recorded according to individual participant levels (variable as individual tissue 
impedance varies). The current was increased from 0 milliAmps (mAmps) until the 
sensory threshold was reached and this was recorded as Sensory Threshold (ST) = 
y mAmps. The participant was then left to undergo a habituation period of 5 
minutes and then the habituated sensory threshold (HST) was recorded as HST= x 
mAmps. 75% of the HST value was then calculated (recorded in the notes) and the 
device was programmed to stimulate at this current; the participants were now 
receiving active sub-sensory stimulation at 75% of their HST. The active testing 
period “on” therefore demanded no further adjustments. The sham testing period 
“off” demanded that the device was simply switched off remotely by the un-blinded 
researcher using the control unit. Two security seals were then placed over the 
front and battery cover to ensure that it could not be powered off or paired with 
another Bluetooth controller. The test stimulator 3531 appeared identical to the 
participants in both active and sham tests and could only be differentiated by using 
the programming control unit which was not supplied to the participants or blinded 
researchers. This model also comprised an internal chip capable of storing 
stimulation data during the testing period, which was used by un-blinded 
researchers at the weekly check to ensure the validity of the preceding testing 
week.  
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5.1.2.4.4. Resetting in the event of a fault  
Participants who reported any problem with their testing box were recalled to the 
hospital at the earliest opportunity (and within 3 days), for an extra study visit 
assessment and to have the box settings checked and validated. If no faults with 
the box or testing leads were found, the test routine as described above was 
followed and the participant continued unaltered in the trial.  If no faults were 
detected and more than 3 days had elapsed then the participant was returned to 
the beginning of the current phase of treatment. (I.e. a participant with a fault 
during weeks 5 or 6 would be returned to the start of week 5 and a participant with 
a fault detected during weeks 1 or 2 would be returned to the start of week 1). If 
this was not acceptable to the participant, they were offered the choice to 
withdraw from the trial. This was to ensure that the peak symptom response was 
after 2 weeks of continuous sham or active stimulation. 
If a fault was detected with the test box or leads this was documented and the box 
or leads replaced. The test routine as described above was followed and the 
participant continued unaltered in the trial. If there was a fault detected within the 
extension exit wire, this was replaced surgically at the earliest opportunity. 
Following replacement of the extension exit wire, the test routine(s) as described 
above were followed and the participant returned to their allocated test box 
routine at the start of their latest two-week testing period (i.e. a participant with a 
wire fault during weeks 5 or 6 would return to the start of week 5 and a participant 
with a fault detected during weeks 1 or 2 would return to the start of week 1). If 
this was not acceptable to the participant, they were offered the choice to 
withdraw from the trial.  
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Figure 10: TiLTS-cc test routine 
 
5.1.2.4.5. Disconnecting in emergencies  
Participants were allowed to disconnect the device externally by pulling out the 
wire from the test box. They were told to do this in emergencies only, and we 
recommended this over turning off the box by breaking the security seals to remove 
the batteries. Emergencies were defined as any unexpected symptom or sign that 
the participants or another doctor attributed to the test box providing stimulation, 
any situation where the test box was accidentally damaged, submerged in water or 
thought to be malfunctioning. A detailed list of known complications of, or effects 
from SNS was provided to the participant (Table 22). To protect participants (as 
distracting stimulation surges are theoretically possible) we recommended that 
participants abstain from driving during TiLTS-cc testing weeks 1, 2, 5 and 6. 
Participants were clearly informed in the PIS not to drive whilst the test stimulation 
was on-going, and if they must drive as a last resort (e.g. emergencies) the box 
should be disconnected by pulling out the wire. Driving was permitted during weeks 
3 and 4 when the stimulator box was not attached to the lead. 
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5.1.2.4.6. Voided Security Seals   
Any participant who had voided the security seals for any reason (including 
emergencies) was referred to the site principal investigator (without revealing the 
blinding) and withdrawn from the study on non-compliance grounds. This fact was 
clearly stated on the participant information sheet (PIS), and was considered vital 
to protect the scientific integrity of the study. Only 1 participant was withdrawn in 
this way, and they followed the normal intention to treat pathway used at Durham, 
and their response to testing classified by these means instead of the TiLTS-cc VAS. 
Their subsequent treatment and standard of care was not affected by being 
withdrawn in this way.  
5.1.2.4.7. End of TiLTS-cc testing visit   
Participants who completed the TiLTS-cc testing phase of the trial were assessed by 
either myself or a delegated investigator, for interpretation of the TiLTS-VAS and 
decision on intention to treat. Both participants and investigators were blind to the 
randomised grouping and so to the order of stimulation during the TiLTS-cc testing 
phase. The efficacy of test stimulation was assessed by a visual analogue scale 
(TiLTS-VAS) of perceived benefit, with 0% as no benefit and 100% as cure. An 
improvement of equal to 25% or greater in the TiLTS-VAS was deemed a positive 
test response. In practice we have found that the different scores correlate very 
closely and that participants responding to test stimulation will show improvement 
in all, or nearly all, scores. We believed 25% (as a measure of response) correlated 
well with a reduction of at least 0.5 in PAC-SYM, and although simplistic was a good 
way of measuring perceived benefit in participant’s symptoms and maximising the 
implantation rate. This would also allow us a secondary analysis to help find the 
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thresholds of PAC-SYM and PAC-QOL in SNS testing as a hypothesis generating 
study. If the participant responded to any of the stimulation periods they were 
offered an implantable pulse generator (IPG) and progressed to the permanent 
sacral nerve stimulation (PSNS) phase 3 of the trial.  They were listed in theatre for 
connection of the internal component of the same tined lead to a permanent IPG 
at the next study procedure which was within 1 week maximum of the end of week 
6 assessment visit. They were blinded to response classification until the day of 
surgery in case any questionnaire data queries arose when investigators classified 
their response between these visits. 
5.1.3. Phase 3- Responders (R) and Non-Responders (NR)  
5.1.3.1. Non-Responders-Tined lead removal  
A participant deemed to be a non-responder from the TiLTS-cc testing phase had 
their theatre booking amended on the day of surgery to “removal of tined lead”, 
and the participant was informed of the testing result on the day of surgery. They 
were also blinded to response classification until the day of surgery in case any 
questionnaire data queries arose when investigators classified their response 
between these visits. The participant was admitted to the day-case unit. Pre-
procedure checks were performed by the theatre team per routine clinical practice. 
The participant was given either a general anaesthetic or local anaesthetic/sedation 
as per centre policy. The surgeon positioned the participant either prone or lateral 
on the operating table. The usual aseptic technique was observed. The lateral 
(potential IPG site) buttock incision was re-opened to assist in lead removal by 
dissecting and disconnecting the boot connector from the tined lead, which would 
be difficult to do without adequate exposure. The midline scar was also reopened 
to assist with tined lead removal from the S3 sacral foramen. The tined lead was 
carefully removed through vertical midline traction over the S3 foramen, and the 
wounds repaired in the usual manner with sutures and a dressing. The discharge 
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procedure was as standard for all day case surgery participants in each site. I 
expected that most participants will be discharged on the same day as surgery, but 
due to some instances where post-operative pain control was inadequate I allowed 
for a maximum stay of 48 hours after which time I would report a serious adverse 
event (SAE) to the data monitoring committee. Participants who had overnight 
stays were placed on a surgical ward. Our participants classified as NR (non-
responders) were followed up in 6 months’ time (by a blinded investigator) after 
discharge to complete the final round of assessments which included PAC-SYM, 
PAC-QOL, Euro-QOL (EQ-5D-3L), and 2 weeks of daily diary cards (Appendix 9). All 
self-completion assessments were posted out more than 2 weeks prior to a 
participant’s attendance in the research clinic to allow adequate time for 
completion. 
5.1.3.2. Responders--IPG implantation    
A participant deemed a test responder would be admitted to the day case surgery 
unit within a week of the end of week 6 assessment, and the participant informed 
of the testing results. The theatre list was amended to “IPG implantation and 
connection of in-situ tined lead.” Prophylactic intravenous antibiotics (as per the 
current antibiotic prophylaxis protocol) were administered by the anaesthetist 
observing any documented allergies. After being induced to general anaesthesia 
the surgeon positioned the participant in the prone or lateral position on the 
operating table. The usual aseptic technique was observed. The lateral (potential 
IPG site) buttock incision was opened and a suitable cavity dissected to contain the 
IPG. This was the contralateral side of the externally tunnelled exiting extension 
lead and ipsilateral to the internally tunnelled tined lead and cannulated S3 
foramen. The extension lead was disconnected internally from the boot connector 
and discarded after being removed entirely via the exit site, with careful attention 
not to contaminate the IPG pocket by internalising the exit lead. This was an 
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important design from the first protocol as I was aware infection would be a risk 
and this was an obvious source of contamination of the IPG. After the extension 
lead was removed the internal electrodes of the tined lead were connected to the 
IPG in the usual manner. The IPG was secured underneath fascia, and the wound 
closed in layers with absorbable sutures as absorbable inverted interrupted sutures 
to fascia, absorbable subcuticular sutures to skin, and the wound sealed with tissue 
glue and a dressing. Local anaesthetic was injected around the wound edges and 
deeper to the IPG cavity to aid with post-operative analgesia. The discharge 
procedure was as standard for all day case surgery participants in each site. We 
expected that most participants would be discharged on the same day as surgery, 
but due to some instances where post-operative pain control was inadequate we 
allowed for a maximum stay of 48 hours after which time I completed a serious 
adverse event (SAE) and recorded this with the data monitoring committee. 
Participants who required overnight stays for pain control were located on a 
surgical ward.  
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5.1.3.3. IPG Activation     
Participants had the IPG activated as per the normal practice of each site within 
two weeks of implantation, and set accordingly to the usual sensory stimulation 
settings by the blinded researchers. The standard IPG setup was to obtain the 
lowest voltage anal sensory response possible between two of the four electrodes. 
Ideally this was between two adjacent electrodes to help preserve battery life (by 
focussing the field). The electrode settings (electrode number +ve and –ve) and 
voltage were recorded at each visit in the notes. Participants were followed up in 
the research clinic for any necessary IPG setting adjustments at the 3 and 6 month 
assessment appointments (Figure 12). Minute movements of the tined lead could 
potentially result in the active electrodes becoming less effective (if they had 
moved slightly away from the nerve), and so the advantage of having four 
electrodes on a tined lead is the ability to manipulate the size and location of the 
field between electrodes to “recapture” the nerve. Participants received the same 
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PSNS follow-up care that is current practice at study sites, which includes urgent 
appointments for IPG re-adjustments if they were experiencing unusual symptoms 
or side-effects. Participants were fully educated in turning the IPG on, and off (for 
emergencies only) using the patient programmer. Participants were also given a 
temporary IPG TiLTS-cc study information card to carry on their person until the 
permanent Medtronic IPG information card arrived. This could be used to avoid 
security scans at airports and to notify clinicians who were considering an MRI 
(prohibited) for an unrelated clinical indication.  
5.1.3.4. PSNS Assessments     
Participants who received the IPGs and therefore progressed onto the PSNS phase 
3 were followed up at the end of months 3 and 6 from the date of implantation, 
and given these assessment dates before discharge. We accepted that there would 
be a degree of variation in timing (due to clinical and service commitments of 
investigators, and participant holidays) but emphasised that a time limit of +/- 2 
weeks be placed on these assessments taking place before a protocol violation 
occurs. In practice we considered a variation of 2 weeks at the 6 month endpoint 
as making no significant difference to the outcome measures.  
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5.1.3.4.1. Month 3 assessments 
Participants completed 2 weeks of daily diaries, EQ-5D-3L / EQ-5D-VAS, PAC-SYM 
and PAC-QOL scores at this visit (Appendix 9). All assessments were posted to 
participants >2 weeks prior to their 3 month follow up appointment in the research 
clinic to allow adequate time for completion. Trial assessments were completed 
prior to any IPG setting changes that were required (Figure 12). It was possible to 
identify participants at this visit that were classified as early non-responders to 
PSNS. Participant response to treatment was classified according to their change in 
total mean PAC-SYM score from baseline, with responders (R) having a greater than 
or equal to 0.5 decrease from baseline and non-responders (NR) a less than 0.5 
decrease from baseline. All participants who were classified at this time as being 
NR were treated as per standard clinical practice in each centre; the assumption 
was that this was due to either a technical fault or tined lead migration. 
Investigations performed to assess non-response included checking the IPG battery 
and settings, and having an additional lateral pelvic X-ray to look for tined lead 
migration. If either device failure or lead migration were confirmed then the 
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participant would have the lead re-sited and/or reconnected to the IPG and /or 
malfunctioning device replaced, and then continue in phase 3. Any of these events 
would be recorded in the CRFs as an adverse event and reported to the data 
monitoring committee. 
5.1.3.4.2. Month 6 assessments   
The 6 month assessment was the primary and secondary endpoint questionnaires. 
All participants completed 2 weeks of daily diaries, Euro-QOL EQ-5D-3L, EQ-5D-VAS, 
PAC-SYM, PAC-QOL and Cleveland and Wexner scores at this visit (Appendix 9). All 
self-completion assessments were posted to participants more than 2 weeks prior 
to their 6 month follow up appointment in the research clinic to allow adequate 
time for completion. Clinical assessment data were collected first at the study visit, 
and then any clinically indicated investigations or IPG adjustments in non-
responders could occur. Participants then entered standard clinical follow up from 
this point.  
5.1.4. Analysis Plan 
The analysis was performed at the end of the study after this analysis plan had been 
agreed between the study data monitoring committee, trial statistician and chief 
investigator. I was involved in this process as a member of the study committee and 
provided input to the whole analysis process. 
5.1.4.1. Demographics 
Participants’ age, sex, and duration of illness are presented in Chapter 6 and data 
analysed with descriptive statistics in SAS 9.4. The data are analysed and presented 
as ranges with mean values, standard deviation and outliers highlighted to provide 
an indication of the characteristics of the cohort. The demographics of the cohort 
are compared to those of other studies of SNS for patients with CC. The 
demographics are compared between the randomisation allocations (group A&B) 
within the cohort to test whether the groups are similar. 
131 
 
5.1.4.2. Medical and surgical history 
Participants’ history of medical illnesses and past abdominal surgery pre-SNS are 
tabulated and presented as frequencies across the whole sample. 
5.1.4.3. Baseline assessments 
All baseline assessments performed during phase 1 of TiLTS-cc are collated and 
analysed within SAS 9.4 to describe the cohort, and tested for similarity between 
the randomisation allocations to groups A&B using appropriate statistical tests. 
5.1.4.4. Primary outcome measures 
The primary outcome measure used in the TiLTs-cc study was the PAC-SYM mean 
total score, and the baseline measures are described in the feasibility cohort as a 
range, mean value, standard deviation, outliers, and tested between groups A&B 
for similarity in the allocation. The testing response classification (TiLTS-VAS) is a 
patient-centred visual analogue scale measurement tool from 0-100%. The 
responses indicated during testing using this tool are described as a range with 
mean values, standard deviation, and the proportion of discriminate (actual 
stimulation > 25%) and indiscriminate (sham stimulation >25%) response 
classifications between the group allocations are compared. A correlation analysis 
between the change in PAC-SYM mean total score from baseline to actual, washout 
and sham SNS testing, and the corresponding TiLTS-VAS response was performed 
to test the association between these two outcome measures and whether the 
threshold of VAS response (using 0.5 reduction in PAC-SYM) changes between 
testing phases. This investigates the validity and consistency of the testing 
classification using the TiLTS-VAS. 
5.1.4.5. Secondary outcome measures 
The secondary outcome measures used in the TiLTS-cc study were PAC-QOL mean 
total score, Wexner total score, EQ-5D-3L total score, EQ-5D-VAS percentage and 
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the 6 diary scores. These comprise Likert scale data of daily symptoms including 
abdominal pain, bloating and straining. Daily spontaneous complete bowel 
movements are numerical counts, daily laxative use is a simple yes or no, and the 
laxative score is a simple +1/0/-1 response scale of actual laxative use. These are 
described within the feasibility cohort as a range, mean value, standard deviation, 
outliers and tested between groups A&B for similarity in the allocation. 
5.1.4.6. Sample Size 
Using data gained from clinical audit and from a small pilot study (n=5) it was 
predicted that In the TiLTS-cc testing phase 40% of participants would have a 
discriminate response and we estimated that 70% of these would respond to 
treatment at 6 months based on the reported 6-12 month response rates in current 
publications at that time (99). We also estimated that for the 60% of participants 
with an indiscriminate response (based on audit data of follow up after IPG), 20% 
of these would respond at 6 months. Assuming a power of 90%, alpha of 5%, and 
an allocation ratio between randomised groups of 1:1.5, we calculated the trial 
sample size to be 50 participants. As the Durham Constipation Clinic frequently 
recruited patients to clinical trials we had a good estimate of loss to follow up within 
the study cohort, and estimated loss to follow-up of 20% which inflated the 
required sample size to 60 participants.  This would make TiLTS-cc the largest 
reported trial in the field of SNS to date. We received further feedback from peer 
reviewers (from National Institute for Health Research: Research for Patient Benefit 
programme) who emphasised that we had likely underestimated loss to follow up 
and that 50% was more realistic, thus inflating the sample size to 75 participants to 
allow for greater loss to follow up.  
5.1.4.7. Analysis Populations 
The primary analysis was based on the intention-to-treat principle, including all 
participants that were randomised and classified as indiscriminate or discriminate 
133 
 
responders at the end of tined lead testing. Additional analyses comparing 
discriminate responder, indiscriminate responder and non-responder were 
planned depending on the availability of data. 
5.1.4.8. Responder Populations 
 All participants who were classified as discriminate responders at the end of 
phase 2 
 All participants who were classified as indiscriminate responders at the end of 
phase 2 
 All participants who achieved the primary endpoint at the end of phase 3. 
 All participants who were randomised 
5.1.4.9. Total Population 
 Responder population 
 All participants who were classified as non-responders at the end of phase2 
5.1.4.10. Safety Population 
 All randomised recruited participants. 
 
5.1.4.11. Covariates and Subgroups 
The main primary and secondary analyses of the study were based on participants 
that were classified as discriminate or indiscriminate responders at the end of 
phase 2. This subgroup of participants are referred to as the “Responder 
population” in order to differentiate them from the “Total population”, which 
includes non-responders at the end of phase 2. 
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5.1.4.12. Missing Data 
All missing data were described using cross-tabulation tables. No further sensitivity 
analysis were performed for missing data as these were deemed unproductive due 
to the small sample size. 
5.1.4.13. Multi-centre Studies 
No adjustments were made to account for centre effect in the analyses, as there 
were only a small number of centres (4) and a small sample size (45) rendering any 
conclusions imprecise and unreliable. 
5.1.4.14. Multiple Testing 
The main finding of the study was based on the primary endpoint. As such, no 
multiplicity corrections were performed for the secondary analyses because they 
were considered supplementary to the primary endpoint. 
5.1.4.15. Summary of Study Data 
All continuous variables were summarised using the following descriptive statistics: 
n (non-missing sample size), mean, standard deviation, median, maximum and 
minimum. The frequency and percentages (based on the non-missing sample size) 
of observed levels were reported for all categorical data. In general, all data were 
listed with separate tables for the demographic variables, study variables and 
safety assessment tables. All summary tables were structured with a column for 
each study group (discriminate, indiscriminate and non-responders) and were 
annotated with the total population size relevant to that table/treatment, including 
any missing observations. 
5.1.4.16. Protocol Deviations 
As the actual sample size (45) was smaller than the target sample size (75) due to 
early termination of the trial, we expected this would result in lack of statistical 
power; unless the effect size was considerably larger than anticipated. The early 
termination of the study also affected the interpretation and validity of formal 
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hypothesis testing comparing discriminate responders, indiscriminate responders 
and non-responder. 
5.1.4.17. Demographic and Baseline Variables 
The baselines variables were summarised using n (non-missing sample size), mean, 
standard deviation, median, maximum and minimum for continuous data, and 
frequency and percentages (based on the non-missing sample size) for categorical 
data. Baseline characteristics of the following demographic variables were 
reported:  
 Duration and onset of illness  
 Demographic profiles (age and gender) 
 Symptom profiles using a questionnaire based on the Cleveland clinic 
constipation score 
 Current symptoms and signs 
 Medication usage (except anaesthesia and other medication around GA) 
 Past medical/surgical history 
 Classification of IBS-C 
 Physiological parameters 
 At baseline assessment clinic: Transit study 
 
5.1.4.18. Prior and Concurrent Medications 
These were assessed from the daily diary cards specifically for laxative regimen by 
reporting the frequencies and percentages of the different laxative used during 
follow-up. 
5.1.4.19. Efficacy Analyses 
Data were summarised by study group. N (non-missing sample size), Mean, 
Standard Deviation, Minimum and Maximum were used to summarise continuous 
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variables, whereas number and percentages were used to summarise categorical 
variables. All analyses of the continuous efficacy endpoints were based on mixed 
effects model. Study groups were tested at the 2-sided 5% significance level. All 
analyses of binary endpoints were based on logistic regression for the primary 
endpoint and generalised estimating equations for the secondary binary endpoints. 
5.1.4.20. Primary Efficacy Analysis 
The primary endpoint was summarised using a 2X2 cross-tabulation table with the 
rows representing “discriminate” and “indiscriminate” responders at the of phase 
2, and the columns representing “responder” and “non-responder” at the end of 
phase 3 (6 months) based on a reduction of 0.5 or more in PAC-SYM score at 6 
month. Fisher’s exact test was used to compare the difference in proportions of 
“responder” at the end of phase 3 between the discriminate and indiscriminate 
responders at end of phase 2. The risk difference and its associated 95% confidence 
interval and p-value were also reported. 
5.1.4.21. Secondary Efficacy Analyses 
The secondary endpoints were summarised by study group (discriminate and 
indiscriminate responders). Specifically, N (non-missing sample size, Mean, 
Standard Deviation, Median and IQR, Minimum and Maximum were reported. The 
endpoint was formally analysed to test the hypothesis of “no-difference” in average 
scores between discriminate and indiscriminate responders using mixed effect 
model for continuous endpoint data and generalised estimating equation for binary 
and ordinal endpoints. The methods were chosen to account for intra-subject 
correlation between the repeated measures at baseline, 3 months and 6 months. 
5.1.4.22. Exploratory Efficacy Analyses 
Longitudinal analysis was performed for all the endpoints in order to investigate 
whether there were significant differences between the longitudinal profiles of 
discriminate and indiscriminate responders. The Longitudinal analysis also 
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included interaction between the study group (discriminate and indiscriminate 
responders) and the time points. The PAC-SYM scores were reanalysed without 
converting to a binary outcome as done for the primary endpoint and primary 
analysis. 
5.1.4.23. Diagnostic accuracy of TiLTS-VAS 
The primary endpoint was re-analysed to estimate sensitivity, specificity, positive 
and negative predictive values (PPV, NPV) between TiLTS-VAS at the end of phase 
2 and the change in mean PAC-SYM score at 6 months. Note that indiscriminate and 
discriminate responders at the end of phase2 were collapsed as “responder” for 
this analysis 
5.1.4.24. Exploratory Efficacy Analysis for Non-responders 
Further analyses as described in 2.3.8.3 above were performed with three groups 
in order to compare discriminate, indiscriminate and non-responders, but only at 
baseline and 6 months. 
5.1.4.25. Safety Analyses 
The safety and adverse events data extracted from the case report forms were 
summarised using frequency tables. The safety and adverse events by study 
groups were explored to investigate whether the events are mostly during the 
TiLTs-CC testing phase or during PSNS phase.  
 
5.1.4.26. Reporting Conventions 
The mean, standard deviation, and any other statistics other than quantiles, were 
reported to two decimal places. Quantiles, such as median, or minimum and 
maximum used the same number of decimal places as the original data. Estimated 
parameters, not on the same scale as raw observations (e.g. regression coefficients) 
were reported to 3 significant figures. 
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5.1.4.27. Technical Details 
A second reviewing statistician independently reproduced the primary analyses and 
summary statistics tables. The reviewing statistician had an overview of the entire 
analyses and explicitly checked the entire code used for the analysis. All statistical 
analyses were performed in SAS 9.4, and R version 3.2.3 software was used for 
figures. 
5.1.5. Provision of on-going care after the study   
Participants who had no response to TiLTS-cc guided SNS testing did not have an 
IPG implanted and simply entered the normal routine clinical NHS care pathway. 
Participants who had a continuing response to the implanted IPG at the end of 6 
months in phase 3 retained the implant with on-going surveillance as part of routine 
NHS care, as was current practice. Participants who lost response from the 
implanted IPG at the end of 6 months in phase 3 were offered either removal of the 
IPG as a day case procedure, or reprogramming of the device in an attempt to 
regain response prior to removal (both of which were standard practices), and they 
remained in routine NHS care. All participants were considered to have completed 
the study per protocol after collection of the 6 month visit assessments.  
5.1.6. Ethical considerations 
All appropriate ethical approvals from the NHS Research Ethics Committee (REC) 
were received before the start of the TiLTS-cc study through an application to the 
NHS Research Ethics Service using the integrated research application system 
(IRAS). The study was approved by the NRES Committee North East-York, REC 
reference number 12/NE/0228 on 24/08/2012. Local trust approval was also 
received from host study sites through their respective research and development 
departments. The study was listed on the comprehensive local regional network 
(CLRN) portfolio and registration completed on a publicly available international 
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clinical trials database on 10/10/2012 https://doi.org/10.1186/ISRCTN44563324. 
There were several ethical dilemmas in this research design that I have outlined 
below. 
5.1.6.1. Alternatives to SNS for CC   
SNS for chronic constipation is a relatively novel therapy and experience was still 
limited. We were recruiting patients who had failed all recognised medical and 
nurse led therapies, and who would normally be offered temporary SNS testing 
using the standard 2 week sensory test. Standard 2 week SNS tests in this patient 
group were funded only on special approval within the NHS until the clinical care 
commissioning group (CCG) restructuring in July 2013 after which it was no longer 
funded. Following this time the only access to SNS treatment patients had was 
through the trial. We ensured that participants were counselled and consented in 
a rigorous fashion and fully aware of the issues surrounding the procedure. 
Conversely, short of SNS, the alternatives for patients with severe refractory 
symptoms were invasive surgical interventions with recognized complications and 
no guarantee of success. In this circumstance, I believed that not to offer SNS as an 
alternative would also create an ethical dilemma. By actively studying the 
predictive ability of our test design in this group I believed we could improve our 
understanding of how to correctly select the long term responders to SNS from the 
group. 
5.1.6.2. Prolonged SNS testing period    
Ethical queries could be raised regarding the design of a prolonged testing 
procedure with a possibility of higher complication rates, and including a sham 
stimulation phase.  However, I would argue that the existing system of assessing 
patients for permanent stimulation is poor, often resulting in failure (in 60%) which 
results in patients having two futile operations (to place, and then remove the IPG) 
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each with their own complication profile.  During study design I discussed the TiLTS-
cc research methods with patients who had undergone SNS, and members of the 
patient and public involvement (PPI) group CRAG, and a clear majority of patient 
members felt the TiLTS-cc testing method would be necessary, acceptable and 
justified for the study. A member of the CRAG committee was also appointed onto 
the trial steering committee in order to facilitate participant perspective feedback 
into future protocol amendments and overall trial conduct. 
5.1.6.3. Placebo /sham responders were implanted with an IPG  
The design of the TiLTS-cc study also demanded that participants who were true 
placebo responders (those who responded to stimulation during the sham period 
only) progressed onto the PSNS phase of the trial, and this is the first study to have 
implanted sham responders. In reality, I believed this was actually no different to 
our then current intention to treat practice, as we could not differentiate between 
true responders and placebo responders with the standard 2 week sensory testing 
method used in the NHS. It was also possible that a proportion of the placebo 
responders may have developed a long-term response to sensory PSNS, as we had 
no evidence to the contrary at the time. 
5.1.6.4. Increased risk of complications   
It was not anticipated that the study design would lead to additional harm: the trial 
design caused participants to receive the same care pathway as under routine NHS 
care, but also deliberately classified the participants into distinct response groups 
(after un-blinding and analysis) in an attempt to improve the predictive power this 
testing method. I perceived the theoretical risk of an increase in the risk of localised 
infection due to the extended testing phase before the study.  In the pre-study 
standard NHS participants these infections were usually routinely managed with 
antibiotics and self-limiting with no serious sequelae. Table 22 demonstrates the 
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potential risks as per reporting from trial site audits and in available studies at that 
time, of which infection was considered the most common and serious. 
The study design did increase the risk of infection as the initial tined lead insertion 
precluded an extended testing phase (ePNE) with an external component to the 
wire called the extension twist lock cable. The IPG implantation involved the same 
tined lead which had been connected to the twist lock cable and could potentially 
be colonised, so I decided with the team to give the participants prophylactic 
intravenous antibiotics before tined lead insertion (not standard practice), and 
during the IPG implantation procedure (antibiotic prophylaxis protocol). I also 
decided to design an exit lead site wound review by weekly inspection through the 
dressing. I designed the participant study visits to minimised dressing changes to 
only when clinically necessary in order to avoid unnecessary pathogen exposure by 
cross contamination or damage to the wire. I was hopeful these measures would 
reduce the risk of infection due to exit site contamination of the internal tined lead. 
Table 22  Expected complications (adverse events) of SNS testing and 
PSNS  
Complication Incidence at 
trial sites %1 
Other 
trials %2 
Overall 
risk % 
Commonest 
Infection at testing Lead site 4 7 7 
Transient electric shock/jolt 3 11 11 
Lead or IPG migration 3 5 5 
Pain at IPG or lead insertion site 2 4 4 
Muscle spasm 2 3 3 
Adverse effect on voiding or bowel 
function 
3 3 3 
Secondary seroma/haematoma 2 2 2 
 Very Rare 
Technical device problem <1 <1 <1 
Infection at IPG site <1 <1 <1 
Nerve injury at surgery 0 <1 <1 
Allergic or autoimmune reaction to 
IPG or Lead 
0 <1 <1 
Paralysis 0 0 <1 
Overall % risk 4 11 11 
1TiLTS-cc Trial site audit data, 2 (99, 122, 125, 126) 
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5.1.7. Ionising Radiation 
5.1.8. Radiation Experts     
The study protocol was designed in conjunction with 3 experts in ionising radiation, 
a clinical radiation officer who was a consultant radiologist at the main site, a 
medical physicist who was a radiation protection officer at the main site, and a 
regional NHS radiation protection adviser. These experts helped to calculate the 
potential doses of radiation patients would receive in standard practice versus the 
study exposure in order to inform on the radiation safety of the TiLTS-cc testing 
technique.    
5.1.8.1. Fluoroscopy and X-Ray    
Ionising radiation was used during the study to guide tined lead insertion and 
positioning, and also to measure transit times at baseline. During design we 
calculated that the level of radiation participants were exposed to was equivocal to 
that experienced by patients undergoing the standard treatment pathway on the 
NHS. In this standard pathway participants would have 2 wires inserted under 
fluoroscopic guidance at separate intervals, and during the ePNE technique this is 
slightly reduced by only having one fluoroscopic exposure. Taking into account the 
plain abdominal X-ray to measure transit time at the beginning of the TiLTS-cc study 
(note some participants did not require this at baseline) the overall dose of 
radiation was equivalent.  
The expected range was calculated by our radiation protection adviser as 0.60mSv 
+/- 0.33mSv depending on screening times.   
Table 23 below demonstrates these calculations and is followed by the concluding 
statement from our radiation protection adviser’s risk assessment: 
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Table 23 Radiation Risk assessment (TiLTS-cc trial) 
 
“Given potential variation in both screening time and patient size, I recommend that 
this proposed change be viewed essentially as dose neutral. For those patients who 
would need longer screening times, there may be a dose advantage. Where pulsed 
fluoroscopy may have been used there would be a small dose disadvantage in the 
proposed technique.” TiLTS-cc study radiation protection adviser Dec 2011. 
 
5.1.9. Trial Conduct and Monitoring   
The TiLTS-cc study was set up as a multiple center trial adhering to the rigorous 
principles set out by the International Conference on Harmonisation (ICH) and 
World Health Organisation (WHO) standards of good clinical practice (ICH-GCP), as 
these are guidelines founded on the clinical research principles of the World 
Medical Association’s Declaration of Helsinki. On behalf of the TiLTS-cc study 
sponsor (CDDFT) I set up a trial steering committee to monitor and ensure these 
standards were adhered to.  
 
5.1.9.1. Trial Steering committee (TSC)   
The TSC was comprised of both clinical and academic members of the research 
team including myself, an independent neuro-gastroenterologist, an independent 
academic who was a professor in clinical gastroenterology research, and a 
participant representative from the local participant and research advisory group. 
Table 23 Potential radiation exposure during TiLTS-cc trial 
 C-Arm 
Intensifier 
Abdominal 
Radiographs 
Total 
Existing technique 0.66mSv 0mSv 0.66mSv 
Proposed 
technique 
0.33mSv 0.27mSv 0.60mSv 
mSv= milliSieverts 
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5.1.9.2. Trial Management Group (TMG)   
The TMG was comprised of the clinical and academic researchers from Durham 
University, CDDFT R&D, and myself. The TMG was responsible for the day to day 
running of the TiLTS-cc study. 
5.1.9.3. Independent Data Monitoring Committee (IDMC)  
An IDMC comprising an independent statistician, clinician and academic was setup 
to monitor safety, and futility (recruitment rates). The IDMC were given access to 
current study data (recruitment, IPG implantation rates including proportions of 
discriminate versus indiscriminate testing responders (un-blinded data), and all 
adverse event reporting) before each TSC meeting and advised the TSC accordingly. 
Of note the TSC and TMG were fully blinded at all times until the study analysis. 
5.1.9.4. Monitoring     
Monitoring of the TiLTS-cc study was conducted by the Durham Clinical Trials Unit 
(DCTU), who ensured strict adherence to the current REC approved study protocol. 
The purpose of these arrangements were to identify any significant developments 
as the research proceeded that may have necessitated alterations to the protocol, 
and to protect the safety and wellbeing of participants. Monitoring consisted of site 
visits to evaluate the site files and verification of source data collected and 
transmitted onto the online electronic case report form (eCRF) system, and co-
ordinating and providing the appropriate data to inform the TMG/IDMC/TSC 
committee meetings. This monitoring ensured prompt escalation of the infection 
adverse events to the sponsor, chief investigator and IDMC, and thus proved 
paramount to participant safety (see Chapter 6 for SAE details). 
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5.1.9.5. Data handling and participant confidentiality   
5.1.9.5.1. Participant trial data   
All information collected was securely stored both electronically, on paper and kept 
confidential. Data were used according to the provision of the 1998 Data Protection 
Act and individuals were not identifiable when data was transmitted electronically.  
All participants were assigned a unique trial number at enrolment. All paper study 
files and documents, including participants consent forms are retained on-site in 
locked filing cabinets and are due to be destroyed after the statutory period. 
Research data were transferred to Durham University for analysis by DCTU staff in 
collaboration with the clinical study team.  
Research data were entered onto an eCRF for each enrolled participant. These data 
were stored on secure servers that are external to both the NHS Trusts and to 
Durham University. This data was accessible to the research team, to Durham 
Clinical Trials Unit staff, to members of the TMG/ TSC/IDMC, and to any auditor or 
regulatory inspector as required. The data on these servers had access restricted to 
authorised personnel and was password protected. The data stored electronically 
contained the age, sex, ethnicity, and assigned trial number for each participant but 
no other personal identifiable data were transferred outside of the participating 
sites. Participants who withdraw from the study had all data collected up until the 
point of withdrawal included in the analysis.   
 
5.1.9.5.2. Electronic Case Report Forms (eCRFs)   
This study used electronic Case Report Forms for every participant enrolled and 
randomised on the study. It was the responsibility of site Principal Investigators (or 
appropriately delegated to site researchers) to prepare and maintain adequate 
documentation in the medical notes (source documents) for each participant, 
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including recording all data and observations relevant to the study. Data that were 
entered into the eCRF was consistent with the information in the medical notes. 
Data were only entered into the eCRFs by persons authorised to make entries and 
corrections, per the delegation of authority log for the site.  
5.1.9.5.3. Records retention     
The Principal Investigators at each site have archived all study related records and 
will retain these for a minimum of 15 years following the end of the study, after 
which they will be confidentially destroyed. 
The Principal Investigators are responsible for ensuring that these archived records 
are accessible, as required by current legislative regulations. 
5.1.9.6. Adverse Events (AEs)     
5.1.9.6.1. Serious adverse events (SAEs)   
All serious adverse events (SAEs) were treated as clinically appropriate and 
reported to Durham Clinical Trials Unit and the sponsoring trust (County Durham 
and Darlington NHS Foundation Trust) within 24 hours of the research team 
becoming aware of the event using a study specific SAE Form. 
  An event was considered serious if it fulfilled any of the criteria in Table 24. 
 
Table 24 Criteria of serious adverse events 
A serious adverse event was considered if it: 
 Resulted in death 
 Was life-threatening 
 Resulted in hospitalisation or extended an inpatient admission 
 Resulted in persistent or significant disability or incapacity 
 Was a congenital anomaly or birth defect 
 Was otherwise considered to be medically significant by the Investigator  
 Was specifically : conception after intervention with SNS 
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There were some exceptions to these rules namely: routine planned admissions, 
including admission for any SNS related procedures as part of this study. SAEs were 
recorded and reported from the day of the first surgical procedure onwards (day 1 
of Phase 2-Tined Lead insertion) until the 6 month follow up visit (phase 3), or until 
the time of withdrawal. SAEs were assessed for expectedness, severity and 
relatedness, and followed until the outcome was apparent; resolution, resolution 
with sequelae or death. SAEs were reported even if the investigator considered 
them expected or unrelated events. 
5.1.9.6.2. Adverse Events (AEs)  
Adverse events were recorded in any participant’s medical notes when they 
occurred, and on the electronic case report forms (eCRFs). All study participants 
were informed about the known complications of SNS in the participant 
information leaflet (PIS). AEs were recorded from the Day 1 of Phase 2 (first day of 
Tined Lead insertion) until the 6 month follow-up visit or withdrawal from the 
study. AEs were defined as any new medical occurrence, or worsening of a pre-
existing medical condition in a participant. All AEs were graded as mild, moderate 
or severe and assessed by the Investigator for relatedness and expectedness to the 
study procedures.  
 
 
5.1.9.6.3. Infection   
The externalisation of the exiting extension lead from the tined lead resulted in a 
predicted increased risk of infection, which logically was thought to increase with 
time, and therefore limited the length of the Tilts-cc testing stimulation phase to 6 
weeks. To minimise the risk of exit lead infection, I designed the study to manage 
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the exit lead as one would clinically manage a central venous catheter or Hickmann 
line exit site. This design entailed a weekly inspection of the exit site through a 
transparent dressing, and re-dressing only if clinically indicated. In practice we had 
found that re-dressing and cleaning the site weekly (i.e. routinely) could increase 
equipment malfunction due to lead or electrode damage. The lead was also fixed 
to the skin with another dressing distally to minimise traction on the exit site skin. 
A strict protocol for managing suspected exit site infections was followed; the PI 
was informed immediately and the participant examined by a senior clinical team 
member with appropriate treatment given. This entailed a course of oral antibiotics 
for relatively minor superficial infections appearing as erythema around the exit 
site, to inpatient treatment with intravenous antibiotics for superficial spreading 
erythema (cellulitis) and removal of the tined lead for suspected deep-seated 
infection. After infection resolution, continuing participants were asked to 
recommence from the beginning of the 2-week testing period at the time of 
diagnosis. A diagnosis of deep infection that required tined lead removal 
necessitated withdrawal from the study. Participants requiring withdrawal from the 
study due to an infection were followed until full resolution or resolution with 
sequelae and the details recorded as part of the study. All reports of infection were 
followed up by the IDMC who advised on subsequent protocol amendments to 
maximise participant safety. 
 
5.1.9.6.4. Antibiotics    
Intravenous prophylaxis was given before each implantation procedure. This was 
initially a standardised dose of 80mg i.v. Gentamycin for all participants. After 
several participants had experienced superficial infections in the study and 
following concerns raised by the independent data monitoring committee and trial 
steering committee, a review of appropriate antibiotic prophylaxis for the study 
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implant procedures was conducted. I contacted and assisted the CDDFT 
antimicrobial management team (AMT) committee with this review of our study 
procedures for antimicrobial prophylaxis. The AMT chair and I jointly conducted a 
literature review of the best antimicrobial practice, consulted SIGN and NICE 
guidance and reported to the independent data monitoring committee and trial 
steering committee that there was no evidence of best antibiotic prophylaxis 
relating to this type of procedure, with only the SIGN prophylaxis guidelines stating 
that prophylaxis should be given “for any implant or device insertion” without 
stating what that prophylaxis should be. The trust AMT committee formed an 
expert consensus opinion by considering the bacterial flora on the implant area, the 
organisms cultured to date from several participants, the duration of the trial 
procedures and recommended the following prophylaxis protocol for the TiLTS-cc 
study (Figure 13).  
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All other forms of antibiotic prescribing for participants during phases 2 and 3 were 
recorded with an associated adverse event also reported. All antibiotics were 
therefore closely monitored by dose and duration of treatment in the CRFs. 
Specifically participants were not withdrawn due to antibiotic use as it was 
accepted that antibiotics were highly unlikely to cause diarrhoea in participants 
with medically refractory constipation (otherwise this would be an acceptable long-
term treatment). 
5.1.9.6.5. Pregnancy      
Any participant who had a newly diagnosed pregnancy during phase 2 or 3 of the 
study would be reported as a SAE. The protocol specified that the site PI should 
discuss the case with the trial chief investigator within 48 hours of SAE reporting, 
and a clinical plan of management devised to care for both the participant and 
foetus. This would involve opinions being sought from obstetricians and 
anaesthetists regarding the safety of surgery or any anaesthetic required. 
Specifically for pregnancy diagnosed in phase 2, the tined lead would remain in-situ 
for a later date, and the extension lead removed under local anaesthetic. In phase 
3 the IPG would simply be turned off with information given to the participant’s 
obstetrician regarding the use of diathermy in the event of caesarean section (there 
is no need to remove the IPG during pregnancy). We planned that participants 
would specifically have any active study intervention stopped if they had a newly 
diagnosed pregnancy and this fact was very clear in the PIS (Appendix 2). This is 
simply because I could find no evidence in the published literature for the safety of 
active SNS during any stage of pregnancy on the developing foetus. The electrical 
stimulation field around the S3 nerve is only a few centimetres from the uterus and 
so it may possibly cause an unknown effect on embryogenesis. 
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5.2 ExperienceS of treatment with Sacral Nerve stimulation (SNS) for 
idiopathic Constipation; a hermeneutic phenomenological study                 
The ESSeNCe study  
The Essence study was devised for two main reasons. Primarily I and my supervisors 
considered the value of undertaking a qualitative study to gain insight into the 
TiLTS-cc study participant’s experiences of and motivations for becoming recruits 
into what we perceived to be an intensive and demanding surgical trial. This study 
was designed, therefore to further complement and inform the TiLTS-cc study of 
participants’ acceptability of a new testing technique (ePNE) for SNS in participants 
suffering from CC. The objectives of the qualitative study are to explore the 
participants’ tolerability of a prolonged test, the interventional treatment in 
general, and their experiences of trial participation.  In addition, the Essence study 
attempted to assess how generalizable and transferable this technique may be in 
the NHS. Secondly, this study was for my own education as I had an interest in 
qualitative research, and as a surgeon I have never actually been formally taught or 
attempted to undertake a proper qualitative study. I attended a qualitative 
research methodology course run at Durham University by my supervisors and 
began reading about the different frameworks that I might utilise to undertake this 
study. In this section I will discuss my choice of theoretical framework selected for 
use, my underlying worldview which may have precipitated this selection and the 
methods I used to perform data collection and analysis from recruited participants. 
5.2.1. Research Aims 
The main aims of the Essence study were to explore the lived experience of 
participants with CC undergoing SNS testing and subsequently living with the 
implanted permanent device. 
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After a thorough review of the literature I identified a knowledge gap which could 
be addressed by further exploring the following topics in Table 25. 
Table 25 Exploratory topics in the Essence study 
 Participant experiences of CC, background treatments and further 
interventions. 
 Motivations of participants to participate in the TiLTS-cc trial (or usual care 
SNS treatment). 
 Experiences of care and support that participants received before/during 
and after the trial (or usual care SNS testing). 
 Perceptions of symptom changes (physical or psychological), to what 
extent this was attributed to SNS, and how important were these changes 
to participants. 
 Experiences of SNS in relation to its effect on other aspects of their life 
(relationships, socially, professionally, and self-perception).  
 Experiences, perceptions and beliefs about the placebo effect associated 
with SNS. 
 Perceptions and beliefs about the overall experience of SNS testing. 
 
5.2.2. Declaration of my worldview 
In order for a qualitative researcher to reliably collect, interpret and report their 
data to peers, I believe that the researcher’s biased worldview should be framed 
for further interpretation by their peers as this will undoubtedly skew their data 
collection and interpretation. The following is therefore a statement of my political, 
sociological and religious views that will bias my attitude towards the theoretical 
framework selected and used for data collection and analysis. 
I am a middle aged man with predominantly clinical training in medical sciences, 
especially general and colorectal surgery in which I am a clinical specialist and a 
Fellow of the Royal College of Surgeons of Edinburgh. I also have a strong 
laypersons interest in all other sciences. I view the world we live in and life in 
general as an absolute consequence of the laws of nature, and to be of no other 
particular significance; I believe that organised religious belief structures are 
inconsistent with human observations throughout history and I reject them all as 
superstition. I believe they persist purely as a psychological comfort to human 
mortality. I reject atheism as an irrational description of reality, coined by religious 
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conservatives as an attempt to redefine realism in religious terms. I do not define 
my worldview as a rejection of a superstition or the supernatural (a-theism), I 
define it by what can be experienced, observed and measured in our natural daily 
lives, i.e. Realism. This is an epistemological philosophy championed by Christopher 
Hitchens that “what can be asserted without evidence can also be dismissed 
without evidence” (Hitchens’s Razor). I view humans as flawed animals (as are all 
evolved creatures) and of no more significance to other known lifeforms than our 
slightly higher intelligence. I believe in the socialist principle that all people should 
be offered an equal opportunity in life by their governing state, and I am particularly 
opposed to the inherited privilege that is common in the UK; I believe in 
meritocracy.  In summary I would best describe myself as a socialist, republican, 
and scientific realist. As a doctor I believe these attitudes help me to strive for 
excellence in treating my patients, whilst also respecting their own unique 
worldviews. 
5.2.3. Theoretical frameworks 
I designed this study mindful that there was a considerable knowledge gap; the 
story of the lived experience of participants undergoing SNS as a test or a long-term 
treatment had not been formally reported in this, or any, population nationally or 
internationally. A range of theoretical frameworks had potential utility to explore 
the aims outlined earlier.  
5.2.3.1. Narrative Inquiry 
I considered Narrative inquiry as a possibility through exploration of biographies of 
participant experiences during SNS testing in combination with open interviews at 
home after trial completion. Reporting data of a narrative inquiry, however can 
sometimes lead to criticisms of the data being too subjective, and without specific 
objectives. A narrative enquiry in general may have yielded an interesting breadth 
of data from participants, but it may also not have been highly specific to the 
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knowledge gap identified. I believed that this study would be best specifically 
investigating the participant experience of an uncommon surgical procedure, and 
the treatment it provides to a severe refractory medical condition, and so this 
required a more focussed approach to answer the research questions. Similarly, I 
considered an action research approach and also rejected this on the basis that as 
little was known about the experience of participants, it would have been 
impossible to integrate the aims of action research into an interventional study 
whose aims and methods were fixed at the point of funding. 
5.2.3.2. Mixed Methods 
“Mixed methods’ is a research approach where both quantitative and qualitative 
data are collected synchronously during an interventional study, and this approach 
to health research has undergone significant growth in recent years due to 
increasingly complex medical studies. This methodology utilises the strengths of 
both research methods which enables researchers to investigate, discover and 
understand more complex relationships, associations and confounding factors that 
can surround the research questions. As the interventional quantitative study 
methods were fixed at the point of the NIHR funding application, a genuinely mixed 
methods approach was also impossible.  
5.2.3.3. Phenomenology 
My literature review has demonstrated that phenomenological approaches are 
commonly used by researchers investigating surgical procedures to good effect, 
offering both depth of experience but also allowing for focussed enquiry about a 
particular phenomenon. Thus, I selected this theoretical framework for use in the 
Essence study. 
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5.2.3.4. Descriptive Husserlian Phenomenology 
Phenomenology has increased in popularity as a research method since the late 
20th century. As a philosophy, phenomenology was originally described by Edmund 
Husserl (1859-1938), and then further developed by Martin Heidegger (1889-1976), 
Jean-Paul Sartre (1905-1980), and Maurice Merleau-Ponty (1908-1961), with whom 
it is most widely associated. In essence phenomenology is a study of human 
consciousness, with the study focus being on a first person description of what and 
how a person experiences a certain phenomenon. It is consequently mostly utilised 
in psychology research and over the past twenty years has been used increasingly 
in health research, notably in fields as varied as psychiatry, medical/nursing 
education and surgery (156, 157, 172-174). It has been used to good effect in a wide 
range of studies seeking to explore experiential elements of illness and healthcare, 
giving access to previously under-explored issues such as lived space/relations, 
insecurities/fear, and changes to the body (153, 158, 175, 176).  
 
5.2.3.5. Interpretative Heideggerian Phenomenology 
The philosophical differences between using a Husserlian or Heideggerian model of 
phenomenology centre on a researcher’s ability to separate their own past 
experiences from the research topic they are investigating (177). Researchers using 
a Husserlian model would aim to describe the experience of the phenomenon 
encountered by the person, leaving their own biases and pre-conceptions aside in 
what is now known as transcendental phenomenology. Researchers using a 
Heideggerian model would aim to declare their presuppositions (and biases) on the 
research phenomenon and try to interpret the description of the phenomenon 
encountered by the subject. In doing this they are accepting that it is impossible to 
be completely neutral in describing and interpreting encountered phenomena. This 
model of phenomenology is also referred to as Hermeneutic phenomenology. A 
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further, more modern, model of phenomenology is known as Interpretive 
Phenomenological Analysis (IPA) in which the researcher moves from a position of 
naivety (transcendentalism) at the start of the research study towards a shared 
understanding of the phenomenon (178, 179).   
5.2.3.6. Selection of hermeneutic phenomenology 
As I was the researcher conducting participant interviews and also the surgeon 
treating and following the participants through the quantitative trial process, a pure 
(or an IPA) transcendental approach would be impossible for me. I could not 
possibly start from a position of naivety: My researcher’s experience of treating 
each and every participant throughout the trial would undoubtedly play a part in 
my understanding of the data collected. Heidegger’s belief that the mind pre-
conceives the experience of a phenomenon, and then either validates or revises the 
pre-conception is highly relevant to this study.  I was a central and consistent 
component of the whole trial experience from the participants’ perspective, just as 
the participants were a central and consistent experience of the trial to me. 
Consequently I selected a Heideggerian hermeneutic phenomenological 
framework, and this had previously been used to explore surgical trials in similar 
populations (Van der Zalm 2000). 
5.2.4. Potential design limitations 
In using a hermeneutic phenomenological approach to data acquisition and 
analysis, based on the principles of phenomenology outlined by Martin Heidegger, 
I freely admitted my life experiences that may have biased my collection or 
interpretation of data from study subjects. I stated these prospectively within the 
Essence study protocol in order that the ethics committee (both Durham University 
and NHS REC) would be able to consider them, and to facilitate any readers of this 
thesis with interpretation of my study findings. The following section was written 
within the study protocol and begins with my personal experiences of the ePNE SNS 
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testing technique (from a clinician and researcher’s perspective) and my 
expectations of what participants would experience during the study treatment: 
These were the beliefs that may have biased my data collection and analysis.  
5.2.4.1. My experiences and expectations of the phenomenon  
                     (ePNE   SNS testing) 
I stated within the Essence protocol: 
“In treating participants as both an operative surgeon performing SNS procedures, 
and a doctor assessing symptom response, I have formed opinions of “what” 
participants will experience during SNS testing, and “how” they will experience this. 
I expect the postoperative period to be uncomfortable initially with the pain easily 
controlled with simple analgesia. I expect the greatest problem participants will 
encounter is due to the dressings. These can cause irritation, pruritus and become 
malodourous. They require help to be maintained from a close member of the 
family (usually but not always a partner) due to the position on the back, and I 
expect will leave the participant feeling dependant on that family member. I expect 
that it may also leave a normally independent person feeling vulnerable if they have 
no close family to help. I expect the driving restrictions during the 4 testing weeks 
to leave most participants feeling a loss of their own independence, and a great 
inconvenience. I expect that participants with no family or poor family support may 
consequently struggle with this form of treatment, and that it may be detrimental 
to their quality of life. However, I am open to the possibility that none of these 
themes might arise from the data, which may illuminate new, previously 
unexplored, areas of enquiry.” 
Appropriate supervision from experienced qualitative researchers was available to 
me during the data collection and analysis phases, and I ensured, as far as possible, 
that findings were grounded in participant data rather than my preconceived views 
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about SNS. An extensive interview schedule was constructed (Appendix 11); I 
simply used this as a topic guide throughout the interviews in order to keep focus 
on the key areas. I ensured time was given for participants to express their own 
views about their experiences, in their own way, and the priorities they assigned to 
the importance of various factors mentioned in the schedule had primacy in this 
study.   
5.2.4.2. Participant factors 
A potential limitation of this study design surrounded the participant’s ability to 
have comfortably reflected and described their experiences to me- a researcher 
who was central in those experiences. It is potentially feasible that participants felt 
unable to be as frank and honest to their treating surgeon as they would have been 
with clinically neutral researchers. They may have potentially described an 
experience that was more agreeable to me than their lived reality. Conversely this 
may have been an advantage too, as participants may have felt more relaxed and 
at ease with a familiar person, and consequently more open, as discussed in similar 
studies with sensitive issues (180, 181). I considered the option of offering a ‘back-
up’ (non-clinical) researcher as an interviewer but this was rejected by the 
constipation research advisory group (CRAG) during the development of this study; 
patients felt that it would be easier and preferable for them to be frank and open 
with a person known to them who already had a working knowledge of their 
medical history, and was known to be respectful and compassionate about their 
difficulties.  The participant information sheet (PIS) was reviewed during the design 
phases by the CRAG, who consisted of Durham clinic patients who had experience 
of constipation trial participation. They advised and helped with the design of the 
PIS, overall study including the interview venues and guides, and approved these 
as acceptable to patients before ethical approval was sought for the study. I was 
given full training and supervision in conducting the interviews, and I performed a 
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mock interview with a specialist nurse who treats participants in the biofeedback 
clinic regularly. This nurse was an expert in managing the complex interpersonal 
problems displayed by participants, and was able to synthesise their likely 
responses to particular lines of enquiry. This interview was transcribed and 
analysed with my supervisor, and I used this to help modify my interview style and 
understand the process of coding and analysing the transcription data. During every 
interview I offered the participants an identical 10 minute opportunity to reflect 
honestly and openly about their experiences, and I assured participants that critical 
or negative accounts of their care did not influence their subsequent care in any 
way. This was an important aspect of the design as there was a high prevalence of 
anxiety within the participant group. I believed the main potential risk of being a 
clinical interviewer in this study was the way in which my clinical/researcher role 
was demarcated and perceived by participants. Even if I was clear about the 
demarcation in my own mind, this may not have been clear to the participants. In 
realising this I made every attempt to assist participants to understand this 
demarcation through the study design; the participant information sheet was 
clearly worded to ensure that participants understood their rights, and the 
responsibilities of the research team towards them. Any requests from participants 
for clinical information during the interview, or the disclosure of clinically relevant 
information during the interview was dealt with [if necessary] during a ring-fenced 
5 minute debrief at the end of the interview. I was clear to participants that during 
the interview I was a researcher not a clinical doctor, and during the ring-fenced 
time I could stop being a researcher and become their doctor again. I again 
emphasised that during this ring-fenced time their care was not influenced in any 
way by the preceding interview discussion, and that if they required clinical 
information, investigation or treatment this was dealt with in the normal way 
within the boundaries of their clinic appointments. These methods were written 
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into the protocol and endorsed by a qualitative peer reviewer who had experience 
of using similar methods (181) which had built on previous work by other doctors 
who had undertaken qualitative interviews with their participants (181 182).    
5.2.5. Methods 
The qualitative data were collected sequentially, following on from the quantitative 
study. This was necessary as the TiLTS-cc study had already commenced 
recruitment and could not be re-designed to allow qualitative feedback into its own 
study design without affecting the outcome measures. Participants within the 
TiLTS-cc study were therefore required to have completed their last quantitative 
data collection visit before being invited to the Essence study interview. 
Participants who were recruited from the NHS usual care pathway were invited for 
interview concurrently with those in the TiLTS-cc study.  
5.2.5.1. Sampling 
I planned a purposive sample of between 5 to 20 participants who were invited to 
interview upon their completion of the TiLTS-cc study. The upper limit was higher 
than might normally be expected in an in-depth phenomenological study (van 
Manen, 1990); this reflected the fact that little was known about the experience of 
SNS and allowed for the possibility of multiple perspectives which would have 
prevented data saturation from being reached in a smaller sample.  In terms of 
phenomenology this was a standard size for this type of study; 5 may have been 
sufficient but 10-20 was more likely. Previous research shows that it was possible 
to reach data saturation in a similar population (154, 157, 174, 176) and 
recruitment could have been extended if data saturation was not accomplished by 
the 20th participant. In order to avoid selection bias all TiLTS-cc participants were 
offered participation in the same sequential order, and only participants refusing 
participation were excluded from the proposed study. Due to the population of 
participants being heavily skewed towards females it was not possible to interview 
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any males during this study, although males were invited to participate if possible. 
Participants who did not speak English were unlikely to be part of this participant 
population, and their cultural experiences of care and surgery were likely to be so 
different as to warrant a separate study. I decided, therefore that Non-English 
speakers were not to be invited to interview. The first interview was performed in 
June 2014, following which the data were fully transcribed and analysed before I 
had a debriefing with my supervisor to decide on aspects of my technique, the 
interview schedule and any relevant participant data that could be used to explore 
topics further in the next set of interviews. I then conducted the interviews in blocks 
of three participants with the subsequent data transcribed, analysed and used to 
modify the interview schedule before the next block of interviews. The rationale 
behind this was to ensure close supervision between interviews as far as logistically 
possible, and to allow me reflective space between the interviews.  In order to 
examine the perspectives of participants experiencing SNS in usual care through 
the DCC, I invited to interview any DCC participants with a historical treatment of 
SNS in the preceding 5 years who had at least 6 months of clinical follow up after 
IPG implantation (to ensure similarity to those in TiLTS-cc). 
The following criteria were used to select and invite participants to interview: 
Inclusion Criteria: 
All participants with all of the following inclusion criteria were included for study 
invitation (Table 26) 
Table 26 Essence study Inclusion criteria 
Female and male Participants aged 18 years or older. 
A history of chronic constipation with treatment by SNS (TiLTS-cc or usual NHS 
care). 
Competent to give informed consent. 
Fluent in English. 
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Exclusion Criteria: 
All participants with any one of the following criteria (Table 27) were excluded from 
invitation: 
Table 27 Essence study exclusion criteria 
All participants 17 years old or younger. 
Treatment with SNS for another medical condition that is not CC. 
Inability to provide competent consent. 
Non-English speaking or no fluency in English. 
 
5.2.5.2. Data Collection 
I invited participants to consider participation in the Essence study via an invitation 
letter offering a participant information sheet (PIS). All participants were given a 
reasonable cooling off period of one week after receiving the PIS before a study 
interview was arranged. Participants were invited to a semi-structured interview at 
the University Hospital of North Durham in a clinic room with which they were 
familiar, and were offered a chaperone to be present if they preferred. This was an 
important design given the known psychological problems participants with CC and 
FGIDs in general are known to suffer from. I believed that participants required the 
security of familiar surroundings and of another professional being present to 
support them and act as an advocate if they desired. Setting this comfortable 
environment, I believed allowed scope for a greater interview enquiry as 
participants were relaxed and had low levels of anxiety. 
I asked all participants to confirm their willingness to participate in the interviews 
and to provide written consent, following confirmation that they understood the 
ethically approved participant information sheet and the nature of the proposed 
study, including that their views may be used as anonymised quotes in a thesis and 
journal publications. The interviews were recorded on a digital dicta phone and 
stored in a secure office within the hospital. Participant identifiable data were only 
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accessed by the research team through the site master file. The audio data were 
stored on the team’s secure encrypted research database on the trust intranet 
server, and transcribed into a pseudonymised (alphanumeric code) text document 
by the team assistants. Pseudonymised audio and text data were transferred to the 
Wolfson Research Institute through a securely encrypted memory stick approved 
by the sponsor’s IT department.  Access to all of these data were restricted to 
named team members. Printed data was pseudonymised and stored until analysis 
of the full study had been completed, and then securely destroyed as per the 
sponsor’s confidential waste protocol. All audio data and transcripts within the site 
file will continue to be kept for 5 years after the full study analysis has been 
completed and then securely destroyed. An agreement between Durham 
University and the CDDFT Caldicott guardian was permitted to allow access to the 
data by named University team members involved in this study. 
5.2.5.3. Timing of Interviews 
Participants were invited for interview after the 6 month follow up visit of the TiLTS-
cc trial or after 6 months following implantation of the device in usual care 
participants. I planned the interview duration to aim to be within 15 minutes to a 
maximum of 90 minutes, after which time I felt it would be unlikely to yield further 
relevant data due to participant fatigue. I ensured all participants were free to 
terminate the interview at any time if desired and without reason; this was 
emphasised in the Participant Information Sheet. For the convenience of the 
participants’, if they were due to have a full clinical review of their care in the DCC 
within one month of the study appointment, I offered to re-arrange this 
appointment immediately after the study interview. I believed this was justified to 
prevent extra travel and time off work for participants, and also to help boost 
recruitment to the study. 
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5.2.5.4. Location 
Based on my previous clinical experience I felt it was highly possible that 
participants may report themes that could be related to very personal experiences 
including histories of abuse; therefore it was important to conduct interviews in an 
environment that was safe, familiar, and comfortable for both participants and 
myself as researcher. A clinic space in the hospital was preferable as this was 
familiar territory to the participant, and would constitute a safe environment for 
both the participant and myself as a researcher. I performed a pre-study participant 
and public involvement activity discussing these design aspects and the feedback 
indicated that this location was acceptable to participants. I did consider home 
interviews and rejected this location due to the possibility of histories of 
psychosocial trauma arising; I felt my presence in their home would be potentially 
inappropriate due to these and the very personal nature of care I had given them. 
The whole supervisory team agreed that professional boundaries were required to 
be maintained. 
5.2.5.5. Transcription and interpretation 
Recorded interviews were transcribed by the DCC team personal assistants who 
were experienced in transcribing clinic letters for this group of participants.  The 
transcribers were paid a reasonable overtime rate for their time helping to do this, 
funded through a springboard grant from the sponsor.  
5.2.5.6. Supervision of researcher and transcriber well-being 
I was concerned that given the possible range of topics may have arisen with 
participants during the data collection, from histories of physical and sexual abuse 
to deliberate self-harm and affective disorders, formal supervision in the form of 
psychological support and debriefing should be provided by the DCC team 
psychologist. Our psychologist was known to all members of the clinical and 
research team, and she was enthusiastic to help by offering debriefing to me and 
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any transcriber as required. I requested that the psychologist should be in a position 
to feedback any concerns they had regarding issues raised (either of the 
participants or researchers) to the supervising consultant who had clinical 
responsibility for the participants and professional responsibility for the 
researchers as the team manager. This process may have appeared to threaten 
participant confidentiality and anonymity, however the psychologist was a 
permanent member of the DCC team with clinical input to the participants’ 
treatment and it was therefore an important way to maintain participant safety. 
Initial participant consultation suggested that as long as this process was made 
clear in the participant information sheet, it was acceptable to participants. 
5.2.6. Analysis Plan 
Thematic analysis was used to interpret the transcribed data. This involved both 
myself and my supervisor thoroughly reading the transcribed data, and 
systematically coding experiences that appeared to be prominent in the text. The 
transcripts were coded line by line, and these codes were used to form generalised 
themes that appeared to describe the experiences or phenomena of most of the 
participants. Transcripts were read and analysed independently by myself and my 
supervisor using thematic analysis to explore the ‘lived experience' of participants. 
Following independent analysis, each analyst developed a list of preliminary codes, 
which were added to and refined as coding progressed. This list of codes was 
captured using Excel spreadsheets with examples of quotes taken from individual 
transcripts. We met to discuss the code list after the first interview and then after 
each set of 3 interviews had been conducted and individually analysed. Consensus 
was thus reached on the code list via in-depth discussion of the transcripts; if 
consensus was not reached we designed the study to allow a third experienced 
qualitative analyst to arbitrate. Codes were grouped into categories by myself and 
from these a set of themes emerged which characterised all of the information 
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within the categories. Again, consensus was reached on the category list via in-
depth discussion of the transcripts; if consensus was not reached we designed the 
study to allow a third experienced qualitative analyst to arbitrate. Emergent themes 
were tested using diverse accounts within cases and between cases, in order to 
challenge the integrity of the boundaries of themes, and to ensure that data 
saturation was accomplished. Data saturation, (which happened when no new or 
interesting data were collected), was expected to occur at around 5-20 participants.  
5.2.7. Ethics  
The quantitative protocol for TiLTS-cc could not be amended as the Essence study 
was considered as a separate follow-on study. Permission was therefore sought and 
approved from the Durham University ethics committee, before the study was 
approved by the East of Scotland Research Ethics service (EoSRES) for NHS 
approval, and County Durham and Darlington NHS Foundation Trust (CDDFT) for 
local NHS approval. 
5.2.7.1. Participant information sheet (PIS) 
Participants were contacted by an invitation letter briefly summarising the study 
(Appendix 12). They were invited to contact the research team in order to receive 
and read the PIS (Appendix 13) before study consent (Appendix 14) was obtained, 
and were under no obligation to be interviewed. The Participant’s GPs were also 
informed of their decision to be interviewed in case of any objections for unknown 
circumstances (Appendix 15). The PIS was posted to them for consideration prior 
to being invited to a study interview, and this included a reasonable cooling off 
period. Patients were informed of their right to refuse and that their treatment 
would not be adversely affected by refusing to participate. Participants who were 
withdrawn from the TiLTS-cc study were also contacted and invited as they may 
have had unique experiences that were relevant to the study population. Two 
participants that had experienced a withdrawal from the Tilts-cc study accepted the 
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invitation. Participants were informed of the confidential nature of these 
interviews, but also that there was a mechanism for raising clinical concerns. In 
particular if they appeared to demonstrate deteriorating mental health, then I 
emphasises that I may refer them to their GP or named psychiatrist for further 
treatment if I deemed it necessary. Participants were also informed of the 
requirement for me and the transcription team to debrief following the interview, 
and that this would not breach their confidentiality as the clinical psychologist was 
part of the multidisciplinary team. I also emphasised that the interview may have 
therapeutic potential for Tilts-cc study participants as a means for their debriefing 
after the study. 
5.2.7.2. Consent 
Written informed consent (Appendix 14) was obtained from all participants prior 
to study inclusion. This consent was in triplicate with one copy provided to 
participants, one copy filed by researchers, and one copy filed in the clinical case 
files. 
5.2.7.3. Researcher bias  
During the design phase of the Essence study I accepted and considered the 
inherent design limitation of using a member of the clinical and research team 
(myself) who had helped in participant recruitment, surgical implantation of the 
testing device, follow-up of participants, and blinded assessment of the 
quantitative data. I considered the fact that I had close contact with the participants 
and likely formed opinions of them and their response to the treatment. I also 
realised that the participants would likely hold views of me as the researcher that 
could have restricted or directly influenced the information they gave to me in the 
interviews. I also declared that I had a vested interest in the study as it formed part 
of my PhD thesis, and therefore I may not have been in a position of equipoise when 
conducting the study. To address these problems, firstly I openly admitted my 
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expectations of the treatment in the Essence study protocol (quoted in this 
methods section for the reader’s consideration of my subsequent thematic 
analysis), and I wrote a detailed worldview as part of my PhD thesis (5.2.2 page 152) 
to lay bare my inherent biases that could influence my interpretation of the subject 
data. Secondly I involved TiLTS-cc study participants in the study design, and 
confirmed that most would be willing and able to be open, honest and frank in the 
interviews with me, and would not feel uncomfortable at doing so. Despite these 
precautions there was still potential for my bias in the collection, analyses and 
reporting of data from participants. I sought further advice from a peer reviewer 
who had proven experience of employing a similar methodology (181), who had 
provided further evidence of doctors conducting similar research (180, 182) and 
who endorsed my plan to receive adequate supervision of data collection and 
interpretation during the hermeneutic circle in order to minimise the potential for 
bias. I completed directed training before undertaking the interviews; performed 
supervised and directed reading, attended a Health Research Qualitative Methods 
course (October 2012), performed mock interviews with specialist nurses who 
treated this cohort of patients, and received supervisor feedback of my mock 
interview style. I received full supervisor feedback on my interview style and 
technique following the first formal study interview, and then subsequently after 
blocks of three interviews. This directed training took place at both UHND and 
Durham University Queen’s Campus. 
5.3 Chapter summary 
This chapter has demonstrated the complex methods and procedures used to 
ethically collect data in the TiLTS-cc study, and the reasons for the key 
methodological features that were written during the design phase to help meet 
the study objectives; namely sub-sensory testing with a central washout period, 
device calibration testing to facilitate consistent stimulation and secure blinding, 
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and a randomised crossover trial approach to control the study participants 
adequately. The methods used to collect data in the follow-on Essence study are 
described along with the reasons for selecting hermeneutic phenomenology, the 
inherent potential design limitations to these framework, and how I sought to 
overcome these with help and advice. The following two chapters will present the 
relevant study findings and highlight their key findings for consideration in the 
overall discussion of this thesis in Chapter 8.  
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Chapter 6 TiLTS-cc study results, adverse events and incidental 
findings. 
 
6. Introduction 
This chapter will present the findings from the TiLTS-CC trial including the baseline 
demographics, analysis of primary and secondary outcome measures, adverse 
events and incidental findings. I will interpret these findings in relation to the 
knowledge gap previously identified and discuss their implications for further 
research and clinical practice. The key findings from this chapter will be used to 
inform a critical interpretation alongside the systematic reviews and qualitative 
study findings (presented in Chapter 7), in Chapter 8. 
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6.1. Figure 14 TiLTS-cc Study Consort Diagram 
 
45 participants were enrolled into the TiLTS-cc study (42 recruited from Durham, 3 
from Gateshead) and received a tined lead during phase 1, of which 6 withdrew 
(Consort diagram). 29 were classified as responders of which 27 received an IPG, 
and 10 entered phase 2 usual treatment follow up. 1 further withdrawal from the 
IPG group and 3 from usual care resulted in 26 participants assessed for 
interventional endpoints at 6 months and 7 from usual treatments. 
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6.2. Stard checklist for the TiLTS-cc Study  
The Stard checklist (Appendix 16) for reporting studies with diagnostic accuracy 
outcomes was completed for reference. 
 
6.3. Demographics of study population 
Of the calculated sample size (n=75) required for an adequate primary outcome 
analysis, 45 participants were recruited and randomised to group A or group B. The 
study was terminated early due to the adverse event profile: The third criterion of 
the early study termination (Table 19) was initiated by the steering group under 
advisement of the sponsor and data monitoring committee when it became clear 
that there was a safety issue with infections that could not be resolved despite 
repeated attempts at reducing this risk. Recruitment was also slower than originally 
anticipated due to 2 lead sites being unable to participate as a result of the 
aforementioned funding changes for SNS by the clinical commissioning groups. Of 
the remaining 3 sites who recruited to the study the vast majority of participants 
were recruited via the Durham constipation clinic. Forty-three of the 45 participants 
were female (96%) with a mean age of 41 years (range 18-68, Table 28). They 
demonstrate chronicity of the disease with a mean duration of symptoms of 17.6 
years, and severity with a mean total PAC-SYM score of 2.19. Their quality of life 
was also severely affected with a mean total PAC-QOL score of 2.70. As expected 
almost all of the patients (42, 93%) were currently receiving treatment for their 
condition (Table 30), and a very high proportion (82%) were suffering from other 
co-morbidities (Table 29) of which anxiety and depression were the most common 
mental health illness. Thirty participants (67%) had slow colonic transit identified at 
baseline by the Sitz marker transit study using the Metcalf protocol. 
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Table 28 Baseline characteristics of the study population 
Characteristics Number (%) Mean ± SD Median       
(Min-Max) 
Total number  45 (100%) - - 
Female  43 (96%) - - 
Age  45 (100%) 40.9±13.5 40.0(18.0 - 68.0) 
PAC SYM 45 (100%) 2.19±0.86  
PAC QoL 45 (100%) 2.70±0.82  
EQ-5D-VAS 45      (100%) 50.93±18.40  
EQ-5D-3L 40        (89%) 0.48±0.37  
Duration of constipation 
symptoms 
45 (100%) 17.64±11.14 18.0(3.0 – 45.0) 
Currently treated for 
constipation  
42 (93%) - - 
Other comorbid conditions 37 (82%) 2.81±1.96 2.0 (1.0 – 9.0) 
Current Mental ill-health 13 (29%) - - 
Previous Appendicitis 7 (16%) - - 
Endometriosis 4 (9%) - - 
PAC-SYM= Patient Assessment of Constipation-Symptoms questionnaire 
PAC-QOL=Patient Assessment of Constipation-Quality of Life questionnaire 
VAS= Visual analogue scale 
EQ-5D-3L-the 3 level version of the EQ-5D questionnaire 
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Table 29 Study Group Co-morbidities at baseline by body system 
Co-morbidity N (%) Co-morbidity N (%) 
Cardiovascular System 
Hypertension 6 (13) Ischaemic Heart Disease 5 (11) 
Respiratory system 
Asthma 10 (22) COPD 2 (4) 
Gastro-intestinal system 
Dyspepsia 2 (4) Folic Acid Deficiency 1 (2) 
Gastro-Oesophageal Reflux Disease 3 (7) Peptic Ulcer disease 1 (2) 
Nervous system 
Epilepsy 9 (20) Insomnia 1 (2) 
Nocturnal Enuresis 1 (2) Positional vertigo  1 (2) 
Stiff Person Syndrome 1 (2) Transient Ischemic Attacks 1 (2) 
Musculo-Skeletal system 
Ankylosing Spondylitis 1 (2) Arthritis 1 (2) 
Lumbago 2 (4) Lumbar disc degeneration 5 (11) 
Osteoarthritis 2 (4) Sciatica 3 (7) 
Spinal pain 6 (13) Tendonitis 1 (2) 
Reproductive system 
Endometriosis  1 (2) Menorrhagia 1 (2) 
Post-Menopause 2 (4)   
Genito-Urinary system 
Atonic Bladder* 3 (7) Erectile Dysfunction 1 (2) 
Recurrent Urinary Tract Infections 2 (4)   
Endocrine System 
Diabetes Mellitus 4 (9) Hypercholesterolaemia 1 (2) 
Hypothyroidism 4 (9)   
Immune system 
Nickel allergy 1 (2)   
Dermatological 
Dermographism 1 (2) Psoriasis 2 (4) 
Mental Health disorders 
Anxiety 4 (9) Depression 14 (31) 
Bipolar affective disorder 2 (4)   
Vascular 
Raynaud's Phenomenon 1 (2)   
This table demonstrates the recorded diagnosed Co-morbidities of participants at baseline.  
*These 3 patients may possibly have an undiagnosed neurological disorder which may be contributory to 
their constipation. (Inclusion / Exclusion criteria 5.1.1.2/ 5.1.1.3 page 95) 
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6.4. Analysis 
Forty-five participants were recruited and underwent tined lead insertion before 
being randomised into group A or group B for testing (Figure 14). There were 6 
withdrawals during testing due to infection of the tined lead (n=5) and non-
compliance with study blinding procedures (n=1) (see section 5.6 on adverse events 
for further detail).  Serious adverse event reports were completed for all of the 
participants with testing lead infections and this was investigated by the DMC and 
trial steering committee who made the necessary protocol changes to try and 
minimise further infections within the study (page 144). The participant who was 
non-compliant was withdrawn by the research team for device tampering, deemed 
to be un-blinded, and received usual SNS testing and care within the NHS. Thus 39 
participants successfully completed phase 2 of the study, of which 29 were deemed 
to be responders using the Tilts-VAS, and 10 were deemed to be non-responders. 
Table 30 Current treatments for constipation 
Treatment N (%) 
Primary Care Prescriptions 
Bisacodyl 11 (15%) 
Sodium Picosulfate 10 (14%) 
Movicol 7 (10%) 
No treatment 5 (7%) 
Phosphate enema 2 (3%) 
Glycerol 1 (1%) 
Lactulose 1 (1%) 
Secondary Care Prescriptions 
Docusate sodium 4 (5%) 
Picolax 3 (4%) 
Orlistat 1 (1%) 
Prucalopride 9 (12%) 
Linaclotide 3 (4%) 
Tertiary Interventional therapies 
Trans-anal irrigation 9 (12%) 
Manual evacuation 1 (1%) 
ACE irrigation 1 (1%) 
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Of the 29 responders to testing 22 were classified as indiscriminate responders and 
7 as discriminate responders (Table 31). 
Table 31 Response classification during TiLTS-cc testing 
Active Sham Response Number (%) 
+ - Discriminate 7 (18) 
+ + Indiscriminate 18 (46) 
- + Indiscriminate 4 (10) 
- - No response 10 (26) 
Tilts-VAS +ve, response to testing period 
Tilts-VAS –ve, no response to testing period 
% of the N=39 completing testing 
 
The 10 non-responders were placed in the usual care pathway per protocol and 3 
were lost to follow up at 6 months (incomplete PAC-SYM), thus 7 participants were 
included for analysis from the non-responder pathway in phase 3. 
The 29 test responders had planned further surgery per protocol to have an IPG 
connected to their in-situ tined lead. One patient declined the IPG procedure due 
to a perceived lack of benefit during testing, and was therefore withdrawn from the 
study after having had the tined lead removed, and entered the usual care pathway. 
Twenty-eight participants were implanted with an IPG, of which 1 was subsequently 
withdrawn due to a tined lead site infection requiring removal of the implant, and 
another was withdrawn due to pregnancy during follow-up (despite being 
counselled at recruitment about the need to avoid pregnancy). Twenty-six 
responders, and 7 non-responders (33 in total) were therefore assessed at 6 
months for the primary endpoint of the study. 
 
 
 
177 
 
6.4.1. Primary outcome measure 
A total of 33 participants were assessed for the primary endpoint of a reduction of 
> 0.5 mean total PAC-SYM score from baseline. Of these, 15 participants with an 
IPG (57%) were classified as long term responders to treatment, and 5 (71%) with 
no IPG also met the primary endpoint.  
There was no evidence of a difference (P=0.76) in the proportions of long term 
responders to IPG SNS between ePNE TiLTS-cc testing discriminate and testing 
indiscriminate responders (Table 32, Figure 15). 
 
Table 32 Primary endpoint analysis 
Testing 
Classification 
Reduction in PAC SYM > 0.5  
Total Long term 
Responder  
(%) 
Long term            
Non-Responder  
(%) 
Discriminate test 
Responder 
 
3 (60.0) 
 
 
2 (40.0) 
 
5 
Indiscriminate test 
Responder 
 
12 (57.1) 
 
 
9 (42.9) 
 
21 
RD = 0.03 (-0.45, 0.51),  P-value =  0.7586 
Fisher’s exact test 
RD= Risk Difference, P= Probability value,  
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Figure 15 Primary endpoint, Response at 6 months
Discriminate
Responder
Indiscriminate
Responder
Overall LTR 
15/27 (56%) 
P=0.76 
LTR =Long term responder to SNS IPG at 6 months follow-up 
Discriminate responder = Responded only to active sub-sensory ePNE test stimulation 
Indiscriminate responder= Responded to sham ePNE test stimulation 
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6.4.2. Diagnostic accuracy of Tilts-cc VAS during testing 
The TiLTS-cc VAS was designed to determine response to testing with a modest 
threshold of improvement in symptoms of > 25%, in order to maximise 
implantation rates for an analysis the predictive value of the tined lead test. The 
Tilts-VAS score at the end of each testing period (weeks 2 and 6) during ePNE was 
therefore evaluated as a diagnostic accuracy measure for long term response to IPG 
at 6 months (using >0.5 reduction in mean total PAC-SYM score). This demonstrated 
TiLTS-cc VAS could not identify long term responders from non-responders to IPG 
SNS, from tined lead testing responders. 
 
Table 33 Diagnostic accuracy of Tilts-cc VAS during testing (Total population) 
TiLTS-cc_VAS 
Classification 
during testing 
Reduction in PAC SYM >= 0.5  
Total Long term 
Responder n (%) 
Long term Non-
Responder n (%) 
ePNE TiLTS-cc 
Testing Responder 
 
15 (57.7) 
 
 
11(43.3) 
 
26 
ePNE TiLTS-cc 
Testing  
Non-Responder 
 
5 (71.4) 
 
2(28.6) 
 
7 
% (95% CI) 
Sensitivity = 75.0 (56.0, 94.0),  Specificity = 15.4 (0.0, 35.0 ) 
PPV  = 57.7 (38.7, 76.7),  NPV = 28.6 (0.0, 62.0) 
PPV=Positive Predictive Value, NPV=Negative Predictive Value 
 
 
Tilts-VAS was also unable to adequately discriminate between active and sham 
stimulation during the testing phase using this threshold for response highlighted 
by the horizontal red line in Figures 16 + 17. 
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Figure 16 Tilts-cc VAS longitudinal response profiles (%) 
The red line corresponds to the response classification 
threshold of TiLTS-cc VAS. Black is group A sequence and blue 
is group B sequence of ePNE. The majority of responses are 
above the threshold during testing, and some even during 
washout at end of week 4.  
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In Figure 17 the mean values and most of the 95% confidence intervals are above 
the threshold for a defined test response during weeks 2 and 6 in both active and 
sham testing periods.  
6.4.3. Secondary outcome analysis 
The secondary outcomes for the total population are demonstrated in Table 34. 
PAC-SYM, PAC-QOL and Wexner scores decrease on improvement, whilst EQVAS 
increases. The testing non-responders did not have a planned 3 month study visit, 
and there was some loss to follow up at 6 months, hence N highlighted for each 
column +/- SD. There is a moderate improvement in mean total PAC-SYM and mean 
Wexner score over the total population, a slight improvement in EQ-VAS and a 
slight deterioration in mean total PAC-QOL. 
Figure 17 Mean Tilts-cc VAS scores during testing  
Active - Sham 3% (95% CI 45-51) 
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Table 34 Secondary outcomes for the total study population   
WEEKS 0 2 4 6 12 24 
PAC SYM 45 
2.19±0.86 
43 
1.52±0.81 
39 
1.73±0.84 
38 
1.24±0.84 
25 
0.95±0.74 
35 
1.37±0.84 
PAC QOL 
      
ALL 45 
1.28±0.64 
   
26 
1.28±0.69 
37 
1.69±0.83 
Physical 45 
2.70±0.82 
   
23 
1.08±0.80 
35 
2.00±1.19 
Psychosocial 44 
2.24±0.96 
   
20 
0.98±1.04 
35 
1.44±1.15 
Worries 44 
2.66±0.82 
   
23 
1.15±0.96 
37 
1.88±1.09 
Satisfaction 44 
1.17±0.47 
   
26 
2.20±0.84 
36 
1.45±0.81 
EQVAS 45 
50.93±18.40 
   
26 
71.85±21.27 
37 
55.68±29.19 
Cleveland 
and Wexner 
45 
2.47±0.54 
    
36 
1.92±0.77 
PAC-SYM= Participant Assessment of Constipation-Symptoms 
PAC-QOL= Participant Assessment of Constipation-Quality of Life 
N= number 
Mean ± SD (standard deviation) 
 
The secondary outcomes for the ePNE testing responder population (all IPG 
participants) are demonstrated in Table 35. This demonstrates the changes from 
baseline at 2, 4, 6, 12 and 24 weeks. There appears to be on average a mild 
improvement across all domains with mean PAC-QOL improving at 12 weeks then 
deteriorating again at 24 weeks (Fig 18), although this change is not statistically 
significant compared to the ePNE testing non-responders at 6 months (N=7). 
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Table 35 Changes in Secondary outcomes from baseline in ePNE testing 
responder population (IPG) N=26 
Mean change  
(95% CI) 
Weeks 2 4 6 12 24 
PAC SYM -0.57 
(-0.86,-0.27) 
-0.45 
(-0.75, -0.15) 
-0.85 
(-1.15, -0.54) 
-1.03 
(-1.39, -0.07) 
-0.69 
(-1.00, -0.37) 
PAC QOL 
     
ALL 
   
-0.84 
(-1.19, -0.48) 
-0.50 
(-0.82, -0.17) 
Physical 
   
-1.56 
(-2.13, -0.98) 
-0.62 
(-1.14, -0.10) 
Psychosocial 
   
-1.10 
(-1.64, -0.56) 
-0.68 
(-1.18, -0.19) 
Worries 
   
-1.22 
(-1.70, -0.75) 
-0.66 
(-1.10, -0.22) 
Satisfaction 
   
-0.98 
(0.61, 1.35) 
0.27 
(-0.09, 0.62) 
EQ-5D    0.21(0.03, 
0.38) 
0.10(-0.05, 
0.25) 
EQ-5D-VAS 
   
15.5 
(3.13, 27.87) 
3.77 
(-8.34, 15.88) 
Cleveland and 
Wexner 
    
-0.54 
(-0.76, -0.32) 
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There appeared to be a mild improvement in constipation symptom scores using 
the Cleveland and Wexner scoring system, from baseline to 6 months in the 
responder (IPG) population, again this was not statistically significant compared to 
the ePNE testing non-responders (N=7) at 6 months. 
 
Figure 18 PAC-QOL mean total scores baseline- 6 months, responder 
population 
Figure 19 Wexner score baseline to 6 months, responder (IPG) population 
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The mean total PAC-SYM scores (with 95% CI) in the responder population were 
plotted from baseline to 6 months by randomisation order (Figure 20). The most 
crucial aspect of the study design for the primary endpoint was the randomised 
sub-sensory blinding of participants. These data imply that participants improved 
and deteriorated synchronously with no significant difference detected between 
the groups during testing and washout thereby suggesting the participants were 
successfully blinded throughout testing.  
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Tilts testing Tilts testing 
IPG stimulation 
Washout 
Figure 20 Mean PAC-SYM by randomisation order in responder population 
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The daily diaries were the only data sheets completed by participants at home and 
not at study visits. On analysis the source diaries were missing from clinical records 
for many participants in the responder population at various weeks, and sometimes 
with omitted data fields within the weeks. Consequently, a full analysis of these 
would not be meaningful and so it was not performed. Figure 21 demonstrates the 
omitted data using the abdominal pain score as an example. 
 
 
6.5. Adverse events 
Across the whole of the study population there were 103 adverse events in 40 
participants (89%) of which 56 (89%) were directly related to the study intervention 
(Table 36).  
 
 
Figure 21 Daily diary abdominal pain score, baseline to 6 months, 
responder population, illustrating missing data. 
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Table 36 Adverse events classified by severity 
Category Number of 
events 
Number of 
participants (%) 
Adverse events (All)  103 40 (89%)1 
Related to study intervention 56 40 (89%)1 
Severe and related 11 11 (24%)1 
Infections (related)  10 10 (22%)1 
Severe infections leading to tined 
lead removal during testing phase 
6 6 (13%)1 
Severe infections leading to IPG 
removal during follow-up 
3 3 (11%)2 
1Of total study population (n=45),2 Of IPG responder population (n=27) 
 
 
Eleven adverse events were classified as severe and related to the study 
intervention (24%) of which 10 were directly due to lead infections (22%). One 
participant (who suffered from epilepsy) developed status epilepticus following 
general anaesthetic and required HDU monitoring with a Phenytoin infusion. One 
participant had a superficial lead infection at the exit site which responded to 
antimicrobial therapy, and 6 (13%) participants had deep seated tined lead 
infections necessitating urgent removal of the tined lead and withdrawal from the 
study during testing, one of whom was profoundly unwell with septicaemia and 
subsequently required inotropic support on the high dependency unit for a short 
time after lead removal. Three (11%) participants had delayed infections at various 
points during follow up necessitating removal of the IPG. The full adverse event 
profile with severity classification is demonstrated in Table 37 below. 
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Table 37 Full adverse event profile with severity classification 
Adverse Event Mild 
N (%) 
Mod 
N (%) 
Sev 
N (%) 
Adverse Event Mild 
N (%) 
Mod 
N (%) 
Sev 
N (%) 
Surgical 
Infection - superficial 
exit site 
 2 (4) 2 (4) Pain - superficial exit site 4 (9) 1 (2)  
Infection - Deep lead 
site 
 1 (2) 3 (7) Pain - IPG wound site 3 (7) 1 (2)  
Infection - Deep IPG 
site 
  2 (4) Pain at stoma site   1 (2) 
Infection - IPG 
wound site 
 1 (2)  Pain – Buttock 1 (2) 1 (2) 
 
Erythema - 
Superficial exit site 
 1 (2)  Pain - Deep IPG site  1 (2)  
Exudate - Superficial 
exit site 
1 (2)   Stoma obstruction   1 (2) 
Burn - left hand  1 (2)  Oedema – Leg  1 (2)  
Haematoma - wound 
site 
 1 (2)  Paralytic Ileus   1 (2) 
Wound dehiscence  1 (2)  Transient Electric Shock 1 (2)   
Gastrointestinal 
Nausea 4 (9) 2 (4)  Pain – Abdominal 2 (4) 1(2)  
Constipation  1 (2) 1 (2) Heartburn  2 (4)  
Diarrhoea  1 (2)  Pain on Defaecation  1 (2)  
Haemorrhoids  1 (2)  Pain – Anus 1 (2)   
Vomiting 3 (7)   Muscle spasm -Pelvic 
floor 
1 (2)   
Cardiovascular Respiratory 
Hypertension  1 (2)  Dyspnoea  1 (2)  
Musculo-skeletal 
Pain – Leg 4 (9) 3 (7)   Lumbar disc protrusion 
L5/S1 
1 (2)   
Reproductive 
Pregnancy     2 (4) Vaginal Candidiasis   2 (4)   
Menorrhagia  1 (2)      
Neurological 
Paraesthesia 4 (9) 2 (4)  Status Epilepticus     1 (2) 
Headache 1 (2) 1 (2)  Fatigue 2 (4) 1 (2)  
Positional Vertigo  1 (2)  Insomnia  1 (2)  
Genito-Urinary 
Urinary Tract 
Infection 
 3 (7)  Urinary frequency  1 (2)  
Nocturia  1 (2)      
Miscellaneous Dermatological 
Allergic reaction   2 (4) 1 (2) Pressure sore  1 (2)  
Hypothyroidism  1 (2)  Skin infection   1 (2)    
Influenza  1 (2)  Generalised rash 1 (2) 1 (2)  
Ear infection  1 (2)  General pruritus  1 (2)  
Ventilation Induced 
Atelectasis 
  1 (2) Pruritus - superficial exit 
site 
1 (2) 1 (2)   
Oral candidiasis   1 (2)      
Mod=Moderate, Sev=Severe 
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6.6. Incidental Findings 
During the pilot phase I noticed considerable variation in sensations at certain SNS 
voltage settings being reported by participants undergoing tined lead testing. After 
discussion with my supervisors, we realised the dials may require frequent 
calibration, and so I investigated the accuracy of the analogue testing device.  I 
consulted with a medical physicist who then trained me to use an oscilloscope to 
accurately measure the output waveform of the testing devices. The original 
analogue model 3625 was thus put through the calibration test laboratory 
experiment described in 5.7.1, and once the latest digital testing device (Verify 
model 3531) was available I also checked this with a similar experiment to compare 
the accuracy of its digital output waveform (5.7.2). Three study participants used 
solely a cross-calibrated model 3625 device during testing, and this was cross-
calibrated at the start of each testing period. As the Verify device was proven to be 
4 orders of magnitude more precise it was the sole testing device used in the study 
from acquisition (at participant 05). Two participants used the analogue device 
during weeks 1-2 of testing and Verify during weeks 4-6 of testing. All other 
participants (n=40) thus used Verify alone. 
6.6.1. Calibration test for SNS testing model 3625 (brown box) 
In January 2013 I performed a prospective calibration test of the model 3625 
devices by connecting 19 test stimulators to a cross-calibrated oscilloscope 
(Tektronix model 2230) and a counter-timer (Black Star Apollo 100). These 
rudimentary analogue testing devices could simply be turned on, dialled to the 
clinical settings and connected by a circuit to the oscilloscope without the need for 
a simulated tissue load. The output Frequency (f), Pulse Width (pw) and Voltage (V) 
of the waveforms generated were measured in 3 runs. The same fully charged 9V 
Duracell (Pro-cell) square battery was used in each of the devices sequentially. 
These batteries can typically last for years. In run 1, I attempted to set the dials to 
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the correct clinical settings for testing sacral nerve stimulation as clinicians do in 
practice with this device namely a pulse width of 210µSec, and a frequency of14Hz. 
I noted that there was no dial increment on the dials of this device to indicate these 
settings. In run 2 I set the dials to the closest dialled increment to the clinical 
settings which was a pulse width of 200µSec, and a frequency of 10Hz. In run 3, I 
measured the output Voltage (V) of the waveform at indicated dial increments of 
0V, 1V, 2V, 5V, and 10V. A very generous margin of error of 20% difference of 
expected waveform pulse width and frequency to observed waveform output and 
a tolerance of +/- 0.5V was considered a pass for each device, and beyond this was 
considered a test failure.  
 
The first finding was that that an output waveform exists when the device is set to 
zero volts, and this was confirmed in all 19 devices as Figure 23 demonstrates. 
 
 
Figure 23 The oscilloscope demonstrates a waveform when the 
stimulator amplitude dials are set to zero volts 
Figure 22 Total of 19, left new 
(8) and right used (11)  
model 3625 SNS testing 
stimulators 
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In run 1 there were marked ranges of frequency values from 10.6 to 29.0Hz (26% 
failed), and run 2 7.9 to 13.0Hz (11% failed). There were similar findings in run 1with 
the pulse width observed as variable from 242 to 326µSec (89% failed), and run 2 
215 to 274µSec (63% failed) Table 9.  In run 3 all devices had a residual positive 
output voltage at zero (range:0.29 to 1.00V), and the failure rates at dialled settings 
of 0,1,2,5 and 10V were 53%, 100%, 100%, 68% and 47% respectively (Table 38). 
Table 38 Results of Oscilloscope and counter timer measurements of model 3625 
Box Run 1 Run 2 
Frequency Hz Pulse width µSec Frequency Hz Pulse width µSec 
1 12.2 259 8.7 215 
2 12.9 292 10.2 241 
3 11.2 278 8.8 222 
4 12 281 8.8 244 
5 12.1 259 9.3 257 
6 10.8 242 8.9 221 
7 12.3 255 10.1 228 
8 18.6 283 9.6 248 
9 14.3 283 10.9 247 
10 11.7 278 9 243 
11 13 283 9.3 237 
12 113 290 9.1 251 
13 12.5 311 9.1 274 
14 29 307 13 261 
15 14.4 326 10.9 265 
16 13.3 296 102 259 
17 13.6 272 9.9 229 
18 17.4 247 11.4 215 
19 10.6 281 7.9 246 
FC 5 (26%) 17 (89%) 2 (11%) 12 (63%) 
Run 1 expected waveform= 14 Hertz, 210 µSec, Run 2 = 10 Hertz, 200 µSec 
Failure Count (FC) of calibration test, tolerance of 20%  
 
Table 39 Results of model 3625 tolerance test for waveform voltages 
Dialled 
Voltage (V) 
0 1 2 5 10 
Observed 
range 
0.29-1.0 1.6-2.56 2.56-3.68 5.12-6.36 10.08-10.72 
Failure 
Count n (%) 
10 (53%) 19 (100%) 19 (100%) 13 (68%) 9 (47%) 
Run 3 test stimulator set to dialled increments of 0,1, 2, 5, 10 V  
Failure count= outside tolerance of +/- 0.5V 
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These results demonstrate the abject failure of the model 3625 testing stimulator 
to stay within very generous tolerances for the measured output waveform. The 
results show a wide range of variability, with 47-100% of boxes failing Voltage 
tolerance, 11-26% failing frequency tolerance and 63-89% failing pulse width 
tolerance levels.  An abstract was published within a month of these findings (BIG 
conference, Belfast March 2013) in order to highlight this issue to clinicians 
performing SNS testing (183) and research with this model, the results of which 
could arguably now be considered unreliable. These surprise findings mandated a 
revision of the Tilts-cc study protocol which emphasised the need to calibrate all of 
these devices using the counter timer and oscilloscope (which itself was cross-
calibrated against another) in order to guarantee that all study participants 
received identical SNS waveforms during the testing period of the trial. The devices 
were calibrated by manually rescaling the dials according to the observed output 
waveforms and clinical settings were marked accordingly (Figure 25) 
  
 
 
 
Figure 24 Re-calibrating 
the external voltage 
amplitude dial A 
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6.6.2. Calibration test for SNS testing model 3531 (Verify) 
Medtronic released the new temporary SNS testing stimulator model 3531, aptly 
named “Verify”, within 3 months of the calibration test abstract being published. 
This device is a digital testing device with no analogue components (dials) and 
entirely controlled by a circuit board and Bluetooth controller unit. The device is 
power by 2 AAAA batteries and needs to detect a resistance within the testing 
circuit equivalent to that of human tissue in order to emit an output waveform. I 
sought to “verify” that the output waveform was indeed as accurate as specified. 
The calibration test was redesigned for the new device by simulating a tissue load 
equivalent to human tissue through a parallel circuit 993 Ohm resistor being placed 
between the stimulator and the cross-calibrated oscilloscope (Tektronix model 
2230) and counter-timer (Black Star Apollo 100).  
 
 
Figure 25 A model 3625 test stimulator 
with fully re-calibrated frequency, pulse 
width and voltage amplitude dials. 
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A prospective output waveform assessment of 15 used Verify SNS test stimulators 
was conducted. Devices were successively loaded with the same fully charged 
AAAA batteries and connected to a constant simulated tissue load (993 Ω) circuit 
with two output electrodes attached to the oscilloscope (Figures 26 
& 27). The output waveform amplitude and pulse width were measured at clinically 
used settings and compared with the expected output values (amplitude by V=IR). 
Devices passed the calibration test if within tolerances of 10% and 20%. 
The new testing stimulators immediately appeared to produce an accurate 
waveform on the oscilloscope (Fig 28). 
 
 
 
993 To Oscilloscope 
 
Verify Box 
Figure 27 Circuit diagram to measure Verify output 
waveform 
Figure 26 Verify ENS, controller and circuit 
with simulated tissue load to oscilloscope 
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At clinical SNS settings (14 Hz/210 µSec) the measured amplitude and pulse width 
did not vary significantly from expected at a programmed current of 0.2, 0.5, 1.0, 
2.0 and 3.0 mAmp, and 100% of devices passed the calibration test (Table 40). 6 
devices failed at 0.1milliAmps due to more variation at low energy settings.  
The variations in device frequency were too small to be measured with the counter-
timer and therefore in the order of magnitude of x 10-4 Hertz. Similarly, the pulse 
width times were just as accurate at 100, 210 and 400 µSec with the standard 
deviations 0.48, 0.93 and 0.69 µSec respectively. 
Table 40 Verify calibration test findings.   
Current programmed 
(mAmp) 
0.1 0.2 0.5 1.0 2.0 3.0 
Expected output (V) 0.099 0.199 0.497 0.993 1.986 2.979 
Mean (V) 0.107 0.205 0.492 0.96 1.911 2.87 
SD (V) 0.004 0.007 0.016 0.023 0.044 0.063 
Mean Pulse width 
(µSec) 
210.5 211.43 211.567 211.267 210.133 210.933 
SD (µSec) 2.652 0.727 0.68 0.772 2.533 0.929 
N Passed (% of total) 9 
(60%) 
15 
(100%) 
15 
(100%) 
15 
(100%) 
15 
(100%) 
15 
(100%) 
 
 
At all clinically relevant settings 100% of the devices passed the calibration test. The 
failures at 0.1mAmps were irrelevant as these settings are below therapeutic 
Figure 28 Accurate square waveform produced by Verify 
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thresholds. Given these results, the lack of manufacturer support for the 3625 
model, and its reported variability, I concluded that only the Verify testing device 
was fit for purpose in clinical practice and research. I presented these data at the 
BSG conference in London in 2015 and published an abstract to highlight these 
findings (184) and the Tilts-cc protocol was amended, and ethically approved to 
only allow testing with the new Verify device. This device had another advantage 
that it was easier to conceal the settings to ensure blinding concealment as the 
digital controller was not issued to participants. 
6.6.3. Analysis of lead fractures 
During the study a participant reported that there was no sensory perception 
during the sensory habituated test performed immediately before I set the sub-
sensory stimulation, and the un-blinded researcher then randomised and 
concealed the actual stimulation (by simply continuing stimulation or turning it off). 
This occurred at week 5 of testing, therefore 1 week into the second testing period. 
All participants had used the same testing twist lock extension cable for the 6 weeks 
of the test. The participant was provided with a new twist lock extension cable and 
the sensory perception immediately returned on habituation testing. The returned 
lead was examined and although the external twist lock cable (28cm) appeared 
normal, an X-ray (Figure 29) revealed that the number 2 and 3 conductor wires 
were fractured in the distal end of the cable. Electrical testing did not reveal any 
short circuits. The manufacturers confirmed that these were due to repeated 
stressing by flexing of the cables which were designed for 2 weeks of continuous 
use only. The protocol was amended to ensure that all trial participants had full 
sensory perception confirmed during habituation and a new twist lock cable was 
issued at the start of each new 2 week testing period.  
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6.7. Discussion 
6.7.1. Key study findings 
The study was terminated early by the DMC and CI before full recruitment was 
obtained (45/75) due to the persistently high rate of infection of participants during 
ePNE testing (22%). 29 participants responded to ePNE (7 discriminate and 22 
indiscriminate), and 27 were implanted with an IPG (2 withdrew). There was no 
significant difference in long-term response (at 6 months) to SNS treatment 
between the sub-sensory test discriminate (60%) and indiscriminate (57%) 
responders P=0.76.  There was no significant difference in secondary outcome 
measures through testing or long term follow up between discriminant and in-
discriminant responders. The original study design included a secondary objective 
to assess the cost effectiveness of TiLTS-cc testing to the NHS in order to inform 
policy decision making. The under-recruitment of participants due to early 
cessation of the study prevented this analysis, but it is clear that this form of SNS 
testing for CC cannot be cost-effective; no evidence of an effect on the disease has 
been demonstrated and the trial was halted early with clear evidence of safety 
concerns. 
Figure 29 X-ray confirming extension lead fractures through flexing 
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The design of the ePNE testing phase (randomised sub-sensory active or sham SNS 
with devices security sealed) protected the blinding of participants as confirmed by 
the synchronous responses between active and sham testing groups. The SNS 
testing devices were subject to scrutiny of their output stimulation waveform, with 
a small pre-trial lab experiment confirming unacceptably high variability in the 3625 
analogue model, and a far more expected and measured precision to stimulation 
waveform parameters in the 3531 model. This model was also far more difficult to 
tamper with as its digital controller was only used by the un-blinded researcher to 
adjust settings, and was not issued to participants. 
6.7.2. How  study findings relate to existing knowledge gaps  
Early studies of SNS for constipation were very positive and seemed to imply that 
response rates may improve to the levels seen in other conditions (up to 80% 
response) such as faecal incontinence and non-obstructive urinary dysfunction. 
More recently SNS studies in two randomised controlled trials testing efficacy for 
constipation have not reported any evidence of a difference between sham and 
active SNS (121-123). In the Dinning et al study, only 16/59 participants (28%) 
responded to a 3 week supra-sensory PNE (non-randomised). All participants were 
implanted however, and in a double-blinded randomised crossover study of the 
IPG, the proportions of participants responding to treatment and meeting the 
primary outcome measure demonstrated no evidence of a difference; supra-
sensory (30%) vs sham (21%) and sub-sensory (25%) vs sham (25%). In the Zerbib 
et al study 20 of 36 (56%) participants responded to a 3 week supra-sensory PNE, 
and only responders were implanted. These participants received an IPG and were 
randomised to periods of active and sham sub-sensory SNS over an 8 week period, 
and then had active SNS until 1 year of follow up. Twelve of 20 (60%) responded to 
sub-sensory SNS during the randomisation period compared to 11 of 20 (55%) 
responding to sham SNS (P=0.75). These studies have slightly different 
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methodology, but have remarkably similar results; Both seem to demonstrate a 
strong and persistent placebo effect during blinded, randomised, sub-sensory SNS 
testing (albeit with IPG), with no ability to predict a long lasting effect to active 
supra-sensory stimulation. The Tilts-cc study findings appear to fit well with these 
other high quality studies in failing to detect any evidence of a response signal in 
the testing or follow up data. The TiLTS-cc study was designed differently by 
primarily attempting to assess whether an extended tined lead test may predict 
longer term responders to SNS, and demonstrated that this test was unsafe for 
these extended durations and had no diagnostic accuracy for predicting long term 
response to SNS. In light of the inability of the TiLTS-cc VAS to discriminate long 
term response using a threshold of >25% during testing, the study team completed 
a post hoc analysis of the TiLTS-cc VAS by altering the diagnostic response threshold 
from >25% to >50% which could be considered a more realistic response level. 
Table 41 below demonstrates the results of this post-hoc analysis, and that there 
was still no improved accuracy at predicting long term response to treatment with 
an IPG, the sensitivity being 60% and specificity 46%.  
Table 41  Post-Hoc analysis of Tilts-cc VAS response threshold  
TiLTS-cc_VAS 
Classification 
 (>50%) 
Reduction in PAC SYM >= 0.5  
Total Responder (%) Non-Responder (%) 
ePNE  
Responder 
12(63.2) 7(36.8) 19 
ePNE  
Non-Responder 
8(57.1) 6(42.9) 14 
Sensitivity(%) = 60.0 (36.1, 80.9),  Specificity(%) = 46.2 (19.2, 74.9) 
PPV = 63.2(38.4, 83.7),  NPV = 42.9 (17.7, 71.1) 
PPV=Positive Predictive Value, NPV= Negative Predictive Value 
 
The PAC-SYM data were synchronous during testing between the sham and active 
stimulation groups (no significant differences statistically); this confirms the 
blinding as intact and I believe points towards a very strong placebo effect which 
seems to persist for months after an IPG device has been fitted. This reinforces the 
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findings from Zerbib, Dinning and Patton that SNS may be no more than a placebo 
effect as a treatment for constipation. 
The main finding which should be highlighted throughout the literature are the 
safety concerns during ePNE tined lead testing. An infection rate of 22% is 
unacceptable for standard clinical practice, especially as this technique has been 
widely adopted in other surgical specialties such as urology without any robust 
prospective trials of safety. This rate was despite repeated attempts by the study 
team to minimise the risk of infection, and with the expert help of microbiologists 
and infectious diseases consultants who advised on antimicrobial prophylaxis 
regime changes around surgery, and with close observation (weekly) of 
participants’ dressings and wounds. Clinicians and researchers should also be aware 
of the variable waveform of the old 3625 testing stimulator and consider the 
implications this has for prior research evidence in SNS and for clinical use. It may 
be true that the analogue device has delivered variable pulse stimulation to 
participants of the other clinical trials and that the results of these trials are 
therefore not reliable. Certainly a variable device should not be used in clinical 
practice and all clinicians should be using the new accurate digital device as a way 
of delivering a consistent and reliable testing therapy. Clinicians and researchers 
should also consider testing and / or replacing the twist lock cables frequently at 
study visits as these can be fractured leading to ineffective therapy. Of concern, 2 
participants became pregnant during our study despite the participant information 
sheet and consent process, one of whom delivered a baby with a congenital heart 
malformation (atrial and ventricular septal defects). There is a possibility that the 
proximity of the SNS field may have affected embryogenesis, postulating that it may 
affect the spin of Hydrogen atoms within water molecules causing alignment to the 
electrical field as is demonstrated in MRI signals. This may or may not affect 
embryogenesis. It could be argued that the informed consent process was not 
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robust enough, as this lady felt that she became pregnant due to her symptoms 
resolving during the trial, and this potentially emphasises that the informed 
consent process should be continually revalidated during the follow up period of 
these interventional studies. 
6.8. Summary of chapter 
In this chapter I have presented the findings of the Tilts-cc study through the 
intended analysis plan as was prospectively agreed within the study team. I have 
demonstrated the primary and secondary outcome measures, and safety data with 
subsequent analysis and interpretation. My main conclusions are that these data 
demonstrate that tined lead testing using an ePNE technique is potentially 
dangerous to participants due to an increased infection risk, and that there is no 
evidence that it is effective in predicting long term response to IPG SNS in 
participants with chronic constipation. This adds weight to the literature that 
observed effects of SNS in treating constipation may simply be placebo effects. 
Safety concerns of ePNE testing will be highlighted to clinicians and researchers 
alongside the key message that the data does not support the future use of SNS in 
routine clinical practice for chronic constipation. 
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Chapter 7 Essence Results and Discussion 
7. Introduction 
This chapter describes findings from a series of semi-structured phenomenological 
one-to-one interviews with eight participants, seven of whom participated in the 
TiLTS-cc trial, one of whom also experienced usual care, and one of whom 
experienced both a pilot version of the TiLTS-cc trial and usual SNS care. The aim of 
this qualitative work was to explore the lived experience of CC and of participation 
in a blinded trial in order to inform future trial design. Although the study is 
described as mixed-methods, the qualitative study was scheduled following 
completion of the testing period and 6 month endpoint of follow up in order to 
avoid contaminating the results of testing (see Methods Chapter 5).  
7.1 Recruitment 
A total of 36 Invitations were made to all 13 (female only) eligible participants of 
the TiLTS-cc study (who had either completed the study per protocol or withdrawn), 
and 23 (22 female, 1 male) participants of the Durham constipation clinic who had 
been historically treated with standard SNS and had previously indicated that they 
were amenable to research invitations. Of these invites 8 people (all female) 
requested further information in the form of the specific PIS, and all consented for 
study enrolment. The recruitment rate was thus 22% in total, and for TiLTS-cc study 
participants and standard SNS participants, 54% and 4% respectively. 
7.2 Participants and Interviews 
The first participant (EE01) was interviewed in June 2014 and data saturation was 
identified by both myself and the senior supervising research team member (HC) 
after re-analysis of all interviews in December 2014. All participants were female 
(only one male was eligible and did not wish to enrol), with an average age of 38 
years (range of 25-57) and participants had a mean duration of symptoms of 13 
years (range 5->30, Table 41). 6 participants were employed at the time of 
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interview, one was unemployed and another retired. 7 participants were living with 
a partner of which 5 were married, and only 3 participants had children: 07EE was 
retired with adult children and also had grandchildren, and 2 had young children 
(03EE and 04EE). Only one participant was single and living alone (08EE). All 
participants attended interviews as invited and no interviews were terminated 
early. Interview durations ranged from 21 minutes to 76 minutes, with an average 
of 46 minutes and a total time across all interviews of 364 minutes. Transcripts were 
over 50,000 words and 114 pages in total with an average of 6,300 words over 14 
pages per participant interview. 
 
 
 
One of the eight participants returned immediately after the interview for a further 
debriefing and was counselled by both the researcher (as a clinician) and a specialist 
nurse. This participant was interviewed for 76 minutes, and returned to the clinic a 
short time after crying and feeling tremendously upset. An opportunity to talk 
Table 42- Essence study participant demographics  
Participant 
Study 
number 
Sex Age 
(years) 
Duration of  
Symptoms (years) 
Family life Employment 
status 
 
01EE 
 
F 
 
37 
 
5 
Married 
no children 
 
Employed 
 
02EE 
 
F 
 
30 
 
>10 
Partner 
no children 
 
Employed 
 
03EE 
 
F 
 
41 
 
8-10 
Married 
young children 
 
Employed 
 
04EE 
 
F 
 
38 
 
>20 
Married 
young children 
 
Employed 
 
05EE 
 
F 
 
47 
 
7 
Married 
no children 
 
Employed 
 
06EE 
 
F 
 
27 
 
5 
Lives with 
partner  
no children 
 
Unemployed 
 
07EE 
 
F 
 
57 
 
>30 
Married              
adult children 
 
Retired 
 
08EE 
 
F 
 
25 
 
17 
Single 
no children 
 
Employed 
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further and debrief with the researcher and a specialist nurse was taken during 
which she stated that she had relived her experiences of suffering from the 
condition and most importantly the effect it had had both on her and her family. 
She had finally realised just how much she had suffered and felt that she had put a 
lot onto her family over the years. This event could be construed as an adverse 
event within the Essence study as the interview had clearly precipitated this recall 
of traumatic life events. It could also be construed as a talking therapy, (like 
cognitive behavioural therapy) as she ultimately felt the benefit of discussing these 
events and then debriefing, as the Essence protocol was designed to facilitate. She 
had been withdrawn from the Tilts study due to life-threatening sepsis and 
returned to usual care during which she had routine SNS as a second attempt, from 
which she thankfully perceived a long term and lasting benefit. 
7.3 Emergent Themes 
Overall, three main themes emerged concerning the lived experience of 
participants;  
 Self-managing the physical, social, and emotional effects of a life-dominating, 
progressive and prolonged disease; 
 An experience of angst characterised by anger at the failure of healthcare to 
provide a cure;  
 A proactive approach to taking personal control by seeking a cure, and participating 
in a clinical trial.  
The main overarching theme linking these is of participants’ regaining and 
maintaining control of their body and lives. The coding and thematic analysis is 
visually demonstrated in Appendices 17-20. Findings describe the shared 
experience among participants of a life-dominating condition and a transition from 
seeking standard medical therapies, through desperation, to a process of self-
management when standard therapies failed. A shared distrust of medical 
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professionals reflects the participants’ sense of personal failure, of being let down 
by medicine, and every participant sought to try and take back control through any 
means possible. This may partly explain their motivation to participate in trials of 
new interventional medical products and their subsequent high recruitment rate, 
and high retention rate. Coding and thematic analysis is demonstrated through 
Appendices 17-20. 
7.4 Self-managing a life-dominating, progressive and prolonged 
disease 
7.4.1. Onset and progression of the disease 
Several participants described symptom onset from childhood to early adulthood, 
some with a defined point of onset, which they each associated with a traumatic 
incident involving physical and/or psychological harm, even though medical 
attribution was not clear.  These participants have been treated by multiple 
clinicians and form interesting and unique case studies – as such further detail 
would render them identifiable so relevant quotes specific to the incidents 
themselves are not included .  What follows are general comments about disease 
onset.  
“Probably in childhood when it originally began, it was awful.  Can’t really 
remember but according to my Mam it was just awful as a Mam to a child.  I went 
on all the normal Lactulose, all the stuff and got by.  Got to teenage years and didn’t 
tell a single soul about it cos that’s what I did as a teenager.  Hit pregnancy and it 
was just absolutely horrific.” Participant 4 
 “It’s a vicious circle, once you start it’s like being on a wheel and the wheel goes 
round and round and round and how do you get off?  You can’t really because even 
now I still think, well I know I’m still on that wheel, for all the treatment that I’ve 
had has helped, it certainly doesn’t cure.” Participant 5 
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 “No, I’ve always known it.  I mean I’ve had bouts where it’s been not too bad and I 
could live with it and then it just hit the stage where it went beyond I couldn’t live 
with it. They did everything that they could.  I felt like they gave me everything that 
they could, but it just wasn’t working.” Participant 8 
“Em …. It’s been a constant sort of  …….(pause)   I would say it’s got so much worse 
since about, think it was 2009 and it just seems to keep slipping downhill all the 
time.” Participant 1 
The condition was described as progressive by all interviewees. Participants 
reported fluctuating symptoms which would improve for short periods of time, but 
in all cases these would recur and gradually appear to deteriorate with time, and 
with increasing age.  
“I think I’m used to it now [medicating] cos it’s 10 years on, so obviously I’m used to 
doing it for 10 years.  It’s getting more difficult now as I get older because I find I’m 
more tired” Participant 2 
“Probably about 8-10 years of constipation………. But as the years progressed, 
initially it [Picolax]would take 3 hours to work, then the longer I was using it, it was 
taking longer – 7-8 hours to work .  So in the end it was pretty much a full day out” 
Participant 3 
7.4.2. Physical impact of the disease 
All participants reported experiencing a range of physical symptoms that were 
resistant to treatment, long-standing, and debilitating. Most of these symptoms 
were commonly experienced by every participant, whilst others were unique to an 
individual. The main shared symptom experience was of prolonged constipation 
over many years (from childhood in some), with constipation for months at a time, 
and which all participants believed was causation for their other shared symptoms. 
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The majority believed that their constipation sapped their energy for daily living, 
leaving them feeling ill and fatigued and constantly deteriorating over time. 
“Basically I think I was going to the toilet like every 12 to 14 weeks.  I just couldn’t 
go at all.  I tried laxatives, I tried everything.   Just nothing worked at all.”   
Participant 8 
“they’re just wasted days, completely wasted days, and sometimes even the day 
after that I don’t function properly because obviously I haven’t got the energy, I’m 
tired and sometimes in a lot of pain  as well, so it’s …  it’s not fun” Participant 1 
“Probably in childhood when it originally began, it was awful.  Can’t really 
remember but according to my Mam it was just awful as a Mam to a child.  I couldn’t 
eat, couldn’t exercise, couldn’t get out of bed some days, I couldn’t live properly.” 
Participant 4 
Another common factor shared by all participants was abdominal pain and bloating 
which was experienced daily, spasmodic in nature, and resistant to strong 
analgesia. The experience of pain and bloating and their effects on daily life formed 
a sense of a constant, ever-present backdrop to the lives of participants, informing 
(and limiting) their day-to-day decisions about social and physical activities, as well 
as being the driving force for a constant pursuit of curative treatments. The majority 
of participants had tried prescribed opiate analgesia and a range of anti-spasmodic 
treatments which had all failed to ameliorate pain (and conversely can aggravate 
constipation), as well as over-the-counter, and non-regulated treatments 
purchased via the internet. This left them with debilitating chronic pain and 
bloating.  
“I got used to it, but it was just so uncomfortable.  Like the discomfort after 7-10 
days and I knew I must have needed to go but my body and my brain didn’t tell each 
other that I needed to go.   So I was bloated, uncomfortable, headaches.   Even 
though I went to work, I was just uncomfortable all the time.” Participant 3 
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“And each time you try these laxatives, you’re getting – well I personally was getting 
pains in my stomach, pains in my back.  It makes normal everyday life not possible, 
and of course when they do work, they work with side effects, i.e. excruciating pain.  
I sometimes just had to go to bed with it cos it was that bad.  Painkillers didn’t touch 
it.” Participant 5 
“Horse riding’s really difficult. I was getting a lot of bloating in my stomach and it’s 
quite painful to do.” Participant 6 
A commonly described experience linked with the experience of pain and bloating 
was one of constant fatigue and lethargy. This was perceived to affect the capacity 
to function and carry out one’s responsibilities effectively.  
“constant fatigue ....I would be in bed for two or three days.” Participant 7 
“it makes you ache, dehydrate, but just very very tired.  And you can write at least 
one day off then, if not two, dependent on how bad it is.” Participant 5 
“I couldn’t do anything, basically ended up just living in the house, not going out cos 
I was just so tired all the time, so run down and bloated and…” Participant 8 
There were other commonly shared symptoms which were sporadic, fluctuating 
and not constant features but considered by most as indicators of worsening 
constipation. These included; loss of appetite, hair and skin changes, headaches, 
and nausea/vomiting. 
“I couldn’t eat, couldn’t exercise, couldn’t get out of bed some days, I couldn’t live 
properly.” Participant 4 
“there’s the spots, there’s the way it affects your skin, the way it affects your hair .  
There’s nothing it doesn’t impact on, absolutely nothing” Participant 1 
“I think the maximum I like to go is 2 – 3 nights, because if I go longer than that I’m 
very, very sick.  It seems to act quite violently, cos obviously there’s a lot of food, 
and I’m quite sick, so it’s worse.” Participant 2 
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Most participants also suffered from at least one additional symptom that they 
attributed to their condition. The type and severity of these symptoms varied 
across individuals. These included pallor, recurrent urinary infections, cognitive 
impairment, faeculent vomiting, loss of urge to defecate and requiring manual 
disempaction procedures.  
“I mean I was getting kidney infections as side effects of it, I was getting extreme 
sickness as a side effect…” Participant 08 
This participant believed that her recurrent urinary and kidney infections were 
directly related to her bowel frequency, and she visualised her symptoms in relation 
to a ‘bowel obstruction’ which she felt caused nausea and vomiting, even though a 
mechanical bowel obstruction had been ruled out. Participant 07 went as far as 
describing an experience when she was admitted to hospital as an emergency with 
a perception of a ‘bowel obstruction’ and faeculent vomiting, which was again ruled 
out following extensive investigations. 
“At one time when I was in they said that my bowel had fused together and I was 
actually throwing up the contents of my bowel.   Because it couldn’t go anywhere, 
it had to get out….” Participant 07  
The three most commonly shared symptoms of all participants, namely abdominal 
pain, bloating and fatigue had the greatest perceived impact on each individual’s 
personal, psychological, social and professional life, described below.  
 
7.4.3. Impact on working life 
All participants reported that their disease affected their working life, with sick 
leave taken by all participants on a regular basis, ranging from an occasional sick 
day to months in duration, leading in some cases to a decision to resign, or being 
asked to leave employment. For these participants, not being in employment was 
perceived as easier to manage than working with their condition.  
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“I was on the sick for quite some time as well” Participant 06 
 “many a time I would have at least a couple of days off a fortnight because I felt so 
bad, but other times I wouldn’t feel quite as bad you know, so I’d go for a few 
months where it just didn’t seem to bother me quite as much but in the end I had to 
leave work because of it.  Because I was having that much time off and when you’re 
the manager it’s not really any good.  You can’t get the others for being off when 
you’re doing the same.  So I just left in the end.  It was easier.  Because as I say as I 
got older it got worse.” Participant 07 
Others felt that their unemployment was directly attributable to being unwell. 
“…it rules your life socially, completely socially as well as doing my job – I mean, it 
stopped me working.  The pain and the fact that I couldn’t go to the toilet and drink 
when I needed to because of the job I did...” Participant 01 
 “Yes, I couldn’t work, I couldn’t do exercise.   Everything I did, I mean I had to quit 
my job….”  Participant 08 
In the 18 months since completing the TiLTS-cc study this participant’s symptoms 
had improved so much that she was managing to hold down a permanent job at 
the time of the interview which was a huge relief and personal gain for her. 
Some participants reported employers who were more sympathetic about their 
medical problems, but these tended to be participants in a higher status, highly paid 
professions. Those who were more likely to report difficulties from employers 
tended to work in lower paid jobs outside of a formal profession. 
“My work and my boss are aware of it. They were aware of my accident but I 
qualified through the same xxx and trained through the same xxx, so they have 
always been very supportive but I don’t get consideration really anyway, but I don’t 
ask for it either.” Participant 02 
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“…because I could get rushed into hospital.  The truth’s got to come tumbling out so 
I sort of got a real bollocking off them because I should have really been under 
Occupational Health.  I should have had more powers to take time off so it sort of 
backfired…” Participant 04 
For most participants, medication routines seemed to be a daily struggle. The 
difficulties centred on juggling an onerous self-medication regime at night-time 
with a busy demanding professional life. 
“It’s very difficult to manage it but obviously you can’t take laxatives during the day 
if you’ve got to be at a particular meeting or … It has to be managed through the 
night, so it’s a bit difficult to manage.” Participant 02 
7.4.4. Social Impact    
The social impact of the condition was perceived to be as severe and long lasting as 
the physical effects of the disease, with all participants reporting a sense of 
restriction of their freedoms, with most feeling a sense of isolation and 
abandonment at home. The symptoms restricted their ability to socialise on many 
levels with friends and family; exercise was painful or embarrassing, fashion choices 
were restricted by their pain and bloating with many feeling uncomfortable in 
feminine clothes, and the proximity and availability of a toilet in any social or travel 
situation was of paramount importance. These led to such a severe loss of 
confidence that when symptoms were severe most felt unable and unwilling to 
leave the house never mind attempting to travel abroad for holidays. Most felt that 
their activities of daily living were completely and totally organised around 
treatments, and some were prepared to overdose on laxative medications in order 
to participate in certain social situations or prevent admission to hospital when 
their symptoms were becoming severe. Repeated unplanned hospital admissions 
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would still occur for many and this in itself would have a significant impact on their 
ability to socialise and to plan for the future. 
“I was in and out of hospital about 6 times in less than 6 months probably….” 
Participant 07 
“I’ve always known like being in and out of hospital, I remember being in xxxxx 
Hospital 3 weeks during like the summer holidays” Participant 08 
The experience of fluctuating abdominal bloating was challenging for most 
participants who required several different sizes of clothes to accommodate this. 
Participants often discussed how their condition forced their appearance as they 
were uncomfortable wearing feminine clothing. The issue of bloating and its effect 
on clothing was discussed by all participants and was extremely important to them 
both socially and professionally. The participants who had no children frequently 
commented that they felt that they looked pregnant when the bloating was severe. 
“I’ve got clothes in different sizes.  Some days I look normal, some days I don’t, to 
the point where I look like I’m pregnant – but what can you do about it.  It’s 
extremely frustrating.” Participant 05 
“On certain days you’re that bloated depending on how long it’s been since you’ve 
had any laxatives, that you don’t feel comfortable wearing nice girly clothes, you 
have to wear big baggy clothes because you’re that embarrassed about your belly 
because everybody thinks you’re pregnant” Participant 01 
All participants spoke at length about how their life revolves around medication 
routines and sometimes more invasive procedures, which left them feeling their 
independence and freedom was restricted with some feeling isolated at home. 
There was a sense of organising daily life according to treatments.  
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“…so I’ve always had to take medication for the last 10 years.  It’s debilitating 
insofar as I have to plan my life around it…” Participant 2 
“I was getting extreme sickness as a side effect.  I couldn’t do anything, basically 
ended up just living in the house, not going out cos I was just so tired all the time, 
so run down and bloated and…” Participant 8 
For most this social isolation or limitation was longstanding as the condition had 
affected most participants for years, and some for their whole life. 
“So the constipation over the years, we’re talking about 30 years –it just seems to 
have got worse…….and now I feel my whole life looks at ‘when can I go to the toilet’, 
you know, so there’s things I haven’t done when I was younger, you know, 
holidays…. It’s not quite the same when you’re on holiday, sitting on the toilet for 
an hour……… But you just kind of learn to live with it even though it’s a pain.  You do 
kind of learn to live with it, it just seems to have got worse…” Participant 7 
“Since it began?  Probably in childhood when it originally began, it was 
awful.........Got to teenage years and didn’t tell a single soul about it cos that’s what 
I did as a teenager…….Hit pregnancy and it was just absolutely horrific. ….Saw the 
GP after that…………I couldn’t eat, couldn’t exercise, couldn’t get out of bed some 
days, I couldn’t live properly.” Participant 4 
 
7.4.5. Family issues 
The majority of participants felt they had very caring, supportive relationships with 
family and friends but some expressed a perception that their illness had led to the 
end of significant relationships with past partners, and all acknowledged the 
burden the disease posed to their loved ones who have had to support them in 
times of crisis. 
“Yeah, so it can cause quite a few arguments on a personal level, probably family 
and relations, but they do allow for this” Participant 02 
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 “Drove my husband and my Mam to the ground with despair but I felt I just brushed 
them off” Participant 04 
“My mother, when I first started with this, was very surprised – ‘I don’t know where 
you get this from’ and to her it was absolutely horrendous………… that so on my 
mother’s side there was no trace at all of bowel problems and she found it quite 
unacceptable” Participant 05 
 
“That I was annoying them, maybe.  Feeling a burden to people, but I would do it 
for them so…” Participant 06 
 
7.5 Angst about experiences of primary / secondary care 
The disease was experienced with such a chronicity and debilitating effect on a 
person’s quality of life, that across the cohort it seemed to be constantly 
deteriorating despite the best medical treatments they received, including novel 
experimental treatments. This led to an experience of chronic and extreme 
psychological angst. This sense of ‘angst’ was directed towards the perceived failure 
of healthcare to treat symptoms, and was expressed in terms of chronic anger, 
disappointment, low mood, and frustration. There was a sense of being willing to 
try anything in order to regain control over their bodily functions and symptoms. It 
was no surprise that all participants described negative healthcare experiences 
over their years of attending hospital for a refractory condition. The eligibility 
requirements for the TiLTS-cc study guaranteed a highly selected group of people 
who had consulted numerous physicians and failed multiple medical therapies, and 
as such may be expected to share negative perceptions about healthcare. Even 
though this was an anticipated finding, the strength of feeling and bitterness about 
perceived negative experiences was much higher than previously thought. In 
particular it was a shared experience of the group to have a lack of faith in their GP 
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for their initial management, investigation and referral for the condition. There was 
a sense that primary care providers failed to understand or acknowledge the 
severity of the condition and its impact on the participant’s life.  
“The fact is going to the GP wasn’t any help whatsoever. Em, I don’t think that the 
GPs understand the problem, in all fairness. And that’s no disrespect to the GPs 
because the general practitioner is not taught about things like this…… I just don’t 
think they get it.  And in my GP practice there’s, crikey, several different GPs and I 
think at one point I’ve seen most of them and they do not understand the impact 
that it has on you.” Participant 01 
“He kind of just didn’t really understand everything that was going on and how 
much it impacted, and seemed to fob me off with different tablets to try, and didn’t 
really take an interest” Participant 06 
“You know, he said we can’t just send you to a specialist…” Participant 7 
Once participants attended secondary care the shared experience was also initially 
disappointing, and most felt they should have been referred to a tertiary centre 
earlier. 
“I think people accept what their GP and possibly their local hospital will say to 
them.  And I’m not criticising every consultant but obviously I don’t have faith in 
******* or the ******. So yes, I think people don’t push and I think there will be 
many people in the UK who have not been referred.” Participant 02 
Specific negative comments had been made by specialists to individual participants, 
sometimes many years ago, which had clearly stuck in their minds and caused 
further healthcare angst. These comments were of a disbelieving nature, indicating 
that it was a psychological problem, or belittling their complaints. 
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“it was ‘typical of my age and I would grow out of it’.  So I hadn’t had a good 
experience.” Participant 02 
“So, those few words … I did put a complaint in about it but he just said he didn’t 
mean it the way it came over.  But he still shouldn’t have said something like that.” 
Participant 07 
GPs deferring responsibility to secondary care and vice versa was another common 
complaint and cause of healthcare angst. All participants felt that no single doctor 
had complete ownership of their management and there was a distinct sense of a 
belief about lack of continuity of care between primary and secondary care.  
“Oh, nothing to do with us, go back to the Professor.  So, I’m really banging my head 
against a wall now if I do have any problems when I go to the GP….Because I think 
they’re frightened to overstep anything that the Professor wants to do but again it’s 
like – oh well you’re under them, and he’s the big guy for it, so…” Participant 01 
“Cos I mean I ring them up now and it’s like we can’t deal with you, you’ve got to 
ring Durham.  And it’s like – you’re my own GP, I should be able to go for help.” 
Participant 08 
Frustration at normal investigation results and a sense of no-one believing in their 
symptoms were frequent. Most participants now understand that normal 
investigations do not exclude ailments, but felt a sense of disbelieving from their 
care providers on receipt of the initial results. 
“He actually told me it would be so much easier if I had bowel cancer.  He would cut 
it out, throw it away and get on with life.” Participant 07 
7.5.1. Psychological response to angst 
Most participants expressed the view that they were overly irritable with loved 
ones and they admitted that despair and anger was a prominent feature of their 
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daily lives, and that this in turn could lead to despair affecting their relationships 
within the family. The perceived failure of healthcare to address their symptoms in 
turn led to stress, frustration and eventually to low mood or depression at the 
thought of no release from the chronic suffering that they perceived to be their lot 
in life. Personal and sexual relationships also suffered as a result of both disease 
symptoms and psychological angst. 
 
 “Yeah, so it can cause quite a few arguments on a personal level, probably family 
and relations, but they do allow for this.” Participant 2 
 
“Honestly, I just can’t understand how with medicines being so clever now, nobody 
can help me go to the toilet.  It seems so bizarre.  You can do nearly everything now, 
and then I can’t go to the toilet.  I get so frustrated.” Participant 3 
 
 “it makes me very self-conscious.  I mean, I hate getting undressed because I feel I 
look an absolute disgrace and a mess and for all he tries to convince me otherwise, 
in my mind I’m a mess……It affected me badly, very very badly.   Frustrated my 
husband to death.” Participant 5 
 
“It used to make me really annoyed, cos it’s like well what else can you give me?” 
Participant 8 
 
7.5.2. Effects on mood and self-perception 
All participants expressed low mood, irritability, stress, frustration, and anxiety 
about their symptoms and treatments.  
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“I’m quite low with everything that’s going on at the minute and I just think that if I 
can help move things on, if we can get something sorted out for people with our 
condition, then that would be brilliant. Participant 1 
 
“Probably just teary, as I am today. I suppose in social situations I’m conscious 
of….obviously I don’t want to take the tablets if I’m out at night” Participant 2 
 
“…..but it also affects all of your life.  It stresses you, it gives you anxiety….” 
Participant 5 
 
The disease was universally presented as being life-dominating and affected all 
aspects of participant’s physical, psychological, and emotional lives. Many 
participants felt self-conscious or embarrassed at their appearance due to their 
bloating, and this in turn led to further social anxiety on the occasions when they 
had the confidence to venture into social circles. This was apparent across the 
whole cohort with a consistent experience of feeling suddenly bloated and larger 
which resulted in an immediate loss of confidence.  
 
“Yes, I wasn’t horrible in other people’s eyes, I was horrible in mine, my eyes.  I was, 
I used to call it the invisible wife cos xxxxx would go to places on his own cos I’d be 
all up to go, then I’d put something on and it wouldn’t fit because I was that 
bloated or I’d break out in spots or … that was it, I wouldn’t go.  So we used to have 
a joke that he just used to have this invisible wife, had a wedding ring but no wife 
to go with him….” Participant 4 
 
“If you want to go out, it’s finding something that’ll fit.  It has greatly affected my 
confidence very much so because I always feel I look a mess..” Participant 5 
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7.5.3. Personal beliefs about the disease 
Some participants had strongly held (and medically unverified) views about the 
perceived ‘toxifying’ dangers of constipation (the old myth of auto-intoxication, see 
Chapter 1), leading to perceptions of prolonged harm to every system in the body.  
 
 “No you can’t fix it because it’s got to be fixed internally and you can’t move the 
toxins through your body, so we can’t …then you’re told, oh you’ve got acne because 
of all the toxins you’re carrying around in your bowel” Participant1 
 
7.6 Taking control 
Overall, participants were very committed to taking control of their own symptom 
management in a variety of ways, some of which were mediated via their 
relationships with clinicians and some of which were self-directed and in some 
cases experimental and potentially dangerous. All participants had followed 
treatment pathways which were unsuccessful and as a result, left them to try to 
maintain a sense of control over the symptoms in ways including strict dietary 
regimes involving low residue diets, individualised laxative regimes, and alternative 
therapies including herbal remedies, Chinese medicine, and coffee enemas. Trying 
these remedies represented the pursuit of hope that a curative treatment could be 
found for their symptoms.   
 
“Just think it’s my body just not wanting to play any-more.  I don’t know.  I’m trying 
every supplement that I possibly can to make things better, even taking something 
called Triphala which is ….it’s the worst thing you’ve ever tried –ha ha it tastes grim 
but ...” Participant 1 
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“I just bought every combination of everything over the counter and tried to do it 
my way. I spent 8, 9 weeks on the cabbage soup diet. I have done everything I could 
do to the ridiculous to the sublime …. Literally everything I could do, I’ve done. … But 
it wasn’t until I got pregnant and realised I had another life to look after, that I 
couldn’t just randomly buy stuff off the internet.” Participant 4 
 
This represented a shift in the locus of control in relation to finding a successful 
treatment away from clinicians, who had failed to do so, to the participants 
themselves who via a process of trial and error, took it upon themselves to pursue 
a miracle cure. One participant recognised the limited effectiveness of these 
treatments and their effect of limiting their loves and social activities even further, 
but elected to continue taking them regardless again underlining the need to 
control one’s self-management. 
 
“Because there will be that miracle” Participant 1 
 
7.7 Taking personal control by participating in a stable and routine 
clinical trial of a surgical procedure 
 
As previously described, participants were highly motivated individuals attending a 
tertiary referral centre which specialised in treating participants with refractory 
bowel disorders and frequently invited these participants to consider novel 
treatments for their condition within clinical trials. Consequently, participants were 
experienced trial participants who had experienced treatment in other novel 
interventions prior to participating in the TiLTs-cc study. 
“Whilst I know that there isn’t a cure, I’m never going to have a cure, I’m able to try 
what’s available as it becomes available.” Participant 2 
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“I had had a few studies, tried a few trial medications which didn’t work for me” 
Participant 3 
 
 “Frustrated,  annoyed , at the stage of where I wanted my life back because at the 
time that I had the operation I was only 24 and it was just like …” Participant 8 
 
7.7.1. Motivations for trial participation 
 
The main motivating factor for participants was the opportunity of trying a new 
treatment for their condition, and a belief or wish that this may actually be the cure 
they have been seeking.  
 
“…so I wanted the pacemaker putting in to see if it would do marvellous miracle 
things!” Participant 1 
 
 “I thought about it quite in depth and discussed it with family members, and 
thought it was better to try it than regret not giving it a go. “ Participant 2 
 
“Picolax was taking longer and longer to work and if that stopped working there 
wasn’t really anything left to try.  So I thought I would just give that a try” 
Participant 3 
 
“Just to see if it would help.  To see if it would make my symptoms either disappear 
or help in trying to get me back to a normal life.”  Participant 6 
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“So I thought if I do something like this and it works, it would just take all that stress 
away and I would feel normal……. So I thought nothing ventured nothing gained.” 
Participant 7 
 
 “Well it was the next thing for me to try and I was getting to the point where I was 
getting so annoyed and frustrated.  I was willing to try anything if it was going to 
help me.” Participant 8 
 
One participant had viewed the trial participant information sheet, and was 
motivated primarily due to a perception that the treatment offered a very high 
chance of success. 
 
“You know you could say it’s clutching at straws but having done the background 
research and having been given the information that I had, we considered it to be a 
very very acceptable success rate.  If it didn’t work it didn’t work, but at least it was 
tried.” Participant 5 
 
Secondary motivating factors were largely due to altruism [as research participants] 
as participants were aware the blinding test being applied during therapy may help 
identify other participants in future who would benefit from treatment.  
 
“Because I want to help other people.  I would like to say that I’m quite low with 
everything that’s going on at the minute and I just think that if I can help move 
things on, if we can get something sorted out for people with our condition then 
that would be brilliant.” Participant 1 
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 “You know if it helps them and helps others.  You know even if it doesn’t really help 
them, I mean it didn’t really help me but there might be something in it for 
somebody else who’s in my position that it would help.” Participant 7 
 
 
Other secondary motivating factors emphasised the recurring theme of 
participants wanting to taking back control of their lives from their disease.  
Participant 4 emphasised this point on describing her inclusion into the trial: 
 
“I felt like everybody just said, whoa this is it, this is it, and I went out feeling like 
on top of the world.  I really did.” Participant 4 
 
7.8 Demands of trial participation 
The burden of testing (and overall trial participation) impacted on participants 
social, personal and professional lives in a number of different ways. Testing 
involved invasive surgery, weekly hospital visits (sometimes from well outside of 
the region), weekly diaries, wound care requirements, against a background of 
being unable to drive for 6 weeks. Dressings were itchy and uncomfortable, had to 
be kept dry, and participants were not allowed to bathe for the duration of testing.  
 
“The worst thing about it was not being able to have a proper shower.  I was pleased 
it wasn’t the summer time, it was more winter so it was a bit easier I suppose, but 
that was one of the worst things, not being able to have a shower properly.” 
Participant 7 
“I just really sat on the side of the bath to be able to wash my hair, to bend my head 
forward to wash my hair cos that was one of the main parts I didn’t really know how 
I was going to wash my hair” Participant 6 
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All participants appeared to adapt to this burden very well, and were motivated by 
a desire for benefit, with only one participant reporting that the daily diaries were 
onerous, although they were still completed with very little missing data.  
 
“They were good, yes.  I found them quite easy after doing a few” Participant 6 
 
“Erm, yes I suppose it is onerous because if you’ve got to remember to do it” 
Participant 2 
 An unexpected consequence of the burden of testing was becoming dependent on 
others, particularly close family members and partners, to help with transport and 
personal care. One busy professional participant reported organising the 
management requirements by relying on a secretary to transport the participant to 
appointments. Others without those professional resources were willing to rely on 
partners and family members. Most participants felt that this was acceptable within 
the time limits of the testing period.  
“I travel the country so I couldn’t drive for that period of time, so running up to it we 
had to make sure that we didn’t book me into any meetings where I needed to drive 
to, or drive to the train station.  I did travel and I did do meetings ……..my secretary 
would have to drive me, and then we would get the train.  So it took quite a lot of 
planning to do it.” Participant 2 
“That was hard cos obviously I’d been passed for some time and my fiancé doesn’t 
drive.  It was a stumbling block but, people kind of rallied round.” Participant 6 
Participants were very willing to manage these burdens because of the sense of 
agency, control, and potential for benefit that trial participation afforded them. 
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For the majority (n=5) of ESSENCE participants, for the duration of testing (and the 
duration of the trial) there was a very marked perception that the TiLTs-cc 
treatment was beneficial in itself, independent of symptom change (and in the full 
knowledge of a sham period of treatment). This lead to a strong sense of regaining 
control in their lives, returning to work and in some instances new relationships and 
peer support opportunities with other trial participants. This perceived benefit 
meant that participants were willing to adapt to the day to day demands of testing. 
It is notable that this sense of control continued during up to 8 months of follow-
up.  One participant experienced similar perceptions of benefit during testing as 
those described above but this did not last for the duration of follow-up. A minority 
(n=2) did not experience any perceived benefit during testing, the TiLTs-cc 
treatment was perceived as yet another failure after a series of treatment failures, 
and the hope of a ‘miracle’ cure and control of their body [and life] had again 
slipped away. However, all participants valued the opportunity to participate and 
did not regret taking part, and again valued the sense of agency and control 
afforded to them during the testing period.  
“But strangely I still have been able to go to the toilet.  So while it was working in 
that period that it was working, it’s stimulated my bowel sufficiently that I now 
know I need to go.” Participant 3 
“It was a relief to maybe be given the opportunity to have the stimulator fitted 
because at that time I didn’t know whether I was going to get it or not.  So it was 
purely and simply a trial.  And it was something I was very keen to do because 
anything to help alleviate the problems that I had have is more than welcome and I 
believe I’m very lucky to have been given this opportunity” Participant 5 
One of the questions during interview focused on perceptions of the blinded 
sham/treatment testing process. Participants felt that this attempt to understand 
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the placebo effect had the potential to reduce the legitimacy of their physical 
symptoms. Two participants felt it suggested to them that their symptoms might 
be perceived as ‘made up’ or psychological.  
“I don’t know, because it makes you think have you made it all up, but I couldn’t 
make 10 years of constipation up.  So I knew it must have been doing something ….” 
Participant 3 
All participants felt that they were unable to differentiate between active and sham 
treatment, supporting the physiological legitimacy of blinding, but they often 
admitted trying to subvert the blinding by monitoring symptoms very closely. At 
the time of interview all participants were still blinded to their randomisation. They 
were unable to tamper with the device undetected, so blinding was protected, but 
participants often wished they could break blinding in order to understand whether 
their perceived benefit was a result of active treatment during testing. 
“I think it’s just you’re wanting to hope that it’s working so you are, whether you 
consciously doing it …” Participant 3 
“So that might have been the implant or it might not.  So I didn’t know whether it 
was switched on at that time or whether it wasn’t.  So that was hard to tell like the 
second period, so I don’t know” Participant 3 
“…you’re waiting to see if during that first two weeks whether it was switched on or 
whether it was switched off and it was constantly on your mind…. So obviously 
however many years you’ve suffered from the condition you obviously want it to 
work, so you are trying to guess it.” Participant 2 
  All participants felt that this process of blinded testing was acceptable and 
understood the reason for this.   
Interviewer:  “Do you think having a pretend test is actually ethical as part of a trial? 
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“If they think it’s worked and then you tell them that actually you had an Aspirin 
instead of what they thought they were getting, or whatever.  But you can convince 
yourself if you want to I think.  So yeah, I think it’s right” Participant 3 
 “I think some people would think it’s not but if they don’t have these kind of 
symptoms then they wouldn’t understand the feeling of it, so you’ve got to go on 
your body’s instincts and I think it was better that way.” Participant 6 
Although participants were concerned that evidence of a placebo response might 
reduce the legitimacy of physical symptoms, they all acknowledged the possibility 
of a placebo response.  
“..because some people could say that oh great, it’s worked, it’s helped, but a lot of 
it could be in their minds as well.  Wondering you know, if you’re the one that’s 
getting the placebo or not.  But no, I can understand why they did it.” Participant 7 
7.8.1. Testing stimulators 
During the trial, some participants were required to move from using an unreliable 
analogue device, to a new more reliable, digital device (Page 181). Participants 
experienced problems in using the analogue device in that they kept shutting down, 
requiring more visits and re-randomisation, and they were six times the size of the 
digital device, with associated implications for managing hygiene and sleep. 
Additionally, the analogue device triggered supermarket alarm systems where-as 
the digital model did not. Despite these additional burdens, no-one in the Essence 
study cohort dropped out of the Tilts testing period, again demonstrating a 
commitment to the trial and individual pursuit of benefit.  
 
“then I had another old one [model 3625] but that was the constant worry that it 
was going to stop again.  But once I got the new one on, that was absolutely 
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brilliant.  It was much easier to cope with as well because it was smaller.”  
Participant 1 
 
“my sister did used to laugh because the barriers would go off if we’d gone to the 
Metro after here, and she’d go “ it’s your butt isn’t it” and I’m like “no, no, no, no 
it’s not my butt!” Participant 8 
 
7.8.2. Living with Permanent Sacral Nerve Stimulation (PSNS) with an 
implantable pulse generator (IPG) 
The majority of ESSENCE participants (n=6) were given permanent SNS, of the 
remaining 2, one did not meet the criteria for implantation and had no further trial 
participation, and the other was a pilot study participant receiving usual care who 
had no testing response to treatment. One of the 6 participants who went on to 
have an implant was excluded from the trial during testing due to a severe adverse 
reaction. The decision was taken to withdraw this participant from the trial 
clinically, but the participant was deemed eligible for SNS implantation outside of 
the trial envelope and ethical approval was granted to include this participant in 
the interviews in order to fully explore the dimensions of the experience.  What 
follows is a description of the experience of those having a permanent implant as 
part of the trial or as part of routine NHS care.  
A number of participants felt that they experienced profound global symptom 
improvement, for example in bloating, pain and bowel function which seemed to 
extend over the period of long-term follow-up.  
“Then obviously I got into doing every trial.  I grabbed everything I can and tried it 
and none of it worked.  Same symptoms, maybe a bit of relief for a month here and 
there, but nothing until I had the SNS and then it was much life-changing….I feel like 
I’m living my life now.” Participant 4 
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However, for this participant, the perceived benefit was complex and difficult to 
disentangle from the apparently modest improvements (or stasis) in quality of life 
measures. Even when participants spoke about life changing effects, the 
measurable effects on pain and bowel function were modest. The positive 
psychological effects, combined with an experience of a large perceived reduction 
in bloating, seemed to be the driver in the perception of benefit for this participant.  
“I’ve still got fat club, still got fat clothes and normal clothes but some days aren’t 
as bad.  Some days are pretty horrific but now there’s an end, every bad day there’s 
an end of maybe 4 days maximum, 5 days.  Before it could be weeks, so everything’s 
just toned down” Participant 4 
She was further questioned on whether she felt she had regained control of her life 
after having the permanent device fitted. 
Interviewer: “You’ve got control back?  Is that a fair point?” 
“Yes, completely.  I can go to the park in my fat clothes because now it’s alright you 
know” Participant 4 
The youngest participant in the study was urging others to have the device fitted; 
her perception was of complete success, and yet her symptoms were still classified 
as severe and chronic under the Rome definitions of CC, but ultimately the marginal 
symptom improvement she experienced, whether placebo or effect, has given her 
a sense of taking back control. 
“I’ve been telling everyone about it and I’ve said I’ve literally got my life back... Cos 
from my experience it’s like changed my life. I started to be able to go like 
swimming, walking, managed to get a job, managed to get out the house, managed 
to start seeing my friends again. I’ve been able to start going to the toilet, everything 
like that.  I wouldn’t hesitate to have it done again.  I‘ve been able to go back to 
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work, I’ve been able to start doing exercise again.  If they’re offered it I’ve said take 
it.” Participant 8 
For this participant, her symptoms had been experienced for her whole life since 
early childhood and the outcomes of importance were fatigue, bowel function, and 
bloating. Her bowel function had improved to opening her bowels just once per 
week which is still defined as severe constipation, but from her perspective the 
impact of the implant was profound, prolonged, and positively affected every 
aspect of her life.  
Another participant who was a test responder and received the IPG implant 
expressed her surprise during the test when she seemed to regain sensation from 
her bowel 
“When you just don’t move your bowel at all then all of a sudden you can feel this 
sensation then it’s like Wow!  You know, it’s totally different.” Participant 5 
She also noticed a profound prolonged benefit regarding pain, bloating, and 
frequency of defecation, and described the experience it in a familiar way. 
“I first started to feel my bowel move, it was so totally unexpected and it was like 
somebody had given me a miracle.” Participant 5 
For the remainder, perceived benefit during up to a year of follow-up was more 
modest, particularly for hard outcomes such as frequency of bowel movements, 
but still conferred a sense of benefit in the symptoms most valued by them, 
particularly bloating. They would be identified in the trial as a non-responder due 
to the lack of significant improvement in symptoms, but they still regarded benefit 
as being significant enough to them to warrant keeping the implant, even if it did 
not result in the much hoped for cure.   
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 “It has helped to an extent …. I am not vomiting as much, I am not bloating as much 
… So I’m still happy, regardless that it hasn’t worked how I wanted it to for the 
moment, I’m still happy that things are doing something….For all that it hasn’t made 
me have my bowels opened yet there has been significant difference that I’m not 
vomiting as much and I’m not getting as much bloating.” Participant 1 
For two participants, they welcomed the sensory effect of being able to turn up the 
voltage of the permanent implant which seemed to reinforce a feeling that it was 
‘working’. Prior to the trial, one of these participants had experienced lack of urge 
and felt that this was returning as a result of the implant, suggesting future avenues 
of enquiry.   
 “I think when you haven’t had any movement at all, you haven’t had any sensation, 
then it makes a big difference.  Because as I’m sitting here talking to you now, I have 
no bowel sensation at all without this stimulator.” Participant 5 
“So while it was working in that period that it was working, it’s stimulated my bowel 
sufficiently that I now know I need to go.” Participant 3 
For one participant, she perceived the long-term benefit to be modest but if 
measured in terms of hard outcomes, benefit was captured by the fact that she was 
able to discontinue all laxatives. She initially had bowel movements once a month 
and was able to move her bowels every 4-5 days as a result of implantation (so 
would be deemed as a non-responder in the trial). Because her baseline symptoms 
were so severe, her perception was of benefit.  
“I was going to toilet a lot more easily and not getting the bloating and stabbing 
pains that I normally got, during some of it and then obviously on some of it I still 
got it.” Participant 6 
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Of those interviewees who did not receive the permanent implant, both felt no 
significant response to the testing period what-so-ever and their experience during 
follow-up followed the same pattern of relapsing remitting chronic severe 
symptoms. For them, they reverted back to a self-management process based 
around control, and a pursuit of a miracle cure.  
“I was hoping that personally I would get a result from it and my condition. I don’t 
regret doing it … so I’ll keep managing it until something … a study, or a procedure 
or a tablet that comes out that is effective for me personally.” Participant 2 
The disappointment of SNS failing in these two participants also had a negative 
feedback into, and perception of their healthcare angst. 
“but I’ve been coming over here now for over 2 years and I don’t feel like I’ve got 
much further forward….. Well when I first saw the doctor again to come and see a 
specialist, he said Professor Yiannakou, he’ll get you sorted, he’s very good at his 
job and he will get you sorted.  So I thought 2 years down the line, something might 
have happened before now.  But …” Participant 7 
This participant, however was also keen to express her gratitude at trying new trial 
therapies in an attempt to regain control of her life, and of the hope that she may 
have helped others in doing so. She had also underwent a normal sensory SNS test 
as part of routine NHS care following on from the Tilts pilot study trial and was still 
deemed to be a non-responder so did not undergo permanent implantation. 
“There’s always that chance it could have helped me, and if I didn’t do it, I would 
think well what if?  What if it did work? So it was worth a go……I mean it didn’t 
really help me, but there might be something in it for somebody else who’s in my 
position that it would help.” Participant 7 
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7.8.3. Managing the permanent implant  
The permanent implant (with internal components and a control device) posed a 
reduced burden to day-to-day life compared to the testing device with external 
components and blinded stimulation. As expected, the more costly device had no 
reported malfunctions compared to the testing device. Driving was permitted with 
the permanent device and wound care was only required for 1 week post-op. The 
main drawbacks identified by participants concerned the device triggering theft 
detection at barriers in shops and airport security but this was seen as a minor 
problem, dealt with using humour.  
“The only time it alters anyone’s perceptions is when I have to be strip searched in 
airports. …. But once they saw the scars they were alright. … I made a joke of it and 
had a laugh …. I would have worn different underwear …” Participant 1 
 “... my sister did used to laugh because the barriers would go off if we’d gone to the 
Metro after here, and she’d go “it’s your butt isn’t it” and I’m like “no, no, no, it’s 
not my butt!” Participant 8 
7.8.4. Psychological response to testing 
The concept of a placebo effect was introduced to participants as a necessary part 
of the consent process in order that participants would understand the need for a 
cross-over trial design. The process of testing seemed to contribute to anxiety 
among several participants about whether or not any effects were down to a 
placebo effect, and contributed to concerns about not having symptoms taken 
seriously. One participant felt it made her question her sanity and worry that she 
might be judged to be mentally ill and admitted to a psychiatric unit if her response 
proved to be due to a placebo effect. In addition, participants expressed anxiety 
about the surgery and the experience of being tested and implanted.  
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“…because every time you were starting to go to the toilet it was like, I am actually 
going to the toilet because of the test or am I going because I’m a nut job…… cos 
you kept thinking well am I just ending up as like a nutcase and going to end up in 
the nut house or have I actually got something wrong, cos there is actually no name 
for what I’ve got wrong..” Participant 8  
In contrast, the permanent device was perceived to be under the control of the 
individual and did not seem to be associated with any psychological detrimental 
effects.  
7.8.5. Adverse effects and reflection on trial participation 
Rates and types of adverse events are reported in Chapter 6. This section describes 
the perceived experience of two Essence study participants who experienced 
severe adverse events, one of which led to trial withdrawal, and the perceived 
negative experiences of participating in the trial, which were not systematically 
recorded but never-the-less have implications for future trial design.  
Of those with severe adverse events, participant 4 experienced life threatening 
sepsis during testing, requiring urgent admission to the high dependency unit and 
emergency surgery overnight. This participant was gravely ill, and as such required 
urgent advice from microbiologists and intensive care specialists. She required 
removal of the implant as the source of the sepsis and made a rapid recovery. In 
line with trial protocol, she was withdrawn from the TiLTS-cc study but elected to 
receive permanent SNS via routine NHS care, and continued to respond positively 
(and continues to at the time of writing), according to long-term NHS measures. 
Despite the severity of her septicaemia, she was very reluctant to allow removal of 
her implant because of perceived benefit, and immediately after the surgery, was 
requesting re-implantation to the surprise of the clinical team.    
“I was very poorly, and I was just like, I remember saying - you’re not touching my 
pacemaker! you’re just not touching it!…. I was just devastated and at the time I 
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thought I wouldn’t get another chance at anything…. I was questioning people to 
ask when I could have it done again.” Participant 4 
This underlines the sense of desperation in pursuit of a cure described earlier; a 
participant would rather risk their life than lose the implant, and also a sense that 
even tiny gains in symptom control were seen as significant to this patient group.  
When asked if she would do anything different in regard to trial participation she 
responded: 
“It’s still an opportunity to try and get over your bad days. If you tried and you had 
one bad day out of 10 or 10 bad days out of 10 and it spoiled it by one, to me that’s 
positive.” Participant 4 
Essentially she is stating that a life threatening event caused by the trial was 
considered to her as nothing more than a normal bad day for her. 
A second participant describes her experience of being assessed for a potential exit 
lead infection (it was erythema cause by the dressing) and her immediate reaction 
to the possibility that the SNS lead may need to be removed. 
“Quite emotional, thinking that it might not work at all, and it might have got 
infected and I’d have to start again…” Participant 6 
A second participant experienced a device malfunction, requiring significant 
additional travel to have the (analogue) device repaired, and personal anxiety 
about legitimacy of the active/sham periods of the testing period. Again, in this 
case, the participant did not choose to be withdrawn, despite the additional burden 
on her time, and felt she did not regret taking part in the trial. 
“That (the device malfunction) was quite devastating …. I got all the way back to 
where I live in XXXX (100+ mile round trip) and it just stopped flashing.”  
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Participant 2 
When asked if she would do anything different, she commented: 
“I was hoping that personally I would get a result from it and my condition. I don’t 
regret doing it. … I’m glad I tried it.” Participant 2 
This lady did not meet the criteria for progression to a permanent implant, but as 
per protocol, she was offered routine NHS testing, which she also failed.  
Aside from the per protocol adverse events, all participants in the Essence study 
described negative experiences during the trial, the majority during testing, relating 
mostly to the physical and social effects of having an implant. Most of these are 
captured above, but these do not fully capture the level of burden required by 
participants and families, and the sense of desperation and disappointment (and 
thus burden on the research team) if there was no perceived response.  
Participants who seemed to be losing long term response to the implant wanted 
the opportunity to find out whether the permanent implant settings could be 
manipulated to regain control.  
“There’s different settings that we can use isn’t there, so we can keep trying.” 
Participant 1 
Overall, participants perceived the trial experience as overwhelmingly positive. 
They enjoyed the experience of additional interaction and care from specialist 
clinicians and welcomed the invasive, demanding nature of surgical interventions, 
testing periods, and treatment, all of which placed high demands on their time, 
energy and resources. This was surprising given that participants were already 
perceived to be, and perceived themselves to be, depleted and fatigued and again 
indicates the willingness of participants to try anything that might relieve 
symptoms.  
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Participants were given the opportunity to reflect on their trial experience, and this 
resulted in several key suggestions for trial design, namely: 
 Telephone follow-up in place of face-to-face 
 Personal experience sheets to qualitatively feedback the level of burden during 
the trial - to capture individual perceptions of benefit rather than global scores 
 Remote data capture to replace paper diaries 
 Improved reliability of devices 
 Ability to change batteries by participants 
 Improved dressings to reduce skin itch 
For a minority, the effects of the permanent implant were experienced as life-
changing, for others the trial did not result in any meaningful improvement in 
symptoms. Despite the high burden on participants, and the negative experiences 
(life threatening for one), all participants stated they had no regrets about 
participating and would do so again. 
“…and like I’ve said now that I’ve had that acceptance of it, it didn’t work anyway.  
I’m glad I tried it.  I would never have known if I hadn’t” Participant 2 
 “Things didn’t go right but I’d still do it again.  If they asked me tomorrow to go 
back to day 1 I would still do it all again” Participant 4 
“Because like I say I believe that it’s improved my situation physically.  I do believe 
it’s helped me.  And for that I have no regrets, in fact I’m very grateful that I was 
given the opportunity.” Participant 5 
“If you’d asked me in the last week of it, I’d have probably said no.  But now when I 
look back it wasn’t as bad as I thought it was going to be so no, I probably would do 
something like that again.” Participant 7 
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 Although there is likely to be selection bias at play, and a potential reluctance to 
be overly critical to members of the research team, this does reinforce the finding 
that participants were so desperate for control and to find a cure that they would 
be willing to undertake almost anything asked of them. This has important 
implications for trial design and is discussed further in the discussion chapter.  
7.9 Discussion 
Three main themes emerged concerning the lived experience of participants which 
describe the process of self-managing the physical, social, and emotional effects of 
severe chronic constipation; An experience of angst (despair and anxiety) 
accompanied by anger at the perceived failure of healthcare to provide a cure; A 
proactive approach to taking personal control by seeking a cure through 
participating in a clinical trial. The main overarching theme linking these is of 
participants’ regaining and maintaining control of their body and lives. As such, this 
qualitative study is the first study to describe not only the experience of 
participating in a trial of sacral nerve stimulation, but also extends knowledge about 
the experience of a functional disorder that has the potential to inform future trial 
design and delivery. Participants describe a chronic condition whose symptoms are 
resistant to treatment and either had an onset coinciding with a traumatic event, 
or traced back to childhood. The effects of symptoms were experienced in 
participants’ social, emotional, professional, psychological and family lives, and 
participants placed individual values on resolution of particular symptoms that 
were not adequately assessed in the quantitative study. In particular, bloating and 
its effect on clothing and subsequently on social self-perception, self-confidence 
and professional life was of particular importance to participants.  
Participants described a long process of negative healthcare experiences 
precipitating their deep dread or anxiety or despair (angst) at being repeatedly told 
everything is normal , ending in a more positive experience of referral to tertiary 
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care, with many investigations and (both licenced and un-licenced) treatments 
along the way. The physical effects of severe chronic constipation are well-
described elsewhere in the literature (27) what is less well understood is the way 
that sufferers turned their angst and secondary anger against the medical model 
into a constant pursuit for control and cure. This meant that patients felt they 
would do anything in pursuit of a miracle cure, including participating in a trial 
which posed significant burden on their personal and professional lives.  The 
implications of this are discussed in more detail in the discussion (Chapter 8) but in 
summary, patients were willing to undertake significant burden during testing and 
follow-up.  
The study has several key strengths. It is the first study to explore perceptions of 
the placebo effect, and the first study to explore motivating factors for trial 
participation in this population. Findings suggest that the key motivating factor for 
trial participation was pursuit of a cure at all costs, with altruism as a secondary 
factor. This is at odds with studies in other populations suggesting altruism as a 
major motivation (145) and is the first to describe the lengths some patients will go 
to in order to participate. In regard to the placebo effect, the qualitative findings 
demonstrated that although blinding was protected via good study procedures, the 
participants felt they would have subverted the blinding if they had the 
opportunity. Findings also suggest that awareness of the possibility of a placebo 
effect had a detrimental effect on a minority of participants who suffered increased 
anxiety about the legitimacy of physical symptoms.  
The study design has several key strengths and weaknesses. The fact that I was also 
the operating surgeon, recruiting clinician, and blinded assessor poses some 
interesting strengths and potential weaknesses. It can be argued that knowing the 
participants so well led to a sense of comfort and familiarity for participants that 
improved the honesty and quality of data.   It can also be argued that this leads to 
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an inherent bias in how I interpreted their descriptions of their experiences as I will 
have had pre-conceived thoughts on their experiences during treatment as I was a 
central and consistent component of that phenomenon. If these were quantitative 
data then they would be judged as having a high risk of bias (111). The design of 
the study was deliberately sequential with the qualitative interviews only allowed 
after either withdrawal from or completion of the TiLTS-cc study per protocol in 
order to prevent contamination or influence of the primary outcome measure in 
the TiLTS-cc study. This was primarily because the studies were designed 
sequentially with the quantitative study first and its methods were fixed at the 
point of funding approval before the qualitative study was designed, and this 
sequential approach protected the integrity of the data.  
The fact that I was a recruiting clinician may have meant that participants felt 
obliged to participate in the qualitative study but we deliberately designed the 
recruitment process so that patients were not approached individually by me. The 
study is inherently biased because patients self-selected from a sub-group of 
eligible trial participants. It is possible that selection bias restricts generalisability 
but the range of views and the depth of findings about trial participation makes this 
a worthwhile exercise. Participants were in effect serial “trialists” from a tertiary 
centre with repeated exposure to research studies; thus findings may be unique to 
this sub-group. However, it is likely that the motivations for trial participation, and 
the response to the placebo effect are more universal. The fact that members of 
this self-selecting sub-group felt that they benefited from trial participation even 
without a measurable quantitative response to treatment is worthy of further 
investigation. It is a weakness of this study that no men were included but this 
reflects the largely female population who have the severest, most chronic form of 
the disease.  In addition, recruitment processes meant that we were unable to 
explore reasons for non-participation. It is possible that TiLTS-cc study non-
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participants had a more negative experience of prior trial participation and this 
would require further investigation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
242 
 
Chapter 8 Discussion of the key study findings and conclusion 
for the thesis 
This is the first study to evaluate a novel ePNE testing technique attempting to 
discriminate those patients most likely to benefit from SNS. It is also the first study 
to adequately assess the safety profile of ePNE SNS testing in this population which 
points to an unacceptably high and severe infection risk.  This chapter summarises 
the key findings presented in each of the previous chapters and discusses their 
implications for policy, practice, and future research, both for SNS, and more 
broadly for any study involving people with functional disorders. I will outline the 
epidemiology and current treatment for chronic constipation, and will highlight the 
key findings from both the trial of SNS and the qualitative exploration of the 
participant experience. This chapter will include a critical interpretation of these 
findings in the context of the gaps in the prior research, consideration of the 
strengths and limitations of the research, and reflection on learning points from 
each phase of the research. 
8.1 Summary of findings chapter by chapter 
Chapter 1 
The critical analysis of epidemiological data on chronic constipation and its 
treatment (Chapter 1) demonstrated a significant prevalence of chronic 
constipation of 14% in western populations (based on pooled data from a 
systematic review of prevalence studies).  It emphasises that this condition 
disproportionately affects women and is a chronic debilitating disease with a 
significant impact on quality of life and activities of daily living. Consequently, there 
is an economic burden on health care providers and a physical, economic and 
psychological burden on sufferers and their families. Medical treatments are 
improving with novel drugs such as Prucalopride, Linaclotide and Lubiprostone, but 
those at the severest end of the disease spectrum usually progress onto more 
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invasive treatments.  These include biofeedback therapy and irrigation, and 
ultimately formal surgery. Sacral nerve stimulation with limited evidence of efficacy 
has been considered a possible intermediate intervention to attempt before 
adopting invasive abdominal surgery such as an ACE procedure, stoma formation 
or total colectomy. SNS treatment is costly and cost-effectiveness may be improved 
if a test predictive of long-term response to therapy were available. There is 
currently no evidence for any test which can adequately discriminate long term 
responders to SNS therapy from non-responders for chronic constipation. 
Chapter 2 
In order to understand the evidence for the use of SNS in functional disorders, a 
background to SNS treatment evolution was written and systematic review of the 
published literature on SNS trials for chronic constipation was performed. Currently 
SNS is approved for other conditions affecting organs with the same S2/3/4 nerve 
supply, namely urinary dysfunction and faecal incontinence, but is not approved by 
NICE for chronic constipation. The early research studies of SNS for chronic 
constipation are based on mostly single centre, single surgeon prospective and 
retrospective cohort studies/ case series. These studies have numerous 
methodological design flaws meaning that the resulting data are of very low quality.  
These very low quality studies implied that treatment was highly effective when 
measured using an un-blinded sensory test. The later higher quality RCTs began to 
detect a placebo effect and hint at much lower response rates, although 
participants were randomised during the implant phase of treatment and not 
during temporary testing, which implies placebo responders (to testing) received 
permanent implants. Based upon data from the included trials there is no evidence 
of a difference in efficacy of SNS for chronic constipation compared with placebo 
therapy.  This finding may be due to the cohort being selected for implantation as 
244 
 
all had supra-sensory stimulation and a short duration of temporary SNS testing 
before implantation.  
The knowledge gap identified for a potential trial of a new testing technique was 
based on an extended peripheral nerve evaluation (ePNE) using the permanently 
implanted tined lead during testing, which allows for a novel sub-sensory and 
therefore a double-blinded temporary testing phase and the basis for the 
quantitative study (TiLTS-cc).  
Chapter 3 
In order to understand the evidence of patients lived experiences of SNS as a 
treatment for this disease, a systematic review of the qualitative literature was 
performed yielding no results, and so a scoping review on patient experiences of 
the disease burden and treatments was performed. The qualitative literature 
review identified no evidence of: the lived experience of patients having sacral 
nerve stimulation testing and subsequently living with the device, the motivations 
of participants with chronic constipation for participating in these trials, and 
experiences / beliefs of the placebo effect in treatments for these patients. Hence, 
these became the core topics to be explored further in the qualitative interview 
study (Essence) which was designed to follow on after the TiLTS-cc study was 
completed in order to prevent data contamination between studies. 
Chapter 4 
Chapter 4 presented the aims and objectives of the quantitative and qualitative 
studies after the knowledge gaps had been identified in Chapters 2 and 3. These 
included the urgent need to develop a test that could adequately identify long-term 
responders to SNS treatment who suffered from chronic constipation, and their 
experiences of the treatment and motivations for participating in these studies. 
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Chapter 5 
Chapter 5 demonstrated the methods adopted for the quantitative (TiLTS-cc) and 
qualitative studies (Essence).  These studies sought to treat participants and collect 
data on their response to treatment and experiences of the disease and trial 
participation. The TiLTs-cc study was designed jointly within a research group but 
included significant design contributions by myself. Notably these included the 
design contribution required to adequately blind the participants at a habituated 
threshold (sub-sensory stimulation) and maintain the integrity of blinding, the 
calibration of devices to ensure identical test stimulation was received by each 
participant, the antimicrobial prophylaxis algorithm before surgery, the consistency 
of the surgical technique (and equipment) and application of dressings, and the 
design of the study schedule and follow up of participants. The crossover design of 
the testing phase and primary endpoint of comparing long-term response to SNS 
between discriminate and indiscriminate testing responders were jointly devised 
by the senior researchers within the team. I was present during the meeting where 
these were decided but my contribution to this aspect of the trial design was 
minimal. As the study research fellow I undertook the majority of the recruitment, 
surgical procedures and follow-up of the participants, and I interviewed all of the 
participants in the qualitative study. The design amendments to the final TiLTS-cc 
protocol was informed by a pilot study undertaken by the research team during 
which I was the lead surgeon.  In this pilot study the potential to blind participants 
through security seals was tested and improvements identified.  Inherent problems 
were also detected with the analogue testing device in common use. In response 
to these problems I developed a laboratory experiment (in conjunction with help I 
sought from a physicist) that demonstrated the variability in the analogue testing 
device, indicating the requirement for precise calibration of each device before 
being used on a study participant. The same experiment was repeated on the new 
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digital testing device which demonstrated an exponential improvement in accuracy 
(4 orders of magnitude) and performance which validated the expected improved 
accuracy of this device over the analogue version. Other design changes that 
became necessary during the TiLTS-cc trial through ethically approved 
amendments to the study surrounded an attempt to minimise infection rates 
through changing the dressings used and modifying the antibiotic prophylaxis after 
a further literature review (designed and conducted by myself) and careful 
consideration and advice from experts in microbiology. I recruited the majority of 
participants to the study through the Durham constipation clinic and was the lead 
surgeon performing the study procedures in over 90% of participants. 
The Essence study was designed jointly by myself and a senior supervising 
qualitative researcher (Dr Helen Close) 6 months after the ethics approval for the 
TiLTS-cc study was given. I attended a qualitative research methodology course run 
by Durham University, and considered various frameworks as possible methods for 
this study. I elected to proceed with hermeneutic phenomenology as this clearly 
had an evidence base in the literature for surgical trials, and would allow my 
detailed interpretation of the participants’ experiences given the central role I 
played to them during the trial. I collected all of the data in the form of semi-
structured interviews with suitable safety mechanisms in place for the participants 
in an environment with which they were all familiar. The data was recorded and 
transcribed verbatim, and data saturation was confirmed by both myself and my 
supervisor before recruitment was halted. 
Chapter 6 findings from the Tilts study.  
Summary of key TiLTS study findings 
The study was terminated by the DMC and CI before full recruitment was obtained 
(45/75) due to the persistently high rate of infection of participants during ePNE 
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testing (22%). 29 participants responded to ePNE (7 discriminate and 22 
indiscriminate), and 27 were implanted with an IPG (2 withdrew). There was no 
evidence of a significant difference in long-term response (at 6 months) to SNS 
treatment between the sub-sensory test discriminate (60%) and indiscriminate 
(57%) responders P=0.76.  There was no evidence of a statistically significant 
difference in secondary outcome measures through testing or long term follow up 
between discriminant and in-discriminant responders. The design of the ePNE 
testing phase (randomised sub-sensory active or sham SNS with devices security 
sealed) protected the blinding of participants as confirmed by the synchronous 
responses between active and sham testing groups. The SNS testing devices 
underwent a pre-trial laboratory test of their output waveform to assess their 
variability. This confirmed unacceptably high variability in the analogue device 
(model 3625), and a far higher precision to stimulation waveform parameters in the 
digital device (model 3531). This model was also far more difficult to tamper with 
as the digital control device was only used by the un-blinded researcher. 
Chapter 7 -findings from the Essence study 
Summary of key Essence study findings 
Three main themes emerged concerning the lived experience of participants which 
describe the process of self-managing the physical, social, and emotional effects of 
severe chronic constipation; An experience of angst (anxiety, dread and despair) 
characterised by a secondary anger at the perceived failure of healthcare to provide 
a cure; A proactive approach to taking personal control by seeking a cure through 
participating in a clinical trial. The main overarching theme linking these is of 
participants’ regaining and maintaining control of their body and lives. This 
understandable need for control over healthcare angst led to a move from passive 
aggressive anger towards constant pursuit for a cure, implying that future trial 
designs should be viewed within this specific context for these participants. 
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Participants placed individual values on resolution of particular symptoms that 
were not adequately assessed in the quantitative study, and as such the 
participant’s perception of benefit didn’t conform to the TiLTS-cc trial definition of 
benefit. Bloating and its effect on clothing and subsequently on social self-
perception, self-confidence and professional life was of particular importance to 
participants. Very small gains in these symptoms were very significant to individual 
participants, regardless of how little quantitative improvement was measured. This 
has implications for trial design and the need for more person centred outcomes 
including the need for more person centred assessments of cost benefits during a 
trial (monitored by a data monitoring committee). The cohort were regular 
participants in trials and thus it could be argued, prevents the generalisability of 
findings; I would argue this should be exploited by methodologists not ignored in 
trial design with this and other similar populations, although I agree that this would 
still limit external validity. This study has also explored perceptions of the placebo 
effect, demonstrating an awareness and acceptance of it through the cohort, but 
also an anxiety that it may demonstrate a psychological cause for their symptoms. 
Participants also admitted to attempting to subvert the blinding either consciously 
or unconsciously due to a desire to gain control of symptoms, and that this was 
futile and the blinding was protected throughout. This study has also found that the 
key motivating factors for trial participation was pursuit of a treatment, cure and 
control of their lives over altruism.  
8.2     Key findings – what does this research add to current knowledge? 
8.2.1. Safety 
The main finding which I believe should have an immediate impact on clinical 
practice is the safety concern surrounding enhanced percutaneous nerve 
evaluation with an extended 6 week test using a tined lead. This form of SNS testing 
has been clearly demonstrated to have a persistently high incidence of infection in 
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our study participants 10/45 (22%) despite numerous attempts to prevent these. 
Of particular note 9 (20%) were categorised as severe infections with one 
participant requiring HDU for treatment of severe sepsis. It is likely that the tined 
lead, although internally connected to an exiting extension lead during testing, can 
easily become colonised causing either immediate or delayed infection to the 
participant. One study has demonstrated that tined leads tips do become colonised 
after ePNE (185), this in combination with our findings of high infection rates 
despite fastidious antimicrobial prophylaxis and dressing management, should be 
a warning to other researchers and clinicians. We have demonstrated that ePNE 
over a 6 week testing duration is not viable in its current design, and should not be 
attempted in clinical practice. As the study was halted with clear evidence of safety 
concerns and with no evidence of a treatment effect, then it cannot be a cost-
effective testing technique for chronic constipation. 
8.2.2. Efficacy of SNS for Chronic Constipation and the placebo effect 
The Tilts study was designed as an attempt to refine the predictive ability of SNS 
testing at identifying long-term “discriminate” testing responders to this treatment. 
The overall efficacy of SNS for CC is questionable as we have measured within this 
thesis. Even considering the possibility of a type 2 error (limitations) there was still 
no evidence of any apparent signal within the data collected during testing in either 
the primary or secondary outcome measures when compared to the sham control 
group. Both the sham control group and the active treatment group improved and 
deteriorated synchronously throughout the testing phase across all measured 
outcome domains. Interestingly the proportion of long term responders at six 
months was almost identical between the test discriminant and test in-discriminant 
groups. Limitations aside, I believe this could be argued as direct evidence of a 
persistent placebo effect, which has rarely been reported in the surgical literature. 
This may explain why SNS appears to benefit some participants in the longer term. 
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The qualitative data also provides further insights into this placebo effect, as it 
clearly highlights that participants had different perceptions of benefit from the 
treatment, and so it may also be true that a signal may have been detectable in the 
quantitative data if the outcome measures were more participant centred and 
specific. The placebo effect detected during the study can be explained very 
succinctly by the participant interviews; this effect was more than just about the 
treatment, it was about the entire experience of trial participation which was 
viewed as therapeutic in its own right by the participants, they were pro-actively 
taking control of their condition through participating. 
8.2.3. Perceptions of benefit and perceptions of burden  
The Tilts trial design attempted to take into account chronicity and severity but the 
Essence study identified cases in which the disease was so severe at baseline that 
any improvement was deemed a success by the participant, but would not be 
captured as such in quantitative terms. It is possible that the implant gave a sense 
of medical legitimacy to the disease that was previously missing, thus reducing the 
sense of angst and distrust of clinicians. Key methodological findings from the 
qualitative study include the use of personal experience sheets which capture 
qualitative symptom benefit and also a recommendation to review these in data 
monitoring committees to address participant burden within the context of 
desperate participants willing to do anything who are open to exploitation.  The 
interviews all took place prior to un-blinding of the Tilts results so it was impossible 
to disentangle at the time whether this perception of benefit was associated with 
a placebo effect. Un-blinded findings suggest that participants in the Tilts trial did 
experience a placebo effect while the SNS was switched off, and that this also 
affected ESSENCE participants. Qualitative data however, suggests that perception 
of benefit was not just associated with a psychological placebo boost but more than 
that, participants experienced a renewed sense of agency and control by taking an 
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active part in the TiLTs-cc treatment, which may have in itself have had a 
therapeutic value. Bloating was the most important outcome for some participants 
and was a significant factor in their perception of benefit, for others, abdominal 
pain, vomiting or bowel function were the most important outcomes. Every 
participant differed in their priorities for outcomes, with important implications for 
trial design; we could argue for a more nuanced outcome framework in 
constipation trials. This could be achieved using alternative frameworks to measure 
outcomes such as a Participant Generated Index. 
8.3. Reflection on the research conduct 
8.3.1. Strengths 
The Tilts study was a prospective methodology powered appropriately to detect 
effect size, utilising a novel double-blinded, sub-sensory sacral nerve stimulation 
crossover testing design. This is the most robust scientific design to date in sacral 
nerve stimulation trials by finally attempting to adjust for and explore the placebo 
effect which has been suspected to play an important part of SNS testing being 
unreliable. The Tilts study is the first study to evaluate SNS testing using this design, 
and the Essence study is first qualitative study to evaluate the testing process and 
trial participation more generally in this population of participants. The Tilts study 
design was informed by piloting of the study methods in a small cohort which 
identified refinements required to guarantee adequate blinding of the participants 
and myself. The security of blinding of TiLTS-cc study participants was then 
validated during the Essence study.  
A separate experiment measured the output waveform of the testing stimulator 
and identified variability in the analogue device, which was addressed by re-
calibration of all devices before the Tilts study commenced, and between each 
single use of the device on the study. This has not been previously reported in any 
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preceding trial of SNS in any field, and given the variability detected in these testing 
devices, prior research may be inaccurate. I participated throughout this research 
as a clinician recruiting patients from an NHS clinic (with senior supervision from 
my consultant), a researcher explaining the study processes and consenting 
patients, a surgeon who operated on the participants, and an interviewer who was 
able to put participants at ease and facilitate their reflection and debrief of the 
whole experience. As a result I was able to form a detailed interpretation of the 
participants’ descriptions of their experiences, which brings the qualitative data 
collected very close to true Hermeneutic phenomenology (152). 
8.3.2. Limitations  
There were several limitations to both the Tilts and Essence studies which may 
influence the interpretation of these findings. 
8.3.2.1. Data Adequacy-Possible Type 2 Error 
A type 2 error is possible from 3 separate factors; sample size calculation error, 
heterogeneity of the population and early trial cessation. 
8.3.2.2. Sample size  
The endpoint for response was a reduction in the mean total PAC-SYM score of 0.5 
which differs from recent evaluations of utilising this outcome measure in clinical 
trials where a defined higher reduction (-0.75) was suggested as a meaningful 
clinical response over placebo (186). Consequently the TiLTS-cc study design may 
have over classified responders to testing (false positives in the endpoint analysis) 
and thus a far larger sample size would have been required to detect any signal 
within the data using a higher response classification (-0.75). Finally, due to the 
persistent infections that participants seemed to suffer from, the DMC ended the 
Tilts study 30 participants short of the sample size target originally calculated as 
required.  
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8.3.2.3. Endpoint variability  
The determination of test responders and long-term responders was deliberately 
different; this may have contributed to the results and can be argued as an error as 
a validated tool was not used to classify the initial testing response. The visual 
analogue scale was invented and used to define a test responder simply to increase 
conversion rates to implantation in order to improve the PPV and NVP analysis of 
the test. The best scientific design would be to implant all participants eligible and 
measure PAC-SYM throughout testing and implant follow up, but this was declined 
by the ethics committee as non-responders would proceed to unnecessary surgery. 
This would have given a very accurate analysis of PPV and NPV.  In order to increase 
the implant rate sufficiently enough to make the required sample size and study 
feasible, the TiLTS-cc VAS scale was devised with a relatively low threshold of 
response decided at >25% improvement in symptoms. This allowed a secondary 
analysis of PAC-SYM which did not demonstrate any difference between active and 
sham groups during testing. 
8.3.2.4. Heterogeneity 
The study was adequately powered but also did not take into account the 
heterogeneity of the participant population; many experts in this field theorise that 
many multiple aetiologies are at work causing chronic constipation(12, 13), 
including but not limited to abdominal surgery and adhesions, myenteric nerve 
plexus neuropathies, smooth circular muscle myopathy, collagen disorders and 
even post exposure to an unknown environmental antigen. Clearly a group with this 
level of heterogeneity will be far more likely to have a false negative result. Indeed 
this may even be part of the explanation as to why some participants feel no effect 
whatsoever from SNS whilst others are reporting a life-changing event.  
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8.3.2.5. Sub-sensory stimulation 
The Sub-sensory design might actually have been both a strength and a weakness 
to the study, as it may not actually work as well as supra-sensory SNS in this disease. 
Outside of clinical trials of participants receiving SNS for faecal incontinence and 
urinary dysfunction this method for SNS has not been utilised. A small physiological 
study attempted to measure colonic propagating pressure waves during sub 
sensory SNS and found that it did not potentiate these compared to supra sensory 
SNS (105). This study assumed that the mechanism of action of SNS for CC would 
be to increase these waves of muscular contraction, but the mechanism for SNS in 
all clinical applications is very poorly understood, with some even hinting at an 
afferent mechanism on the cerebral cortex (102). Overall it may be that sub-sensory 
SNS has no effect for participants with chronic constipation, this simplest of 
explanations for the results may be true. 
8.3.2.6. Human error- Complex study with complex patients 
It is possible that the TiLTS-cc study, in trying to perform a randomised and 
completely double-blinded SNS tined lead testing for the first time, became far too 
complex a study. Running the study was incredibly demanding on myself and the 
study team. Typically 2-3 researchers were required per participant visit in order to 
protect blinding and perform the correct assessments.  
8.3.2.7. Not a mixed Methodology 
The overall thesis research utilised two methodologies but was not a mixed-
methods study. The Tilts study design prohibited interviewing participants before 
the endpoint to avoid any contamination of the primary trial outcome.  This 
occurred as the study design was fixed at the point of funding approval, which 
preceded the qualitative study design. Thus the results of the qualitative study 
could not be used to inform the design of the trial itself. The overall study was 
therefore sequential and not “mixed-methods”, but these qualitative findings still 
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have important implications for the design of future trials in participants with 
chronic constipation, and methodologists should take this learning into account for 
mixed-methods design. 
8.3.2.8. Equipoise 
It can be argued that I was not in true equipoise during the Essence study as I was 
the interviewing researcher who was also the participants’ surgeon during the 
TiLTS-cc trial. This raises the possibility that participants may have been too 
optimistic, positive or polite towards me in their descriptions of their experiences 
within the trial, and that the truth was that their experience was more negative.  
Conversely it could be argued that the professional relationship that I had 
developed with all participants actually meant they trusted me more than most 
clinicians and as such would be frank, open and honest. 
8.3.2.9. Possible biases 
 
8.3.2.9.1. Recruitment Bias 
There was potentially recruitment bias in both the Tilts and Essence studies as these 
participants were serial trialists in a tertiary centre. They therefore represent a 
highly selected group of patients who are at the severe end of the disease spectrum 
and are therefore not generalizable to the population at large. The question of 
whether the informed consent process was truly valid is also linked to bias – 
consent was taken from clinicians who weren’t impartial (I was a researcher in both 
studies) and participants were desperate and vulnerable and “willing to try 
anything” for their condition “in pursuit of a miracle cure”. This is a specific 
weakness within the research performed in these studies and that we may have 
recruited severely refractory patients who were desperate and as such unable to 
give properly informed consent to us as clinicians. I would argue that our participant 
information sheets were informative and that patients had an appropriate cooling 
off period to consider the information prior to agreeing and consenting to become 
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study participants. Future studies in this patient group may want to consider using 
neutral non-clinical researchers to take informed consent in order to address the 
concerns highlighted above. 
8.3.2.9.2. Selection Bias 
During the Essence study participants self-selected for recruitment after receiving 
an invitation letter. The results demonstrate that we interviewed only 2 
participants who did not have a response to the testing phase, so it can be argued 
that these data represent a self-selecting sub-group who gained a lot from trial 
participation and felt they derived benefit from this.  
8.3.2.9.3. Interpretation bias 
As the primary researcher performing both the surgery and interviews I was in the 
unique position of having pre-conceived ideas (declared within the methodology) 
about their experiences. It can be argued that I have been biased towards my own 
perceptions rather than interpretative of the participant’s individual phenomena 
during the trial. I would argue against this as I explained in detail in the 
methodology of the Essence protocol (Chapter 4) about my preconceptions of the 
trial experience, and these have been proven to be inaccurate. I did not predict or 
expect that participants would on the whole have a positive or beneficial 
experience, or presume that the overarching theme would be about regaining 
control of their lives. I remained blinded to the participants’ quantitative results 
throughout the qualitative interviews; my naivety prevented bias at the time of 
data collection.  I accept that despite all of these measures, however that a 
subconscious bias on my part may still have influenced the interview conduct and 
my interpretation of the data. I also felt that there was a cost to myself as the 
researcher doing both the surgical intervention and qualitative interviews; it was 
mentally exhausting and I became very involved in the participants’ follow up and 
subsequent care, far closer than in the usual clinical doctor-patient relationship. In 
257 
 
future similar surgical studies I believe it would be more beneficial for participants, 
clinicians and researchers to have dedicated qualitative researchers embedded in 
the trial design from the beginning in a true mixed methodology; this would allow 
appropriate amendments to the quantitative strand as qualitative issues are 
reported. 
8.3.2.10. Participant Demographics 
Only two men were recruited to the Tilts study, and no men were recruited in the 
Essence cohort, but this demographic is representative of the wider population of 
participants with this condition. It is possible that men would have given differing 
qualitative findings to the study, and this will remain a knowledge gap. 
8.4. Personal lessons learned during the research 
8.4.1. Adopting mixed methods in pilot phase 
As previously stated, this thesis has demonstrated to me the importance of 
feedback into study design within the context of designing complex surgical trials.  
There is a deficit of such research methods being employed within the surgical 
literature and I believe this learning opportunity will help me to promote it in 
future.  
8.4.2. Quantitative trial design 
I have gained considerable insight into research design within surgical trials, in 
particular how difficult it can be to adequately control these trials, and I would 
advise colleagues accordingly. Techniques such as crossover trials where subjects 
can become their own control group are very useful in patients with stable and 
chronic diseases. I would advise colleagues of the importance of utilising an 
experienced university research team to help with these designs, pilot them and 
feedback into the research design for either a hypothesis generating or definitive 
hypothesis testing study. I would also advise on the importance of utilising help in 
the statistical aspects of study design, data collection and analysis, especially where 
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preserving data integrity through monitoring and cleaning are concerned in order 
to produce the highest quality of research output from a prospective study.  
8.4.3. Qualitative study design 
The importance of using hermeneutic phenomenology in surgical trials, especially 
in heterogeneous patient groups such as those suffering from chronic constipation 
is clearly evidenced by this thesis. This is the first time I have undertaken qualitative 
research in any form, and although this was a new technique and philosophy I had 
to think very carefully about, I have embraced this framework and will promote this 
within my specialty as a design necessity in future clinical trials.  
8.4.4. Calibrating equipment. 
 I learned a valuable lesson from this experience; clinicians should not always 
assume that medical devices behave as they are intended or designed. All fields of 
clinical practice have their instrumentation that requires re-calibration to provide 
verifiable readings and consistent results. Failure to calibrate during temporary SNS 
may result in participants receiving variable stimulation, potentially reducing the 
clarity of research findings, and may have been a factor in the poor predictive 
power of testing in chronic constipation reported in all prior studies of SNS. To date 
this is the only reported study to calibrate these devices before a trial. 
8.5. Implications to further research 
8.5.1. SNS for faecal incontinence and urinary dysfunction 
The main clinical indications for SNS are faecal incontinence and urinary 
dysfunction, studies of which demonstrate far greater efficacy and test response 
(80%). It is clear that clinicians and researchers in these fields have been utilising 
ePNE instead of the standard 2 week test with a plain temporary electrode. This 
thesis demonstrates that the 6 week ePNE testing would also be unsafe in these 
participant populations due to the increased infection risk of up to 22%. Using the 
ePNE technique this thesis has demonstrated the potential ability to conduct a 
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double-blinded sub-sensory sham controlled crossover test in other groups, but we 
would not recommend 6 week testing given the adverse events, and this should be 
considered by clinicians and researchers alike. 
 
8.5.2. SNS testing for chronic constipation 
This thesis in combination with other studies (121, 123) has failed to detect any 
signal within any testing data that would suggest we can go onto discriminate long-
term response effectively between testing responders and testing placebo 
responders. This is more than likely due to the heterogeneity of their undiscovered 
aetiologies, where some participants report no symptom change whatsoever in the 
qualitative data and others report a life-changing event. I agree that it is still 
possible a small subgroup with a very particular aetiology may respond well to SNS 
therapy and report a life changing event; however trials to date of sensory 2-3 week 
unipolar lead testing, and now blinded 6 week quadripolar lead testing have failed 
to discriminately identify these patients. Given the current expense of this 
treatment (now over £12,000 in the NHS) if overall testing responders do not 
translate into long term responders then it is unethical both clinically and financially 
(for the NHS) to offer this as a treatment. Further research may potentially 
concentrate on blinded physiological response to SNS testing, as this is an 
underexplored area within SNS testing for chronic constipation. 
8.5.3. For other SNS work/research 
Future researchers in SNS studies may want to pay attention to the specific details 
we have learned from our participants during the qualitative interviews. 
Participants wanted the ability to change the SNS testing box batteries to prevent 
an unnecessary extra trial visit, but this would obviously not be possible in a blinded 
control trial. They also specifically commented on the occlusive dressing being too 
itchy, and tissue glue may be worth an attempt as an alternative temporary 
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dressing instead. Paper diaries were easily completed, but could be forgotten and 
so some suggested an online data collection system for participants to complete in 
real time at home. A telephone preference for routine follow up appointments was 
also expressed and this could be feasible for many study designs that do not require 
physical examination. A simple but important point emphasised repeatedly in this 
thesis is the unreliable variable nature of the old analogue testing stimulator (model 
3625) and we would clearly not recommend using this during clinical practice or 
future research (183, 184). More consideration should be given by clinicians and 
methodologists in estimating the efficiency of trial participation for patients so 
desperate for benefit, where any improvement is a success to some patients and 
this should be taken into account in trial design. This may be achieved through more 
consideration of experience sheets, patient-centred outcomes and “patient-
meaningful differences in outcomes”, alongside definitions of “clinically meaningful 
differences in outcomes.” One of the most interesting findings [from my 
perspective] was that participants were not predominantly motivated by altruism 
but by a desperate pursuit of a cure for their condition which helped them to feel 
they were regaining control of their bodies and life. This potentially leaves them 
vulnerable to exploitation, and this is an important addition to the literature and 
for methodologists to consider during trial design. I would suggest that researchers 
who are clinicians treating patients with severe functional gastrointestinal 
disorders should not be taking informed consent for their inclusion in clinical trials. 
These patients clearly depend greatly on these clinicians as their last hope of finding 
a treatment or cure, and they are “willing to do anything” to achieve that control. 
This is therefore not informed consent, and I would suggest a neutral research team 
member (who is not a treating clinician) should do this instead. 
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8.6. Concluding comments  
The efficacy data presented in this thesis is consistent with other recent quality 
studies of SNS for chronic constipation and in combination with these findings on 
the placebo effect, I would suggest that SNS is unlikely to be an effective treatment 
and that it is clinically and financially unethical to offer this as such to patients with 
chronic constipation.  Given the findings recorded within this thesis any future 
clinical trials on SNS for chronic constipation would be too expensive to justify with 
the current level of evidence. This relatively low cost study has therefore offered 
value for money to the NHS by evaluating feasibility. We can now avoid any 
definitive hypothesis testing study in this population, thus saving on further NHS 
clinical and research resources. The prolonged placebo response that has been 
demonstrated is very likely due to the higher therapeutic contact with participants 
during the trial; this is directly measured in the quantitative data, and substantiated 
through participant experiences in the qualitative data. Two participants 
qualitatively reported a life changing event after SNS therapy, although their 
quantitative data did not demonstrate an effect over placebo therapy in the 
efficacy measurements taken. It is still possible a small subgroup (from the overall 
heterogeneous group) with an unknown aetiology may benefit from SNS, although 
I believe these data are more likely to represent a pronounced and prolonged 
placebo response.  
In future trials within this population a mixed-methods approach should be 
considered as every patient seems to differ in their priorities for outcomes. This 
could be achieved using approaches that allow patients to value what they think is 
important using methods such as a Patient Generated Index (187).   
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Appendix 2-TiLTS- study Participant information Leaflet 
Tined lead testing in patients with chronic constipation: Patient Information Sheet 
We would like to invite you to take part in a research study. It is important for you to 
understand why the research is being done and what it involves before you decide if you 
want to take part or not. Please read the following information carefully. Ask us if anything 
is unclear or if you want more information. Taking part is entirely up to you and does not 
involve any financial cost. The study involves several steps so it will take us a few pages to 
explain everything properly to you. Please don’t worry if you do not understand it all – we 
can explain it all face to face if you would like to talk it over with us. If you decide you would 
like to take part but then change your mind, that is okay. You can withdraw at any time.  
What is the purpose of the study?  
We are studying a condition called severe refractory constipation. This means that the 
symptoms of constipation have not responded to other treatments and are causing many 
problems in daily life. We want to understand more about a treatment called sacral nerve 
stimulation (SNS) which may be able to help the bowel to work better. A fine wire is placed 
through the skin near to the spine sending mild, painless, electrical pulses to the nerve 
which controls the bowel. We already know that this treatment is safe and effective if you 
suffer from certain bowel and bladder problems. Permanently implanted SNS can help 
peoplelive a more normal life, but it only provides lasting benefit for about 4 in 10 people. 
We want to find out the best way to decide who will benefit from SNS.  
Currently, doctors use a temporary wire near the spine for 2 weeks (as a testing period) to 
see who might benefit, before giving those who do benefit a permanent wire. This has some 
problems. Firstly, it may not be possible to place the temporary and permanent wires in 
exactly the same place changing the benefit you receive. Secondly, you may improve simply 
because you are being cared for: this is known as a placebo effect. It means you may feel 
better and be given permanent SNS but your symptoms may quickly become severe again. 
We will use a different type of wire and a different kind of assessment to address these 
problems. Firstly, we will use the wire that is normally used for permanent SNS which is 
designed to prevent movement and has a greater number of electrodes causing a more 
focussed “electrical field” area. This is more likely to contain and therefore activate the 
nerve which controls the bowel. Secondly, we will use the testing period to assess you using 
both real (‘active’) and pretend (‘sham’) stimulation time periods. You will not be able to 
tell which stimulation you are receiving. This assessment has the potential to tell us if you 
will benefit long-term from SNS. Patients that have a good level of response to either of the 
testing periods will be given a permanent implantation of a pulse stimulator. We will assess 
you at 3 months and 6 months (after permanent implantation of a pulse stimulator-IPG) to 
measure quality of life, symptom benefit and costs to the NHS. Better targeting of this 
treatment will prevent disappointment for other patients suffering from this condition. 
Why am I being invited to take part? 
You are being asked if you would like to participate because your doctor has found that you 
have severe constipation that is not responding to other treatments. Your doctor will be 
giving this information sheet to all patients who are in the same position as you.  
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Do I have to take part?  
No, you don’t have to take part. If you want to take part, we will ask you to sign a consent 
form. You are free to withdraw at any time, without giving a reason. This will not affect the 
care you receive. If you don’t take part in the study all other care will continue as normal.  
Can I have the standard SNS testing? 
Recent changes to funding SNS treatments for severe constipation mean that SNS is now 
only funded by the GP care commissioning groups (CCGs) through this trial. Standard SNS is 
therefore not available. 
What will happen to me if I take part?  
Before the study:  
We will ask you to sign a consent form. We will ask your permission to look at information 
about you that is held by the NHS in your medical records. This information will be used to 
make sure you are suitable for the SNS treatment, and to follow up your care and health 
during and after the study. Then we will arrange for you to visit the out-patient clinic for a 
health check. You will be asked to have an X-ray of your tummy taken after swallowing X-
ray markers in an examination called a transit study. Ladies will also be asked to have a 
pregnancy test at the beginning and be asked to use appropriate contraception during the 
study. It is very important that you do not get pregnant during the study as the study 
procedures may harm you and your baby. (There are no known risks to men who go on to 
father children). We will also ask you about your general and past health, your current 
medications, and ask you to complete a short questionnaire to understand your quality of 
life at this time. Some of the measures done at this stage will be repeated at different stages 
of the study. We will give you some diary cards to take home to record your symptoms and 
medications over the next 2 weeks.  
At day one of the study: 
After this, we will ask you to come to the out-patient clinic for a day. You will be given a 
short anaesthetic (and some antibiotics to prevent infection) to have the wire fitted to your 
back (more information about this is included on page 7). The wire will be connected to a 
small electronic box (which connects to the wire outside of the body and you wear on a 
belt) for 4 of the next 6 weeks. We will show you how to keep the wire and the box safe. 
The electronic box will be switched on to create an electric current to help your bowel to 
work. 
During the 6 week testing stage: 
For the next 6 weeks, we will test whether SNS works for you by switching the current on 
and off at certain times. One group of patients will have the current switched on for the first 
two weeks and off for the last two weeks, and the other group will have the current 
switched off for the first two weeks and on for the last two weeks; your group will be 
decided by a process called randomisation so all patients will get at least one ‘active’ period. 
Each group will have half of the study participants randomised to it. You will not be told 
which group you are in because patients can improve simply because they are being cared 
for: this is known as a placebo effect. You will feel no difference when the device is switched 
on or off, and this means that you cannot tell when you are receiving active or sham 
stimulation. Not telling patients which group they are in will help us to find out who gets 
true benefit from the SNS and who would benefit from having it over a long period of time.  
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We will ask you to visit the out-patient clinic once a week for these 6 weeks so we can check 
how you are, check your wound, and will check that the wire and the box are working 
properly. At some of these weekly visits, we will ask you to complete more of the 
questionnaires and will ask you to take home some more diary cards to tell us how you feel, 
what medications you are taking, how your bowels are doing, and how this affects your 
daily life. During the central 2 weeks the device will be removed to allow the bowels to 
normalise between testing (we call this a washout period). You will simply have the wire 
under a dressing at this time.  It is important that you understand that you will be unable to 
bathe or swim for the entire 6 week period, and that driving is not permitted during testing 
(the first and last 2 week periods connected to the box). Driving is permitted during the 
central washout period of 2 weeks. 
If you respond to treatment after the 6 weeks testing stage: 
After 6 weeks, we will ask you to tell us if you have seen any improvements in your 
symptoms and we will then decide if you are suitable for a permanent SNS implant. If you 
agree to this, this will involve a short procedure to place a small implant in your buttock. 
This does the same job as the previous treatment but the wire and electronics will all be 
placed under your skin which will heal over. We will ask you to visit the out-patient clinic 
again after 3 and 6 months for another health check, including another transit study (X-ray 
of your tummy). At this point, your participation in the study will be over but you can choose 
to keep the implant in after this time if it is helpful for you. If you choose to do this, you 
would be cared for in the usual way by your consultant.  
If you do not respond to treatment after the 6 weeks testing stage: 
If the SNS is not working well we will discuss further options to treat your symptoms and 
will discuss the option of removing the wire with you. This will involve another short 
procedure and recovery time. We will ask you to visit out-patient clinic again after 6 months 
for another health check, including another transit study (X-ray of your tummy). At the end 
of the 6 months your participation in the study will be over.  Everyone should be aware that 
no matter what happens during the study, every patient will receive the same standard of 
care as you would normally expect from the NHS, and continue to receive this after the 
study.  
What are the benefits of taking part? 
We understand that you might be wondering whether or not to take part in this study which 
asks you to take part in a lot of clinic visits, asks you not to bathe or swim for 6 weeks, and 
not drive for 4 weeks. We invite you to take part because we believe that there is a 
reasonable chance that you may benefit from the treatment. Currently, around four in ten 
people have long-term benefit from the treatment, but the standard testing is inaccurate. 
By participating you may be more likely to receive the permanent implant, as we expect the 
trial design will increase the implant rate from about 50% to an estimated 80%.This is what 
some patients who have tried SNS have told us:  
“It has given me a new lease of life and a real sense of freedom from the condition for 
the first time in my life” 
 
“SNS was an extremely cumbersome experience that unfortunately did not work for me” 
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Our study might increase the number of patients who get long-term benefit from SNS but 
there are no guarantees. These two quotes demonstrate why the testing needs to be 
changed to identify the patients who will benefit from SNS. They also show that we cannot 
guarantee success or failure of SNS either on the study or through our normal testing 
procedure. 
Expenses and payments. 
You will not be given any payments or expenses for taking part in this study. If you find 
travelling to appointments is causing financial hardship the research team may be able to 
help with some or all of the travel costs. 
 
What are the possible disadvantages and risks of taking part? 
All of our surgeons are very experienced in performing sacral nerve stimulation procedures 
and the risks are very small. The most common risk is of infection or bleeding from the small 
wound in your back (where the wire is inserted). Infection is almost always successfully 
treated with antibiotics but very occasionally this does not work and we have to remove the 
wire or implant. Bleeding is usually only of a very small amount, but can sometimes occur 
around the testing wire after the surgery. Severe reactions to the device or permanent 
injuries to the nerves are also possible but this has never happened in any of the institutions 
participating in the study.  Some patients experience electric “shocks “or “jolts” from time 
to time, and this is due to small currents being generated in the wire either from nearby 
magnetic fields or sudden movements. This is not harmful and does not cause any problems. 
However, we ask you not to drive during the 4 weeks of testing (connected to the box) 
because the jolts may distract you and cause an accident. It is safe to drive during the middle 
2 weeks of “washout”(not connected to the box). Strong electromagnetic fields such as in 
MRI scanners or power generators must be completely avoided as they can cause 
permanent injury to you by heating the wire. Weak electromagnetic fields such as theft 
detectors or security gates in shops and airports should be avoided if possible but are not 
dangerous. You may experience a “jolt or shock” on passing through them, so we would 
recommend asking a member of staff to bypass the gates. We will provide a study card to 
explain the reason to security staff discreetly. Please make sure you contact the team if you 
have any concerns or if you experience any signs that concern you such as redness around 
the wound, oozing, pain around the wound, high temperature, odour from the wound. The 
study requires 2 X-rays to be taken which are above normal practice. Our medical physics 
expert has calculated that the radiation risk is considered to be the same as if you were 
receiving the standard care for SNS. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then you 
may have grounds for legal action but you may have to pay for it.  Regardless of this, if you 
wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms should be available to you. The hospital you are being treated at 
will have a complaints procedure (page 6). 
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Loss of capacity  
In the very unlikely event that you lose capacity to make decisions about your health during 
the study, you will be withdrawn from the study and continue to be looked after by the 
clinical team. Any data already collected will be used as part of the study.   
Will my taking part in this study be kept confidential? 
All information which is collected about you during the study will be kept confidential.  Any 
information and data about you which leaves the hospital will have data which identifies 
you (such as your name and address) removed so that you cannot be recognised from it. 
However, the following data about you will be leaving the NHS Trust: your unique study 
identification number, your age, gender and your ethnicity. Your medical records may be 
inspected by the regulatory authorities or monitors from Durham University who are 
helping to manage the running of the trial to check that the study is being carried out 
correctly.  Your name, however, will not be disclosed outside the hospital.  
What will happen to the data collected? 
Your data will be analysed by the team organising the trial to determine which of the 
treatment options is better. You will be assigned a unique number which will be used 
instead of your name when the team discuss your data. This team includes the Clinical Trials 
Unit at Durham University (who will analyse the data), and a small committee of 
independent doctors, academics and a lay person who have responsibility for overseeing 
the quality of data and conduct of the study. The results of the study will be used in reports 
and scientific presentations or publications. Your data will not be transferred outside of the 
UK and it will be stored securely for a period of time as required by the authorities in the 
UK before being destroyed. Your data will be stored both electronically and in paper form; 
this will be held in a database, operated by a third party, but only accessible to the research 
team. Your data will be stored for a period of 15 years after the end of the study by both 
Durham University, on the database and at the Trusts following the end of the Study. It will 
be confidentially destroyed after this point. If you decide to withdraw from the study at any 
time, the information collected on you up to that point will be kept and used in the analysis 
of the study.  
Who is organising and paying for the research? 
The study has been started and planned by doctors in various hospitals across England, 
together with researchers at Durham University. The Study is funded by the National 
Institute of Health Research (NIHR) through their Research for Patient Benefit (RfPB) 
scheme. The sponsor for the research is County Durham and Darlington Foundation Trust. 
Who has reviewed the study? 
The study protocol has been reviewed and approved by the National Institute of Health 
Research. The study has also been given a favourable opinion by “The Northern and 
Yorkshire” NHS Research Ethics Committee who are part of the central body for ethical 
approval of research studies in the NHS in the UK. 
What will happen to the results of the research? 
The results will be published in scientific medical journals and presented at national and 
international medical meetings. You will not be able to be identified from any of the results 
or reports that are produced and published from this study. We hope that the results of this 
study will enable us to manage patients with severe constipation better in the future. A 
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summary of the results will be available to all participants. Please let us know if you would 
like these to be sent to you so that we can record your address at your Trust.  
 
Further information needed? 
If you would like to discuss this information in more detail or want further information 
please contact: 
Your Consultant in your NHS hospital. 
Details will be inserted for individual Principal Investigators and the study nurse 
Details of the local site complaints process to be inserted here: 
If you decide to take part in this study you will be given a copy of this information sheet and 
a signed consent form to keep. We will also write to your GP to let them know you have 
agreed to take part.  
Thank you for reading this information sheet 
Further Information on the procedures  
The insertion and removal of the testing wire, and the insertion of the permanent implant 
are procedures that are performed under a general or a local anaesthetic. It is important 
that you have fasted for 6 hours before anaesthetic, that you have arranged an escort to 
accompany you home and there is somebody to be with you for 24 hours following 
discharge. Once you have returned from theatre you will be able to eat and drink as you 
would previously. There are no restrictions on eating and drinking within the SNS testing 
periods.  
Insertion of the SNS wire (“tined lead”) 
This is a simple procedure under an anaesthetic where the surgeon will position the lead 
near the sacral nerve by threading it through a needle under X-ray guidance. It is then 
“tunnelled” (a tiny passage is created through the fat) from the spine to the buttock where 
it might be later connected to an implanted stimulator (IPG). After being attached to a 
connecting wire it is then tunnelled again where the wire exits the skin. The reason for this 
is that we want to reduce the chance of an infection in the lead that goes to the nerve. You 
will have 2 very small (<1cm) scars which will be closed with glue, and through the 
outermost scar the wire will exit and be covered by a dressing. You will have a slightly larger 
scar (3-5cm) over the buttock where the lead is connected to the external wire, and this 
same scar will be used to implant the device if you respond well to testing. This scar will be 
closed with stitches internally and dressed with tissue glue. 
Implantable Pulse Generator (IPG) 
This is a simple procedure under an anaesthetic where the surgeon will disconnect the 
external wire from the internal tined lead (which goes to the nerve). A permanent IPG is 
then connected to the tined lead at the scar on the buttock made during the previous 
operation, and positioned in a pocket of fat where it will be more protected from damage. 
The wounds will be closed again with stitches and glue, and within 7 days you will return to 
the clinic and will be shown how to programme and use the IPG through a remote 
programmer. 
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Removal of tined lead 
This is a simple procedure under a general anaesthetic where the surgeon will disconnect 
the external wire from the internal tined lead, and then remove the tined lead from the 
spine. The wounds will be closed with stitches and glue. 
Some Do’s and Don’ts for participants 
We have some rules that need to be followed by everyone involved to ensure that you are 
safe and that the study produces valid scientific results.  
You should be aware that you may cease participation at any time you like during the 
study, immediately if you so wish, and that doing this will not affect your care. Any data 
that we have collected from you so far in the study, however, will still be used in our 
analyses. 
 
We ask that you do not try to remove or adjust the security labels that are placed on the 
testing stimulator box. If these labels are voided through tampering then we have to 
invalidate the test and withdraw you from the whole study. These security labels are also 
to protect you as they stop the batteries being removed and the Bluetooth “bonding” 
button from being depressed and altering the stimulation. 
We ask that you please attend all weekly review appointments during testing. We will 
routinely change the battery after each week of testing to prevent it from running out, and 
monitor the dressing and wound. It is essential that the dressing is not removed or changed 
by anyone other than a researcher.   
Please do not drive during the 4 weeks that you are connected to the testing box (the first 
and last two weeks of the testing phase).  Your car insurance will be invalid if you do so.  
Please tell medical staff of your SNS testing, or permanent SNS implant if you have any 
other treatment during the study.  
Please contact us if you think the wound site is sore or inflamed, or if you are concerned 
about the wire or the box, or any other symptoms or problems that develop during the 
study.  
Please, for ladies, do not get pregnant during the study as the study procedures may harm 
you and your baby.  
 Frequently Asked Questions (FAQs) 
 
 Can I have a shower instead of a bath during the 6 week testing? 
No, unfortunately not. We recommend using a flannel cloth only to prevent damage to 
the wire and testing box, and minimise the infection risk around the wire exit site. We 
understand that most people who suffer from this condition have extremely high 
personal hygiene standards, but our patient testimonials inform us that this short term 
inconvenience is worth doing to find out if SNS works for you in the longer term. 
 Will I still be able to have a normal sex life during the study? 
This is a question that many people find difficult to ask and wish to be informed of 
before starting SNS testing or treatment. There is no known reason why your sex life 
should change by participating in the study. We would ask that care is taken not to 
dislodge the wire or dressings.  The stimulation being provided to the sacral nerves, 
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may cause changes to occur to the normal sensations experienced during sex – these 
may be higher or lower than nomal. If you have the permanent device (IPG) this can 
obviously be turned off at this time. 
 How will the testing device affect me physically? 
The testing can very occasionally result in electric shocks or jolts in your bottom, pelvic 
muscles or legs which can occur at random and be uncomfortable. These usually stop 
very quickly and do not return. If they happen more than once or you are concerned 
you should contact us to check the device and settings. 
 How will the testing device affect me socially? 
-The testing box will need to be carried on your person at all times day and night for 
the testing period of 2 weeks at a time. It can be attached to clothing via a belt clip and 
is the size of a matchbox. It can easily be concealed under clothes but in practice might 
be noticed by close family and friends. You might want to decide what to tell people 
who ask if they notice the device.  
-You will not be able to drive during the two separate testing periods of 2 weeks at a 
time, and should consider how this would affect you and whether you would be able 
to obtain help with travel during this time. You will be able to drive at all other times 
on the study. 
 Can I be seen if there are any emergency problems? 
We will provide you with the details of your local study investigators who will be able 
to advise you in the event of unexpected complications or problems. Your medical 
notes will also contain details of the study for other doctors’ information if you need 
treatment for another unrelated problem. 
 What will happen to me if it does not work? 
You will need to have either the testing lead or the implanted device (IPG) removed. 
You will then need to consider other more invasive forms of treatment through your 
specialist in the constipation clinic. 
 Has anyone died during these operations? 
There have been no known fatalities to date either from the SNS testing, implanted 
device (IPG) or during anaesthetic for these. In any surgical procedure there are always 
risks of unforeseen serious complications, however, but we would emphasise that 
these are incredibly small. 
Contact details of study team 
Prof Yan Yiannakou Chief Investigator Durham  0191- 3332889  
Mr Kevin Etherson Research Fellow  Durham  0191-3332333  
Mr Charles Knowles Principal Investigator London  020-78828757  
Mr Mark Mercer-Jones Principal Investigator  Gateshead 0191-4820000 
Mr Stefan Plusa  Principal Investigator Newcastle 0191 282 4744 
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Appendix 3 –TiLTS-cc trial Consent form 
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Appendix 4 TiLTS-cc trial GP letter 
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Appendix 5 PAC-SYM questionnaire 
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Appendix 6 –Daily Diary exercise cards 
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Appendix 7-PAC-QOL questionnaire 
 
 
 
 
287 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
288 
 
 
Appendix 8 –EQ-5D-3L and EQ-VAS 
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Appendix 9- Participant self-completion assessment schedule 
 Self-completion assessment schedule for all study participants. 
R=responder, NR=non-responder. 
 
Assessment 
 Phase 
Baseline 
Assessment 
Tilts-cc 
end of 
week 2 
Tilts-cc 
end of 
week 4 
Tilts-cc 
end of 
week 6 
R-PSNS  
3 months 
R-PSNS 
6 months 
NR                 
6 months 
PAC SYM        
PAC QOL        
2 week daily diary         
Euro-QOL   EQ-5D         
EQ-VAS        
TiLTS-cc VAS        
 Phase 1  Phase 2   Phase 3  
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Appendix 10 TiLTS-cc-VAS 
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Appendix 11 Essence Study Participant interview guide 
 
The interviews will last between 15-90 minutes and follow a semi-structured 
format. 
The interview will start by confirming that the patient understands the interview 
process and agrees to take part. Written consent will be taken before the interview 
starts. Participants will be reminded of their right to withdraw at any time and to 
stop the tape if they so wish.  
The open and specific questions for each of the topics will be as follows: 
 Experiences of CC and its treatment 
  
“Can you tell me a bit about how your condition has affected you since it started?” 
“Can you tell me what has been done to try to help your condition?” 
 Motivations of patients to participate in the trial (or usual care SNS testing). 
 
“What made you want to take part in this study?” 
“Why do you think other people with your condition take part in these trials of 
surgical procedures?” 
“Should people take part in this type of research?” 
• Experiences of care and support that patients received before/during and after the 
trial (or usual care SNS testing). 
 
 “Tell me about the process of being recruited into the trial….” 
 “How much information were you given?” 
 “How did you feel about having SNS?” 
 “What was it like to have the surgery (the first and second procedures)?” 
 “What were the 6 (2) weeks of testing like?” 
 “What was it like filling out diaries and questionnaires?” 
“How has your life been since receiving the implant or having the SNS lead 
removed?” 
 “Tell me about the care and support you received from the study team…” 
• Perceptions of symptom changes (physical or psychological), to what extent was this 
attributed to SNS, and how important were these changes to patients. 
 
“Can you tell me a little about how SNS affected your condition?” 
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“How important were these changes to you?” or “ How do you feel about having 
no effects from the treatment” 
“Did SNS affect you mentally or psychologically ?” 
• Experiences of SNS in relation to its affect other aspects of their life (relationships, 
socially, professionally, and self-perception). 
 
“Can you tell me a little on how/if SNS affected your private or social life?” 
 
“Can you tell me a little on how/if SNS affected you professional life?” 
 
“How did you view yourself during the treatment?” 
 
“How did you perceive others viewed you during the treatment?” 
 
“Are there other ways SNS affected you that we have not discussed?” 
 
• Experiences, perceptions and beliefs about the placebo effect associated with SNS. 
 
“As you know one of the two testing periods was a placebo……what was your 
experience of having a placebo test?” 
“Could you work out the real stimulation from the placebo stimulation, and if so 
how?” 
“What do you think about doctors using a pretend test as part of the trial?” 
“Do you think it is an acceptable way to give a treatment?” 
(For all participants who lost a treatment response at 6 months) 
“Why do you think you lost response to the treatment?” 
• Perceptions and beliefs about the overall experience of SNS testing. 
“Overall are you happy with the experience?” 
“Can you suggest anything that would improve SNS for others?” 
“What do you think about the length of the test?” 
“What do you think about living with the dressings?” 
“How could the staff help you more than they did?” 
“If you could turn back the clock would you participate in the trial (have SNS) 
again?” 
“Why or why not?” 
• “Are there any other issues or points you would like to mention or discuss?” 
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Appendix 12 Essence Study Participant interview letter 
 
 
ExperienceS of treatment with Sacral Nerve stimulation (SNS) for idiopathic 
Constipation; a hermeneutic phenomenological study (ESSeNCe) 
 
Patient’s name, DOB, NHS number 
 
Dear Mrs/Ms/Miss/Mr 
 
I am writing to you because you have chronic constipation and you have been treated with 
sacral nerve stimulation (SNS) under the care of Professor Yiannakou at the University 
Hospital of North Durham. We would like to invite you to consider participating in the 
research study named above. This research study will explore experiences of chronic 
constipation  and SNS treatment. If you choose to take part, the interview will take place at 
the hospital at a time to suit you and will last between 15 to 90 minutes. We will reimburse 
your travel expenses.  
If you are interested in knowing more about the study, we will give you an information 
booklet which has been ethically approved by Durham University and the NHS ethics 
service. If you are interested in participating in the study, please contact me through the 
details below.  
 
Please note that your treatment will not be affected in any way whether or not you choose 
to take part. Thank you for reading this.  
 
Yours Sincerely, 
 
Kevin Etherson, 
PhD student Durham University, 
Research Fellow to Professor Yan Yiannakou, 
University Hospital of North Durham, 
DH1 5TW. 
Phone: 0191-3332889 
Email: kevin.etherson@cddft.nhs.uk or k.j.etherson@dur.ac.uk  
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Appendix 13 Essence Study Participant Information Sheet 
 
ExperienceS of treatment with Sacral Nerve stimulation (SNS) for idiopathic 
Constipation; a hermeneutic phenomenological study (ESSeNCe) 
 
We would like to invite you to participate in a study of patients’ experiences of sacral nerve 
stimulation (SNS) during the TiLTS-cc study. Before you decide whether to participate you 
need to understand why the study is being undertaken and what it would involve for you. 
Please take time to read the following information carefully. This information leaflet will 
provide you with details of the purpose of the study and what will happen if you decide to 
participate. Please do not hesitate to ask us if there is anything that is not clear or if you 
would like more information.  Take time to decide whether or not you wish to take part. If 
you do wish to take part then there is a consent form for you to complete and return. You 
do not have to take part if you do not want to and declining involvement will not affect 
your future treatment. 
What is the purpose of the ESSeNCe study? 
The research team who treated you during the TiLTs-cc study would like to explore the 
experience of having the SNS test and follow up, from your point of view. Very little is known 
about what patients actually experience during this kind of treatment or how it feels to take 
part in a study of this kind: This is an opportunity for you to help us understand the 
acceptability of SNS and to decide on the future use of the test and treatment. 
 
Why have I been invited? 
You have been invited to take part because you have been identified as a patient who has 
been treated with SNS for chronic constipation on the TiLTS-cc trial. 
What will happen to me if I take part? 
This study will comprise an interview typically lasting for about 15 to 90 minutes, during 
which the researcher will ask you questions about your experiences of receiving sacral nerve 
stimulation as part of the TiLTS-cc trial and give you the opportunity to say whatever you 
want to about your experience of SNS. At the start of the interview I will ask you to sign a 
consent form to confirm that you are happy and willing to take part in this study. The 
interview will take place in the Durham Constipation Clinic in a private room at a time that 
is convenient for you. The interview will be carried out by myself, Kevin Etherson. At any 
time during this process you will be free to end the interview and leave, and the recording 
of the interview up until this point would not be retained. 
What are the possible benefits of taking part? 
There are no direct benefits to participation other than you may enjoy sharing your 
experiences of SNS in the interview, and find this a helpful experience as a way of reflecting 
on your involvement in the TiLTS-cc trial. You may also feel satisfied that you have 
contributed towards further research into the condition and treatment, and this may 
indirectly benefit other patients. 
 
Do I have to take part? 
Participation is entirely voluntary and it is up to you to decide if you take part. After you 
have read this information sheet, if you would like to participate, please complete the 
consent form and sign it to show that you have agreed to take part. There is a copy of the 
consent form for you to keep with this information sheet. 
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What will happen if I start the interview but don’t want to continue? 
You are free to withdraw from the study at any time without giving a reason, either before, 
or during the interview. At any time during this process you will be free to leave, and the 
recording of the interview up until this point would not be retained. 
Will my interview be kept confidential? 
Yes. The only people who will know that you have taken part will be the research team and 
your GP. The interview will be recorded on a digital Dictaphone, and then written 
(transcribed) into text by Anne Kelly or Julie Bushby the team assistants. Your name and any 
identifiable details will not be attached to the text; instead we will give you a unique ID code 
so that it is anonymous. The interview and anonymous text document will be kept securely 
until all patients involved have had their interview data completely analysed, and then it 
will be destroyed after storage for 5 years. The interview and transcription files will be 
encrypted and stored on a secure part of the team research database on the trust intranet 
server. Access requires 3 levels of password protected identity verification, and then the 
encryption password. Your confidentiality will be respected at all times as in the same 
manner as a clinical consultation. In order to analyse the interview properly we will ask for 
your permission to allow specialist researchers at Durham University (Dr H Close and Dr H 
Hancock) to supervise the analysis of the interview recording and transcription. They will 
not be provided your personal details and will simply refer to you by the unique ID. The 
interviewing researcher (Kevin Etherson) is a trained clinical doctor who also has a clinical 
responsibility for your care (under the supervision of Professor Yiannakou), and so has an 
obligation of care to you if there is a suspicion of deteriorating clinical or mental health as 
a result of the treatment or interview. In this unlikely situation it may be deemed necessary 
to discuss concerns raised in the interview with either your GP and/or named psychiatrist 
to give you the appropriate help. We would discuss this with you immediately after the 
interview and would let you know if we were doing this in advance. 
The researcher and the team assistant will be offered debriefing sessions with the team 
psychologist in order to protect your and their wellbeing, but this will not compromise your 
confidentiality as the psychologist is part of the Durham multidisciplinary team who care 
for you. At all times we will comply with the Data Protection Act 1998 as per the trust 
information governance policy. 
What will happen to the results of the ESSeNCe study? 
The results of the ESSeNCe study will be presented at national and international 
conferences, and published as a peer reviewed paper in a medical journal. Direct quotes 
from interviews may be published, but no information will be published that would allow 
anyone else to identify you as a participant. 
Will it cost me anything to take part? 
No, but we are asking you to give up some of your time, which might be unpaid time from 
work. 
As you will incur costs for travel and parking we will reimburse these. 
Who has reviewed the ESSeNCe study? 
This qualitative study has been approved by the Research Ethics Committee at the School 
of Medicine and Health at Durham University. It has also been approved by both the NHS 
Health Research Ethics Service (HRES) committee of North East and York, and the research 
and development department of County Durham and Darlington NHS Foundation Trust.  
Harm 
A potential psychological impact on your mental health may occur due to the process of 
reliving and describing life experiences related to either your condition or the SNS 
treatment. It is possible that you might find it upsetting to talk about your illness and its 
treatment, in which case you can stop the interview at any time and support will be offered 
to you following the interview by Sister Debbie Rowley-Conwy (nurse specialist) or Mrs 
Jackie Pearn (team assistant) who you know from the clinic.  
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Further information and contact details  
If you would like any more information or if you would like to discuss anything verbally or 
in person please contact the lead researcher, Mr Kevin Etherson, on 0191 3332889, or e-
mail kevin.etherson@cddft.nhs.uk or k.j.etherson@dur.ac.uk  
If you have concerns about the research and wish to speak to someone confidentially at any 
point before or after the interview then you can contact: 
Professor Yan Yiannakou on 0191 3332889. 
If you have a complaint you can contact your local PALS office: 
Patient Experience Team 
Darlington Memorial Hospital 
Hollyhurst Road 
Darlington 
DL3 6HX 
Telephone: 01325 743626 
List of Researchers in the ESSeNCe study: 
Mr K Etherson  Lead researcher   UHND & Durham University 
Dr H Close  Supervising Researcher  Durham University 
Dr H Hancock  Supervising Researcher  Durham University 
Mrs R Maier  Supervising Researcher   Durham University 
Prof Y Yiannakou Supervising Researcher   UHND & Durham University 
Prof J Mason  Supervising Researcher  Durham University 
 
If you decide to take part in this study you will be given a copy of this information sheet and 
a signed consent form to keep. We will also write to your GP to let them know you have 
agreed to take part. 
 
We would like to take this opportunity to thank you for reading this information sheet 
and considering the interview. 
 
 
Please keep this information sheet and the consent form for your records 
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Appendix 14 Essence Study Consent form 
 
 
 
 
 
 
 
ExperienceS of treatment with Sacral Nerve stimulation (SNS) for idiopathic 
Constipation; a hermeneutic phenomenological study 
Lead researcher: Mr Kevin Etherson,  
PhD student, School of Medicine, Pharmacy & Health, Durham University. 
Research Fellow / Specialist Registrar, University Hospital of North Durham  
Contact email:    k.j.etherson@dur.ac.uk or kevin.etherson@cddft.nhs.uk 
              Phone:  0191-3332889 
Participant name: __________________________________________________________ 
 
Patient study number: ______________________________________________________ 
Please initial the following statements in the box opposite: 
I confirm that I have read and understand the information sheet dated 12/12/2013 (version 2) for 
the above study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
I understand that my participation is voluntary and that I am free to withdraw at any time without 
giving any reason, and without my medical care or legal rights being affected.  
I understand that all relevant regulations regarding data protection will be adhered to, and that 
confidentiality will be protected and anonymity assured by the research team. I understand that 
relevant sections of my medical notes or data collected during the study may be looked at by 
staff from regulatory authorities or from the NHS trust, where it is relevant to my taking part in 
this research. I give permission for these individuals to have access to my records. I understand 
that individuals from Durham University (Dr H Close or Dr H Hancock) will have access to 
interview recordings and transcripts. 
I understand that if concerns are raised during the interview the researcher may contact 
Professor Yiannakou, my GP or named psychiatrist in order to provide help. I would be advised 
of this in advance. 
I agree to take part in the above study interview and I confirm that I am aged  
18 years or older. 
Name of participant Date Signature 
Name of person taking consent Date Signature 
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Appendix 15 Essence Study Participant’s GP letter 
ExperienceS of treatment with Sacral Nerve stimulation (SNS) for idiopathic 
Constipation; a hermeneutic phenomenological study (ESSeNCe) 
Patient’s name, DOB, NHS number 
 
Dear Dr 
 
Your patient named above has agreed to participate in a qualitative study exploring sacral 
nerve stimulation (SNS) for patients who suffer from chronic constipation. The aims of this 
study are to explore the experiences of the disease, the SNS testing and implantation 
procedures, and the motivations patients may have for participating in surgical research. 
The ESSeNCe study has been approved by both the ethics committee of Durham University 
School of Medicine, Pharmacy and Health, and the North East-York research ethics 
committee (REC) of the NHS national health research ethics service (NRES).  
The study involves a qualitative interview lasting between 15-90 minutes, during which I 
will conduct a semi-structured phenomenological interview. This will be recorded and 
transcribed, and analysis will be performed in conjunction with and under the expert 
supervision of qualitative researchers who are fellows of the Wolfson Research Institute of 
Durham University. No significant risks have been identified or are expected from this study. 
As you are no doubt aware, asking patients to describe life experiences that may potentially 
be traumatic can very occasionally lead to deterioration in mental health. We have designed 
this study with this in mind and mechanisms are in place to report concerns to yourself or 
the relevant mental health team if this is deemed necessary. 
 
If you have any questions or would like to discuss the study I would be delighted to provide 
further information, 
Yours Sincerely, 
 
Kevin Etherson, 
PhD student Durham University, 
Research Fellow to Professor Yan Yiannakou, 
University Hospital of North Durham, 
DH1 5TW. 
Phone:0191-3332889 
Email: kevin.etherson@cddft.nhs.uk or k.j.etherson@dur.ac.uk  
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Appendix 16 Stard checklist (188) for the TiLTS-cc Study 
 Section & Topic No Item 
Reported 
on page # 
     
 TITLE OR 
ABSTRACT 
   
  1 Identification as a study of diagnostic accuracy using at least one 
measure of accuracy 
(such as sensitivity, specificity, predictive values, or AUC) 
2 
 ABSTRACT    
  2 Structured summary of study design, methods, results, and 
conclusions  
(for specific guidance, see STARD for Abstracts) 
2 
 INTRODUCTION    
  3 Scientific and clinical background, including the intended use and 
clinical role of the index test 
81 
  4 Study objectives and hypotheses 83 
 METHODS    
 Study design 5 Whether data collection was planned before the index test and 
reference standard  
were performed (prospective study) or after (retrospective study) 
85-142 
 Participants 6 Eligibility criteria  89 
  7 On what basis potentially eligible participants were identified  
(such as symptoms, results from previous tests, inclusion in 
registry) 
89 
  8 Where and when potentially eligible participants were identified 
(setting, location and dates) 
89 
  9 Whether participants formed a consecutive, random or 
convenience series 
85-142 
 Test methods 10a Index test, in sufficient detail to allow replication 107-116 
  10b Reference standard, in sufficient detail to allow replication N/A 
  11 Rationale for choosing the reference standard (if alternatives exist) N/A 
  12a Definition of and rationale for test positivity cut-offs or result 
categories  
of the index test, distinguishing pre-specified from exploratory 
102 
  12b Definition of and rationale for test positivity cut-offs or result 
categories  
of the reference standard, distinguishing pre-specified from 
exploratory 
N/A 
  13a Whether clinical information and reference standard results were 
available  
to the performers/readers of the index test 
N/A 
  13b Whether clinical information and index test results were available  
to the assessors of the reference standard 
N/A 
 Analysis 14 Methods for estimating or comparing measures of diagnostic 
accuracy 
171, 189 
  15 How indeterminate index test or reference standard results were 
handled 
N/A 
  16 How missing data on the index test and reference standard were 
handled 
N/A 
  17 Any analyses of variability in diagnostic accuracy, distinguishing 
pre-specified from exploratory 
171, 189 
  18 Intended sample size and how it was determined 125 
 RESULTS    
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 Participants 19 Flow of participants, using a diagram 164 
  20 Baseline demographic and clinical characteristics of participants 165 
  21a Distribution of severity of disease in those with the target 
condition 
165-167 
  21b Distribution of alternative diagnoses in those without the target 
condition 
N/A 
  22 Time interval and any clinical interventions between index test and 
reference standard 
N/A 
 Test results 23 Cross tabulation of the index test results (or their distribution)  
by the results of the reference standard 
N/A 
  24 Estimates of diagnostic accuracy and their precision (such as 95% 
confidence intervals) 
171 
  25 Any adverse events from performing the index test or the 
reference standard 
178 
 DISCUSSION    
  26 Study limitations, including sources of potential bias, statistical 
uncertainty, and generalisability 
243 
  27 Implications for practice, including the intended use and clinical 
role of the index test 
249-251 
 OTHER 
INFORMATION 
   
  28 Registration number and name of registry  
 
http://apps.who.int/trialsearch) with a registration number 
ISRCTN44563324 
. 
  29 Where the full study protocol can be accessed  
 
http://www.isrctn.com/ISRCTN44563324 
 
  30 Sources of funding and other support; role of funders  
 
NIHR-RfPB grant approval number: PB-PG-1010-23212 
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